A systemic review of T-cell epitopes defined from the proteome of SARS-CoV-2

Highlights

• •A systemic review of T cell epitopes of SARS-CoV-2 proteome.
• •The HLA restriction of defined T cell epitopes of SARS-CoV-2.
• •The methods identifying the T cell epitopes of SARS-CoV-2.

Abstract

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection remains in a global pandemic, and no eradicative therapy is currently available. Host T cells have been shown to play a crucial role in the antiviral immune protection and pathology in Coronavirus disease 2019 (COVID-19) patients; thus, identifying sufficient T-cell epitopes from the SARS-CoV-2 proteome can contribute greatly to the development of T-cell epitope vaccines and the precise evaluation of host SARS-CoV-2-specific cellular immunity. This review presents a comprehensive map of T-cell epitopes functionally validated from SARS-CoV-2 antigens, the human leukocyte antigen (HLA) supertypes to present these epitopes, and the strategies to screen and identify T-cell epitopes. To the best of our knowledge, a total of 1349 CD8⁺ T-cell epitopes and 790 CD4⁺ T-cell epitopes have been defined by functional experiments thus far, but most are presented by approximately twenty common HLA supertypes, such as HLA-A0201, A2402, B0702, DR15, DR7 and DR11 molecules, and 74-80% of the T-cell epitopes are derived from S protein and nonstructural protein. These data provide useful insight into the development of vaccines and specific T-cell detection systems. However, the currently defined T-cell epitope repertoire cannot cover the HLA polymorphism of major populations in an indicated geographic region. More research is needed to depict an overall landscape of T-cell epitopes, which covers the overall SARS-CoV-2 proteome and global patients.

1. Introduction

The SARS-CoV-2 infection remains in a large-scale epidemic. As of October 12, 2022, there were over 619.8 million cases diagnosed and over 6.5 million deaths worldwide due to this disease. Numerous studies have shown that SARS-CoV-2-specific T-cell responses have important effects on viral clearance (Yu et al., 2020), disease progression (Rydyznski Moderbacher et al., 2020), antiviral efficacy (Oberhardt et al., 2021) and superinfection (Zuo et al., 2021), especially CD8⁺ T cells, which are important effector cells that kill virus-infected cells and secrete cytokines. Therefore, specific T cells against SARS-CoV-2 are not only potential markers to monitor the efficacy of antiviral therapy and predict the possibility of reinfection (Toor et al., 2021) but also potential specific immune modulators (Caccamo et al., 2020). Identifying as many T-cell epitopes as possible from SARS-CoV-2 antigens is of great significance for designing and developing epitope-peptide-based T-cell therapeutics and detecting host SARS-CoV-2-specific T-cell immunity.

This review systematically collected the CD8⁺ T-cell epitopes and CD4⁺ T-cell epitopes functionally defined from the SARS-CoV-2 proteome. The information is based on English-language journal papers indexed in databases such as PubMed, Scopus, Embase, SinoMed, and Google Scholar. The latest online search was conducted on August 15, 2022. “T-cell epitope” and “SARS-CoV-2” were used as specific search terms. An initial search identified 367 studies from multiple databases and manual searches. All articles were imported into Endnote software 20 (Thompson and Reuters, Philadelphia, PA, USA), and 60 duplicates were removed. In total, 307 studies from 2019 to 2022 were collected. Then, 237 articles were filtered out after abstract and full-text screening, according to the following exclusion criteria: (1) not related to the screening or identification of T-cell epitopes; (2) using only in silico prediction or molecular structure bioinformatic analysis rather than cell functional experiments, tetramer staining, binding assay, stabilization assay, or immunization; and (3) incomplete information regarding epitope sequences. Finally, 70 articles were used and referenced in this review.

2. Relation of HLA allele polymorphisms with SARS-CoV-2 infection

Human leukocyte antigen (HLA) class I molecules (classical HLA-A, HLA-B and HLA-C) expressed by virus-infected cells present viral endogenous epitope peptides to specific CD8⁺ T cells, thereby initiating the activation, proliferation and differentiation of naive T cells into cytotoxic T lymphocytes (CTLs). Then, virus-specific CTLs induce cytolysis of virus-infected cells through the Fas/FasL, TNF/TNFL and perforin/granzyme pathways (Nitschke et al., 2016). HLA class II molecules (classical HLA-DR, -DQ and -DP) on antigen-presenting cells (APCs, such as monocytes, macrophages, dendritic cells, and B cells) present exogenous viral polypeptides to CD4⁺ helper T cells, thereby inducing naive CD4⁺ T cells to differentiate into efficient Th1 or Th2 cells. The former mechanism helps the activation of virus-specific CD8⁺ T cells, and the latter mechanism assists virus-specific B cells in producing antibodies (Roche and Furuta, 2015). However, HLA molecules are highly polymorphic in the general population. According to information provided by the International Immunogenetics Information Project/HLA database (IMGT; https://www.ebi.ac.uk/ipd/imgt/hla/), as of July 2022, a total of 35077 alleles were found at HLA class I and class II gene loci in the global population, including 7562 HLA-A, 9000 HLA-B, 7513 HLA-C, 4149 HLA-DRB, 2278 HLA-DQB1, and 2067 HLA-DPB1. HLA genotypes vary from person to person, and the antigenic epitope peptides presented by different HLA allotypes are also distinct. Therefore, the immune patterns of different individuals to the same pathogen show large diversity (Elahi and Horton, 2012; Wang et al., 2016). Furthermore, there are significant differences in the distribution of HLA alleles in different ethnic populations and geographic regions (http://www.allelefrequencies.net).

An increasing number of studies have revealed the correlation between HLA allotypes and the occurrence of certain diseases (Boeijen et al., 2017; Medzhitov, 2007). Although the association of HLA alleles with SARS-CoV-2 infection is not fully understood, this relationship continues to be revealed by past and present studies. In a study of the Italian Sardinian population, the 4 alleles (HLA-A*02:05, B*58:01, C*07:01, DRB1*03:01) played a positive role in the protection of host against SARS-CoV-2 infection. The presence of the HLA-DRB1*08:01 allele has an adverse effect on the disease progression of COVID-19 patients (Littera et al., 2020). A study in a Caucasian population in the United States showed that HLA-B*15:01 was closely associated with asymptomatic infection with SARS-CoV-2 (Augusto et al., 2021). A study conducted in Zhejiang Province found that HLA-A*11:01, B*51:01 and C*14:02 alleles were associated with poor prognosis in SARS-CoV-2 infection (Wang et al., 2020). In the past two years, a large number of studies on the correlation between SARS-CoV-2 infection and HLA alleles have emerged, but some results seem to be inconsistent, which can be attributed to the polymorphism of host HLAs in different races and regions (Matern et al., 2020; Zidi et al., 2016). Therefore, further studies should be conducted in different regions to reduce the heterogeneity.

3. SARS-CoV-2 proteins

The genome of SARS-CoV-2 is a positive single-stranded RNA with a length of 29.9kb. Proteins translated from the SARS-CoV-2 genome are classified into three main groups: nonstructural proteins, structural proteins, and accessory proteins. The ORF sequences of nonstructural proteins are located upstream of the genome encoding pp1a and pp1ab, and the ORF sequences of structural and accessory proteins are located downstream of the genome. The structural protein coding region mainly encodes the spike (S) protein, envelope (E) protein, membrane (M) protein and nucleocapsid (N) protein. The accessory proteins included ORF3a, ORF3b, ORF6, ORF7a, ORF7b, ORF8, ORF9b, ORF9c and ORF10.

The binding of the S protein to host cells via its receptor binding domain (RBD) plays an important role in pathogenesis, since it initiates infection by attaching viral particles to host cells. The S protein consists of 1273 amino acid residues, including three subunits, namely, S1, S2 and S2′, which play different roles in the process of adhesion to host cells. By interacting with human angiotensin-converting enzyme 2 (ACE2), the S1 subunit is involved in the attachment of virions to the host cell membrane and subsequently initiates the infection process (Lan et al., 2020). The S2 subunit functions as a fusion protein that facilitates the fusion of the virion with the cell membrane (Naqvi et al., 2020). The relatively smaller E protein (75 amino acids) plays an important role in viral morphogenesis and assembly, and acts as a viral pore protein that is assembled into the host cell membrane to form protein-lipid pores for ion transport. The M protein, with a length of 222 amino acids, plays a role together with the E, N and S proteins in the process of virus infection of the body, and plays a major role in the assembly process of viral RNA (Tang et al., 2020). The M protein is the most abundant viral protein in coronaviruses and is involved in the composition of different shapes of the virus. The N protein performs viral assembly by interacting with the viral genome and M protein. This protein binds to viral RNA in a "beaded" manner through an RNA-binding domain of approximately 140 amino acids in its core (Li et al., 2020), helping to enhance viral RNA transcription and replication (Cong et al., 2020).

4. Strategies for screening T-cell epitopes

The first step in screening T-cell epitopes is selecting the candidate epitope peptides. Generally, two strategies have been used. One is to generate an overlapping peptides (OLP) library that spans the entire proteome or indicated proteins (peptide scanning) (Zelba et al., 2021). Another strategy is to use predicted epitope peptides that bind to indicated HLA allotypes as predicted in silico through a variety of epitope prediction tools and algorithms (Grifoni et al., 2020). Epitope prediction tools can also be used to assess the HLA restriction of epitope peptides defined by cellular experiments. In a recent study, the researchers used the NetMHCpan Version EL4.1 algorithm in the IEDB database to evaluate the binding ability of the reported epitope peptides to MHC-I molecules in order to screen out those with stronger binding ability, and a predominant epitope peptide was used to immunize mice with an epitope peptide vaccine (Jiang et al., 2022).

Over the past two decades, methods for verifying the immunogenicity of candidate epitope peptides have undergone numerous improvements. Currently, widely used methods include: cytotoxicity assays, lymphocyte proliferation assays, intracellular cytokine staining (ICS), enzyme-linked immunospot assays (ELISpot)/fluorescence immunospot assays (FluorSpot), activation-induced marker assays (AIM) and polypeptide-MHC multimer staining. The cytotoxicity assay validated CD8⁺ T-cell epitopes by stimulating PBMCs with candidate epitope peptides and coculturing them with Cr⁵¹-labeled target cells (Shafer-Weaver et al., 2003). At present, the more common methods used are ICS, AIM and ELISpot/FluorSpot. PBMCs from patients were stimulated in vivo or in vitro with candidate epitope peptides, followed by the detection of cytokines secreted by CD4⁺ T cells or CD8⁺ T cells or markers on activated T cells (Freer and Rindi, 2013). ELISpot or FluorSpot technology can detect single activated cells in one million PBMCs. Because of its accuracy, sensitivity, and repeatability, the technology has been widely used in research and has promising clinical prospects for detecting antigen-specific T cells (Ji and Forsthuber, 2016; Portilho et al., 2022). Peptide-HLA multimer staining has become the gold standard for enumeration of antigen-specific T cells because of its high specificity and also has been used to identify T-cell epitopes in many studies. Yuri et al. used peptide-HLA multimer staining to verify the SARS-CoV-2 epitope peptides predicted by the IEDB database, and defined 31 CD8⁺ T-cell epitopes and 19 CD4⁺ T-cell epitopes (Poluektov et al., 2021). Many researchers have also established HLA transgenic mouse models to map HLA-restricted epitopes. Lauren et al. predicted 32 SARS-CoV-2-specific T-cell epitope peptides by the EpiMatrix algorithm and selected 20 peptides to generate epitope peptide vaccines followed by immunization of HLA-DR3 transgenic mice for the evaluation of protective effects (Meyers et al., 2021). Peptide-HLA molecule binding and stability assays are also used to identify antigenic epitopes. More recently, a high-throughput genome-wide screening by identifying target cells expressing T-cell epitopes recognized by T cells (T-Scan) was used to define T-cell epitopes of SARS-CoV-2 (Zhang et al., 2021).

5. Identified SARS-CoV-2 antigen-specific T-cell epitopes

Tables 1 and 2 present the CD8⁺ T-cell epitopes and CD4⁺ T-cell epitopes identified from SARS-CoV-2 proteins, respectively, and display the HLA restriction of these eptiopes and the methods validating the immunogenicity of these peptides. The CD8⁺ T-cell epitopes collected in this review are 8-15 amino acids in length; the CD4⁺ T-cell epitopes are 10-20 amino acids in length. Epitope peptides with the lengths that are too long or too short easily produce false-positive results in validation experiments (Paul et al., 2020), so they are excluded from this review.

Table 1.

List of CD8⁺ T-cell epitopes validated from SARS-CoV-2 antigens.

Sequence	Protein	Start	End	HLA restriction	Methods to validate the epitope peptides	References
AADLDDFSKQL	N	397	407	A*02:01	multimer staining	(Saini et al., 2021)
AEGSRGGSQA	N	173	182	HLA class I	HTMA	(Snyder et al., 2020)
AGLPYGANK	N	119	127	A*30:01	AIM	(Tarke et al., 2021)
ALALLLLDRL	N	218	227	A2	ELISPOT	(Lee et al., 2021)
ALNTPKDHI	N	138	146	A*02:01	ICS	(Szeto et al., 2021)
APRITFGGP	N	12	20	A*02:01/B*07:02	multimer staining	(Weingarten-Gabbay et al., 2021)
APSASAFFGM	N	308	317	B*07:02	AIM/multimer staining	(Saini et al., 2021; Tarke et al., 2021)
AQFAPSASA	N	305	313	B*15:01/A*02:01	ICS	(Wagner et al., 2022; Habel et al., 2020)
AQFAPSASAF	N	305	314	B*15:01/A*24:02	ICS/ELISA/multimer staining	(Saini et al., 2021; Titov et al., 2022; Schulien et al., 2021; Swaminathan et al., 2022)
AQFAPSASAFFGMSR	N	305	319	HLA class I	HTMA	(Snyder et al., 2020)
ASAFFGMSR	N	311	319	A*68:01/A*11:01	AIM/ELISA/cytotoxicity	(Tarke et al., 2021; Ferretti et al., 2020)
ATEGALNTPK	N	134	143	A*11:01	AIM/ELISA/cytotoxicity/ICS/ELISPOT	(Tarke et al., 2021; Wagner et al., 2022; Titov et al., 2022; Swaminathan et al., 2022; Ferretti et al., 2020; Nelde et al., 2021)
ATEGALNTPKDHI	N	134	146	HLA class I	HTMA	(Snyder et al., 2020)
AYKTFPPTEPK	N	359	369	HLA class I	HTMA	(Snyder et al., 2020)
DLSPRWYFYY	N	103	112	A2/A29	ELISPOT	(Schmidt et al., 2021)
DLSPRWYFYYL	N	103	113	A2/A29	ELISPOT	(Schmidt et al., 2021)
DLSPRWYFYYLGTGP	N	103	117	HLA class I	ICS/AIM	(Schmidt et al., 2021)
DYKHWPQIAQF	N	297	307	A*24:02	ELISPOT/ICS	(Nelde et al., 2021)
ELIRQGTDY	N	290	298	A*26:01	AIM	(Tarke et al., 2021)
EVTPSGTWLTY	N	323	333	A*26:01	AIM	(Tarke et al., 2021)
FAPSASAFF	N	307	315	B*35:01	ELISPOT/AIM	(Tarke et al., 2021; Somogyi et al., 2021)
FPRGQGVPI	N	66	74	B*07:02/B*08:01	ICS/AIM/multimer staining/ELISPOT	(Saini et al., 2021; Tarke et al., 2021; Schulien et al., 2021; Swaminathan et al., 2022; Nelde et al., 2021)
FSKQLQQSM	N	403	411	HLA class I	ELISPOT/HTMA	(Snyder et al., 2020; Somogyi et al., 2021)
GMEVTPSGTWLTY	N	321	333	HLA class I	HTMA	(Snyder et al., 2020)
GMEVTPSGTWLTYTG	N	321	335	HLA class I	AIM/ELISPOT	(Zhao et al., 2021)
GMSRIGMEV	N	316	324	A*02:01	ICS/AIM/ELISPOT/multimer staining	(Saini et al., 2021; Tarke et al., 2021; Szeto et al., 2021; Habel et al., 2020; Schulien et al., 2021; Hu et al., 2022)
GMSRIGMEVTPSGTW	N	316	330	HLA class I	HTMA	(Snyder et al., 2020)
GPQNQRNAPRITF	N	5	17	B*07:02	AIM	(Tarke et al., 2021)
GTGPEAGLPY	N	114	123	HLA class I	HTMA	(Snyder et al., 2020)
GTRNPANNA	N	147	155	A*30:01	AIM	(Tarke et al., 2021)
HWPQIAQF	N	300	307	A*24:02	multimer staining	(Saini et al., 2021)
IGYYRRATR	N	84	92	A*33:03	ICS	(Jin et al., 2021)
IIWVATEGA	N	130	138	A*02:01	ICS/AIM	(Lee et al., 2021)
IKLDDKDPNFKDQVI	N	337	351	HLA class I	AIM	(Zhao et al., 2021)
ILLNKHID	N	351	358	A*02:01	ICS	(Szeto et al., 2021)
ILLNKHIDA	N	351	359	A*02:01	HTMA/ICS	(Snyder et al., 2020; Szeto et al., 2021)
KAYNVTQAF	N	266	274	B*35:01/B*57:01/B*51:01	ELISPOT/AIM/ELISA/HTMA	(Snyder et al., 2020; Tarke et al., 2021; Titov et al., 2022; Somogyi et al., 2021)
KFPRGQGVPI	N	65	74	HLA class I	HTMA	(Snyder et al., 2020)
KIFPPTEPK	N	361	369	A*11:01	ELISA	(Hu et al., 2022)
KKQQTVTLL	N	387	395	C*07:01	multimer staining	(Saini et al., 2021)
KLDDKDPNF	N	338	346	A*02:01	ELISPOT/multimer staining	(Hu et al., 2022; Poran et al., 2020)
KMKDLSPRW	N	100	108	B*57:01	AIM/HTMA	(Snyder et al., 2020; Tarke et al., 2021)
KPRQKRTAT	N	257	265	B*07:02/B*08:01	ICS/AIM/ multimer staining	(Saini et al., 2021; Tarke et al., 2021; Schulien et al., 2021; Swaminathan et al., 2022; Panikkar et al., 2022)
KSAAEASKK	N	249	257	A*11:01	AIM	(Tarke et al., 2021)
KTFPPTEPK	N	361	369	A*03:01/A*11:01/A*68:01/A*30:01	ICS/ELISPOT/multimer staining / AIM/ ELISA/cytotoxicity	(Saini et al., 2021; Tarke et al., 2021; Titov et al., 2022; Ferretti et al., 2020; Hu et al., 2022; Kared et al., 2021; Gangaev et al., 2021; Zhang et al., 2022; Peng et al., 2020; Zhang et al., 2022)
KTFPPTEPKK	N	361	370	A*11:01/A*03:01		(Tarke et al., 2021; Wagner et al., 2022; Titov et al., 2022; Nelde et al., 2021)
KTFPPTEPKKDKKK	N	361	374	A*03:01	AIM	(Tarke et al., 2021)
KTLPPTEPK	N	361	369	A*11:01	ELISA	(Hu et al., 2022)
LQLPQGTTL	N	159	167	A*02:01	ICS	(Szeto et al., 2021)
LALLLLDRL	N	219	227	A*02:01/A*02:06	ICS/ELISPOT	(Szeto et al., 2021; Schulien et al., 2021; Hu et al., 2022; Jin et al., 2021)
LLLDRLNQL	N	222	230	A*02:01	ELISA/multimer staining/cytotoxicity/AIM/ICS/ELISPOT/proliferation	(Saini et al., 2021; Tarke et al., 2021; Szeto et al., 2021; Wagner et al., 2022; Titov et al., 2022; Schulien et al., 2021; Ferretti et al., 2020; Hu et al., 2022; Jin et al., 2021; Poran et al., 2020; Kared et al., 2021; Sekine et al., 2020; Quiros-Fernandez et al., 2021)
LLLLDRLNQL	N	221	230	A*02:01	ELISA/multimer staining/ELISPOT/ICS	(Saini et al., 2021; Titov et al., 2022; Nelde et al., 2021)
LLNKHIDAY	N	352	360	B*15:01	multimer staining	(Saini et al., 2021)
LPAADLDDF	N	395	403	B*35:01	AIM/ELISA/HTMA	(Snyder et al., 2020; Tarke et al., 2021; Titov et al., 2022)
LPNNTASWF	N	45	53	B*07:02	AIM/HTMA	(Snyder et al., 2020; Tarke et al., 2021)
LPYGANKDGI	N	121	130	B*51:01	AIM	(Tarke et al., 2021)
LSPRWYFYY	N	104	112	A*24:02	ICS	(Wagner et al., 2022)
LSPRWYFYYL	N	104	113	A*24:02	HTMA/ICS	(Snyder et al., 2020; Jin et al., 2021)
MEVTPSGTW	N	322	330	B*44:03	ICS/multimer staining/AIM/ELISA	(Titov et al., 2022; Schulien et al., 2021)
MEVTPSGTWL	N	322	331	B*40:01/B*40:10/B*44:10	multimer staining/ELISPOT/ICS/AIM/ELISA	(Tarke et al., 2021; Wagner et al., 2022; Titov et al., 2022; Schulien et al., 2021; Swaminathan et al., 2022; Nelde et al., 2021; Panikkar et al., 2022; Peng et al., 2020; Agerer et al., 2021)
MKDLSPRWY	N	101	109	C*07:01	multimer staining	(Saini et al., 2021)
MSDNGPQNQ	N	1	9	A*02:01	multimer staining	(Xiao et al., 2022)
MSRIGMEVTPSGTWL	N	317	331	HLA class I	ELISPOT	(Keller et al., 2020)
NQLESKMFG	N	228	236	A*02:01	multimer staining	(Xiao et al., 2022)
NPANNAAIVL	N	150	159	B*07:02	AIM/ELISPOT	(Tarke et al., 2021; Nelde et al., 2021)
NSSPDDQIGYY	N	77	87	A*01:01	multimer staining	(Nagler et al., 2021)
NTASWFTAL	N	48	56	A*02:06/A*02:01	ELISPOT/proliferation/ICS	(Habel et al., 2020; Somogyi et al., 2021; Jin et al., 2021)
NTNSSPDDQIGYY	N	75	87	A*01:01	AIM/HTMA/multimer staining	(Snyder et al., 2020; Tarke et al., 2021; Minervina et al., 2022)
NTPKDHIGTR	N	140	149	A*33:03	ICS	(Jin et al., 2021)
NVTQAFGRR	N	269	277	A*33:03	ICS	(Jin et al., 2021)
QLQQSMSSA	N	406	414	A*02:03	ICS	(Jin et al., 2021)
QELIRQGTDY	N	289	298	B*44:02	AIM/multimer staining	(Tarke et al., 2021; Minervina et al., 2022)
QELIRQGTDYKHW	N	289	301	HLA class I	HTMA	(Snyder et al., 2020)
QFAPSASAFF	N	306	315	A*24:02	AIM	(Tarke et al., 2021)
QGLPNNTASW	N	43	52	B*57:01	AIM	(Tarke et al., 2021)
QQQGQTVTK	N	240	248	A*11:01	ELISA/proliferation	(Titov et al., 2022; Jin et al., 2021)
QQQQGQTVTK	N	239	248	HLA class I	HTMA	(Snyder et al., 2020)
QRNAPRITF	N	9	17	B*27:05/C*07:02/C*07:01	multimer staining /ICS/ELISPOT	(Saini et al., 2021; Wagner et al., 2022; Swaminathan et al., 2022; Nelde et al., 2021; Peng et al., 2020)
QTVTLLPAA	N	390	398	A*02:06	proliferation	(Jin et al., 2021)
QVILLNKHIDAYKTF	N	349	363	HLA class I	AIM	(Zhao et al., 2021)
RIRGGDGKM	N	93	101	B*07:02	ICS/AIM	(Swaminathan et al., 2022; Panikkar et al., 2022)
RIRGGDGKMK	N	93	102	HLA class I	HTMA	(Snyder et al., 2020)
RLNQLESKM	N	226	234	A*02:01	ICS	(Szeto et al., 2021)
RNPANNAAIVL	N	149	159	HLA class I	HTMA	(Snyder et al., 2020)
RPQGLPNNTA	N	41	50	B*07:02	AIM	(Tarke et al., 2021)
RRGPEQTQGNF	N	276	286	C*07:01	multimer staining	(Saini et al., 2021)
RTATKAYNV	N	262	270	A*02:01	ICS/AIM	(Lee et al., 2021)
SASAFFGMSR	N	310	319	A*68:01	AIM	(Tarke et al., 2021)
SPDDQIGYY	N	79	87	B*35:01	AIM	(Tarke et al., 2021)
SPRWYFYYL	N	29	37	B*07:02/B*08:01/B*35	ICS/multimer staining/AIM/ELISA/ELISPOT/cytotoxicity	(Saini et al., 2021; Tarke et al., 2021; Weingarten-Gabbay et al., 2021; Wagner et al., 2022; Titov et al., 2022; Schulien et al., 2021; Swaminathan et al., 2022; Ferretti et al., 2020; Schmidt et al., 2021; Panikkar et al., 2022; Kared et al., 2021; Peng et al., 2020; Sekine et al., 2020; Lineburg et al., 2021)
SQASSRSSSR	N	180	189	HLA class I	HTMA	(Snyder et al., 2020)
SSPDDQIGYY	N	78	87	C*04:01/B*35:01/B*35:02	ELISA	(Titov et al., 2022)
SSPDDQIGYYR	N	78	88	A*01:01	multimer staining	(Saini et al., 2021)
SSRGTSPAR	N	201	209	HLA class I	HTMA	(Snyder et al., 2020)
TPSGTWLTY	N	325	333	B*35:01	AIM	(Tarke et al., 2021; Panikkar et al., 2022)
TPSGTWLTYTGAIKL	N	325	339	HLA class I	ELISPOT	(Zhao et al., 2021)
TPSGTWLTYTY	N			B*35:01	ICS	(Swaminathan et al., 2022)
VLQLPQGTTL	N	158	167	A*02:01	multimer staining	(Saini et al., 2021)
VTPSGTWLTY	N	324	333	A*30:02	AIM	(Tarke et al., 2021)
WLTYTGAIKL	N	330	339	A*02:01	ICS	(Jin et al., 2021)
YKTFPPTEPK	N	360	369	A*68:01/A*11:01	AIM/ICS	(Tarke et al., 2021; Jin et al., 2021)
YLGTGPEAGL	N	112	121	A*02:01	ICS/AIM/multimer staining	(Poran et al., 2020; Quiros-Fernandez et al., 2021)
YYRRATRRIR	N	86	95	HLA class I	HTMA	(Snyder et al., 2020)
FLAFVVFL	E	20	27	A*02:01	multimer staining	(Poran et al., 2020)
FLAFVVFLL	E	20	28	A*02:01/A*02:07	ELISPOT/proliferation/ICS	(Jin et al., 2021; Prakash et al., 2021)
FLAFVVFLLV	E	20	29	A*02:03	ICS	(Jin et al., 2021)
FLLVTLAIL	E	26	34	A*02:01/A*02:07	ELISPOT/multimer staining/ICS	(Jin et al., 2021; Prakash et al., 2021; Deng et al., 2021)
FYVYSRVKNL	E	56	65	A*24:02	ELISPOT	(Nelde et al., 2021)
IVNSVLLFL	E	13	21	A*30:01	proliferation/ICS	(Jin et al., 2021)
LFLAFVVFLL	E	19	28	A*02:07	ICS	(Jin et al., 2021)
LIVNSVLLFL	E	12	21	A*02:06	ICS	(Jin et al., 2021)
LVKPSFYVY	E	51	59	C*07:02	multimer staining	(Saini et al., 2021)
NIVNVSLVK	E	45	53	A*11:01	proliferation/ICS	(Jin et al., 2021)
RLCAYCCNIV	E	38	47	A*02:01	ICS	(Jin et al., 2021)
RVKNLNSSR	E	61	69	A*30:01	ICS	(Jin et al., 2021)
SEETGTLIV	E	6	14	HLA class I	HTMA	(Snyder et al., 2020)
SLVKPSFYV	E	50	58	HLA class I	HTMA	(Snyder et al., 2020)
SSRVPDLLV	E	67	75	A*30:01	proliferation	(Jin et al., 2021)
SVLLFLAFV	E	16	24	A*02:07	multimer staining/ICS	(Jin et al., 2021; Deng et al., 2021)
TLAILTALR	E	30	38	A*33:03	proliferation	(Jin et al., 2021)
TLIVNSVLLF	E	11	20	A*24:02	ICS	(Jin et al., 2021)
VFLLVTLAI	E	25	33	A*24:02	ICS	(Jin et al., 2021)
VLLFLAFVV	E	17	25	A*02:01	ICS	(Jin et al., 2021)
VLLFLAFVVF	E	17	26	A*24:02	ICS	(Jin et al., 2021)
VNSVLLFLAF	E	14	23	A*24:02	ICS	(Jin et al., 2021)
VSLVKPSFY	E	49	57	A*11:02	ICS/proliferation	(Jin et al., 2021)
YVYSRVKN	E	57	64	HLA class I	ELISPOT	(Somogyi et al., 2021)
YVYSRVKNL	E	57	65	C*06:02	HTMA/multimer staining	(Saini et al., 2021; Snyder et al., 2020)
ANVYLKHGGGVAGAL	pp1a	243	257	HLA class I	ICS/AIM/intracellular staining	(Eggenhuizen et al., 2021)
LKHGGGVAGALNKAT	pp1a	247	261	HLA class I	ICS/AIM	(Eggenhuizen et al., 2021)
YLKHGGGVAGALNKA	pp1a	246	260	HLA class I	ICS/AIM/AIM	(Eggenhuizen et al., 2021)
AAISDYDYY	pp1ab	4840	4848	A*01:01	multimer staining	(Saini et al., 2021)
AAISDYDYYR	pp1ab	4840	4849	A*68:01	AIM	(Tarke et al., 2021)
AANFCALILA	pp1ab	1707	1716	A*02:01	multimer staining	(Xiao et al., 2022)
ADNFCALILA	pp1ab	1707	1716	A*02:01	multimer staining	(Xiao et al., 2022)
AEAELAKNV	pp1ab	2616	2624	B*44:02/B*44:03	AIM	(Tarke et al., 2021)
AELAKNVSL	pp1ab	2618	2626	B*44:02	AIM	(Tarke et al., 2021)
AELAKNVSLDNVL	pp1ab	2618	2630	HLA class I	HTMA	(Snyder et al., 2020)
AESHVDTDLTKPY	pp1ab	4645	4657	B*44:02	AIM	(Tarke et al., 2021)
AEVAVKMF	pp1ab	2584	2591	B*44:02	AIM	(Tarke et al., 2021)
AEWFLAYIL	pp1ab	2325	2333	B*40:01/B*44:02	ICS/AIM	(Tarke et al., 2021; Schulien et al., 2021)
AEWFLAYILF	pp1ab	2325	2334	B*44:02	AIM	(Tarke et al., 2021)
AGFSLWVYK	pp1ab	6429	6437	A*11:01	multimer staining	(Kared et al., 2021)
AHAEETRKL	pp1ab	1380	1388	C*06:02	multimer staining	(Saini et al., 2021)
AMRNAGIVGV	pp1ab	4587	4596	A*02:01	ICS	(Jin et al., 2021)
AMYTPHTVL	pp1ab	5315	5323	A*32:01	AIM	(Tarke et al., 2021)
APHGHVMVEL	pp1ab	79	88	B*07:02/A*02:01	multimer staining	(Saini et al., 2021; Weingarten-Gabbay et al., 2021)
AIILASFSAST	pp1ab	474	484	HLA class I	HTMA	(Snyder et al., 2020)
AIMTRCLAV	pp1ab	6199	6207	HLA class I	HTMA	(Snyder et al., 2020)
AISDYDYYR	pp1ab	4841	4849	A*11:01	AIM/proliferation	(Tarke et al., 2021; Jin et al., 2021)
AIVSTIQRK	pp1ab	1397	1405	A*03:01	AIM	(Tarke et al., 2021)
AIVSTIQRKYK	pp1ab	1397	1407	A*03:01	multimer staining	(Saini et al., 2021)
AKSHNIALIW	pp1ab	2704	2713	B*57:01	AIM	(Tarke et al., 2021)
ALLADKFPV	pp1ab	6245	6253	A*02:01	HTMA/multimer staining	(Saini et al., 2021; Snyder et al., 2020)
ALRANSAVK	pp1ab	4130	4138	HLA class I	HTMA	(Snyder et al., 2020)
ALRKVPTDNY	pp1ab	1316	1325	B*15:01	multimer staining	(Saini et al., 2021)
ALRKVPTDNYITTY	pp1ab	1316	1329	HLA class I	HTMA	(Snyder et al., 2020)
ALWEIQQV	pp1ab	4094	4101	A*02:01	multimer staining	(Saini et al., 2021)
ALWEIQQVV	pp1ab	4094	4102	A*02:01	ELISA/HTMA/multimer staining/cytotoxicity	(Saini et al., 2021; Snyder et al., 2020; Titov et al., 2022; Ferretti et al., 2020; Kared et al., 2021)
APKEIIFL	pp1ab	735	742	B*07:02	multimer staining	(Saini et al., 2021)
APKEIIFLEGETL	pp1ab	735	747	HLA class I	HTMA	(Snyder et al., 2020)
APTLVPQEHYV	pp1ab	5561	5571	A*02:01	multimer staining	(Saini et al., 2021)
APYIVGDVV	pp1ab	1283	1291	B*51:01	AIM	(Tarke et al., 2021)
ARAGEAANF	pp1ab	1702	1710	C*07:01	multimer staining	(Saini et al., 2021)
ARLYYDSMSY	pp1ab	4904	4913	C*07:02	multimer staining	(Saini et al., 2021)
ASFDNFKFV	pp1ab	1923	1931	A*02:06/C*06:02	AIM/multimer staining	(Saini et al., 2021; Tarke et al., 2021)
ASFNYLKSPNFSK	pp1ab	2213	2225	HLA class I	HTMA	(Snyder et al., 2020)
ASGNLLLDK	pp1ab	4775	4783	A*11:01	proliferation	(Jin et al., 2021)
ASMPTTIAK	pp1ab	2192	2200	A*11:01/A*30:01/A*03:01	ICS/AIM/ELISA/ELISPOT	(Tarke et al., 2021; Wagner et al., 2022; Titov et al., 2022; Schulien et al., 2021; Nelde et al., 2021)
ATVVIGTSK	pp1ab	4977	4985	A*11:01	AIM/HTMA	(Snyder et al., 2020; Tarke et al., 2021)
AVAKHDFFK	pp1ab	4487	4495	A*11:01	proliferation	(Jin et al., 2021)
AVASKILGL	pp1ab	5844	5852	A*02:01	multimer staining	(Saini et al., 2021)
AVFDKNLYDK	pp1ab	1176	1185	A*11:01/A*03:01	multimer staining	(Kared et al., 2021)
AVHFISNSW	pp1ab	2355	2363	B*57:01	AIM	(Tarke et al., 2021)
AVLQSGFRK	pp1ab	3260	3268	HLA class I	HTMA	(Snyder et al., 2020)
AWPLIVTAL	pp1ab	4123	4131	A*24:02	multimer staining	(Saini et al., 2021)
AYILFTRF	pp1ab	2330	2337	A*24:02	AIM	(Tarke et al., 2021)
AYILFTRFF	pp1ab	2330	2338	A*24:02	multimer staining	(Saini et al., 2021)
AYILFTRFFYV	pp1ab	2330	2340	HLA class I	HTMA	(Snyder et al., 2020)
ASRELKVTF	pp1ab	1951	1959	A*30:01/B*57:01	AIM	(Tarke et al., 2021)
AYVDNSSLTI	pp1ab	2098	2107	A*24:02	AIM	(Tarke et al., 2021)
AYVNTFSSTF	pp1ab	2593	2602	A*24:02	AIM	(Tarke et al., 2021)
CATVHTANKW	pp1ab	6913	6922	B*57:01	AIM	(Tarke et al., 2021)
CLEASFNYL	pp1ab	2210	2218	A*02:01	ELISPOT	(Prakash et al., 2021)
CSLSHRFYR	pp1ab	5038	5046	A*11:01	proliferation	(Jin et al., 2021)
CSQHTMLVK	pp1ab	5205	5213	A*11:01	proliferation	(Jin et al., 2021)
CTDDNALAY	pp1ab	4163	4171	A*01:01	ICS	(Schulien et al., 2021)
CTDDNALAYY	pp1ab	4163	4172	A*01:01	ICS/multimer staining /AIM/ELISA/cytotoxicity	(Saini et al., 2021; Titov et al., 2022; Schulien et al., 2021; Ferretti et al., 2020; Gangaev et al., 2021)
CTEIDPKLDNY	pp1ab	1889	1899	A*01:01	multimer staining	(Saini et al., 2021)
DAMRNAGIV	pp1ab	4586	4594	B*51:01	AIM	(Tarke et al., 2021)
DASGKPVPY	pp1ab	2924	2932	B*35:01	AIM	(Tarke et al., 2021)
DAVNLLTNM	pp1ab	3022	3030	B*51:01	AIM	(Tarke et al., 2021)
DDYQGKPLEF	pp1ab	953	962	A*24:02	multimer staining	(Saini et al., 2021)
DFYDFAVSKGFFK	pp1ab	4810	4822	A*33:01	AIM	(Tarke et al., 2021)
DGTLMIERFVSLAID	pp1ab	5243	5257	HLA class I	ELISPOT	(Swadling et al., 2022)
DLKGKYVQI	pp1ab	4344	4352	B*08:01	ICS/ELISPOT	(Nelde et al., 2021)
DSAEVAVKM	pp1ab	2582	2590	A*26:01	AIM	(Tarke et al., 2021)
DSCNNYMLTY	pp1ab	2668	2677	A*01:01	multimer staining	(Saini et al., 2021)
DTDFVNEFY	pp1ab	5130	5138	A*01:01	ICS/ multimer staining /ELISA/cytotoxicity	(Wagner et al., 2022; Titov et al., 2022; Schulien et al., 2021; Swaminathan et al., 2022; Ferretti et al., 2020; Kared et al., 2021; Gangaev et al., 2021; Minervina et al., 2022)
DTFCAGSTF	pp1ab	2456	2464	A*26:01	AIM	(Tarke et al., 2021)
DTIANYAKPF	pp1ab	2136	2145	A*26:01	AIM	(Tarke et al., 2021)
DTVIEVQGYK	pp1ab	828	837	A*68:01	AIM	(Tarke et al., 2021)
DVDTDFVNEFYAYLR	pp1ab	5128	5142	HLA class I	ELISPOT	(Swadling et al., 2022)
DVFYKENSY	pp1ab	1865	1873	A*26:01	AIM	(Tarke et al., 2021)
DVLLPLTQY	pp1ab	3196	3204	B*35:01	AIM	(Tarke et al., 2021)
DVVAIDYKHY	pp1ab	1966	1975	A*26:01	AIM	(Tarke et al., 2021)
DYKHYTPSF	pp1ab	1971	1979	A*24:02	AIM/multimer staining	(Saini et al., 2021; Tarke et al., 2021)
DYVYLPYPDPSRI	pp1ab	5217	5229	B*51:01	AIM	(Tarke et al., 2021)
EAFEKMVSL	pp1ab	3906	3914	B*08:01	ELISPOT	(Nelde et al., 2021)
EAKKVKPTV	pp1ab	1048	1056	B*51:01	AIM	(Tarke et al., 2021)
EEAIRHVRAW	pp1ab	6002	6011	B*44:03	ICS	(Schulien et al., 2021)
EEFEPSTQYEY	pp1ab	939	949	A*02:01/B*07:02	multimer staining	(Weingarten-Gabbay et al., 2021)
EEIAIILASF	pp1ab	471	480	B*44:03	ICS	(Schulien et al., 2021)
EESSAKSASVY	pp1ab	2550	2560	B*44:02	AIM	(Tarke et al., 2021)
EEVGHTDLMAAY	pp1ab	2088	2099	B*44:03	AIM	(Tarke et al., 2021)
EEVVENPTI	pp1ab	2049	2057	B*44:03	AIM	(Tarke et al., 2021)
EGYLNSTNV	pp1ab	2268	2276	B*51:01	AIM	(Tarke et al., 2021)
EIDPKLDNY	pp1ab	1891	1899	A*26:01/A*01:01	AIM	(Tarke et al., 2021)
EIKESVQTF	pp1ab	670	678	A*02:01/B*07:02/B*15:01	multimer staining	(Saini et al., 2021; Weingarten-Gabbay et al., 2021)
ELDERIDKV	pp1ab	844	852	A*02:01	multimer staining	(Saini et al., 2021)
ELKHFFFAQDGNAAI	pp1ab	4828	4842	A*24:02	ELISPOT	(Swadling et al., 2022)
ERHSLSHFV	pp1ab	2514	2522	C*06:02	multimer staining	(Saini et al., 2021)
ESKPSVEQR	pp1ab	1217	1225	A*68:01	AIM	(Tarke et al., 2021)
ETIQITISSF	pp1ab	2305	2314	A*26:01	AIM	(Tarke et al., 2021)
EVARDLSLQF	pp1ab	2468	2477	A*26:01	AIM	(Tarke et al., 2021)
EVAVKMFDAY	pp1ab	2585	2594	A*26:01	AIM	(Tarke et al., 2021)
EVGHTDLMAAY	pp1ab	2089	2099	A*26:01	AIM	(Tarke et al., 2021)
EVKPFITESK	pp1ab	1210	1219	A*68:01	AIM	(Tarke et al., 2021)
EVTGDSCNNYMLTY	pp1ab	2664	2677	A*26:01	AIM	(Tarke et al., 2021)
FADDLNQLTGY	pp1ab	1937	1947	A*01:01	AIM/HTMA	(Snyder et al., 2020; Tarke et al., 2021)
FAIGLALYY	pp1ab	5615	5623	C*07:02	multimer staining	(Saini et al., 2021)
FASEAARVV	pp1ab	536	544	A*02:01/B*07:02	multimer staining	(Weingarten-Gabbay et al., 2021)
FAVDAAKAY	pp1ab	4272	4280	A*02:01/B*07:02	multimer staining	(Weingarten-Gabbay et al., 2021)
FAVSKGFFK	pp1ab	4814	4822	A*11:01	AIM	(Tarke et al., 2021)
FAYTKRNVI	pp1ab	4920	4928	B*51:01	AIM	(Tarke et al., 2021)
FDIYNDKVAGF	pp1ab	4427	4437	A*24:02	multimer staining	(Saini et al., 2021)
FELDERIDKV	pp1ab	843	852	A*02:01	AIM	(Tarke et al., 2021)
FELDERIDKVL	pp1ab	843	853	B*40:01	AIM	(Tarke et al., 2021)
FEPSTQYEY	pp1ab	941	949	B*44:02	AIM	(Tarke et al., 2021)
FEYYHTTDPSF	pp1ab	1632	1642	A*24:02	multimer staining	(Saini et al., 2021)
FGDDTVIEV	pp1ab	825	833	A*02:01/B*07:02	multimer staining	(Saini et al., 2021; Weingarten-Gabbay et al., 2021; Poran et al., 2020)
FGEYSHVVAF	pp1ab	3071	3080	B*40:01	AIM	(Tarke et al., 2021)
FIERYKLEGY	pp1ab	6673	6682	A*01:01	multimer staining	(Saini et al., 2021)
FIPMDSTVKNY	pp1ab	6720	6730	A*01:01	multimer staining	(Saini et al., 2021)
FLAHIQWMV	pp1ab	3122	3130	A*02:06/A*02:01	AIM/multimer staining	(Saini et al., 2021; Tarke et al., 2021)
FLARGIVFM	pp1ab	3753	3761	A*02:01	multimer staining	(Saini et al., 2021)
FLCLFLLPSLATV	pp1ab	3635	3647	HLA class I	HTMA	(Snyder et al., 2020)
FLGRYMSAL	pp1ab	1642	1650	HLA class I	HTMA	(Snyder et al., 2020)
FLIGCNYL	pp1ab	7003	7010	A*02:01	ICS/AIM/multimer staining	(Quiros-Fernandez et al., 2021)
FLLNKEMYL	pp1ab	3183	3191	A*02:01/C*12:03	ELISPOT/ELISA/HTMA/multimer staining/ICS	(Snyder et al., 2020; Habel et al., 2020; Titov et al., 2022; Prakash et al., 2021)
FLLPSLATV	pp1ab	3639	3647	A*02:01/C*07:01	ICS/multimer staining	(Schulien et al., 2021; Poran et al., 2020; Nagler et al., 2021)
FLLPSLATVA	pp1ab	3639	3648	A*02:01	multimer staining	(Saini et al., 2021)
FLNGSCGSV	pp1ab	3403	3411	HLA class I	HTMA	(Snyder et al., 2020)
FLNRFTTTL	pp1ab	3482	3490	HLA class I	HTMA	(Snyder et al., 2020)
FLPGVYSV	pp1ab	3100	3107	A*02:01	AIM	(Tarke et al., 2021)
FLPRVFSAV	pp1ab	2884	2892	A*02:01	AIM/HTMA/multimer staining	(Saini et al., 2021; Snyder et al., 2020; Tarke et al., 2021)
FLTENLLLYI	pp1ab	1248	1257	A*02:01	multimer staining	(Saini et al., 2021)
FLYENAFLP	pp1ab	3605	3613	A*02:01	AIM	(Tarke et al., 2021)
FLYENAFLPFA	pp1ab	3605	3615	A*02:01	multimer staining	(Saini et al., 2021)
FNKWGKARLYYDSMS	pp1ab	4898	4912	HLA class I	ELISPOT	(Swadling et al., 2022)
FPLKLRGTA	pp1ab	7048	7056	B*07:02	AIM	(Tarke et al., 2021)
FPLKLRGTAV	pp1ab	7048	7057	B*08:01	multimer staining	(Saini et al., 2021)
FPPTSFGPL	pp1ab	4713	4721	HLA class I	HTMA	(Snyder et al., 2020)
FRYMNSQGL	pp1ab	3820	3828	HLA class I	ELISA/HTMA	(Snyder et al., 2020; Titov et al., 2022)
FSAVGNICY	pp1ab	2889	2897	A*01:01	multimer staining	(Saini et al., 2021)
FTCASEYTGNY	pp1ab	1821	1831	A*01:01	multimer staining	(Saini et al., 2021)
FTDGVCLFW	pp1ab	6302	6310	A*01:01	multimer staining	(Saini et al., 2021)
FTEQPIDLVPNQPY	pp1ab	1907	1920	HLA class I	HTMA	(Snyder et al., 2020)
FTSLEIPRRNVATLQ	pp1ab	5911	5925	HLA class I	ELISPOT	(Swadling et al., 2022)
FTYASALWEI	pp1ab	4089	4098	HLA class I	HTMA	(Snyder et al., 2020)
FVDGVPFVV	pp1ab	4726	4734	A*02:07/A*02:01	ICS/HTMA/multimer staining	(Saini et al., 2021; Snyder et al., 2020; Swaminathan et al., 2022)
FVENPDILRV	pp1ab	4557	4566	A*02:06	AIM	(Tarke et al., 2021)
FVKHKHAFL	pp1ab	3628	3636	B*08:01	ICS/ELISPOT	(Wagner et al., 2022; Nelde et al., 2021)
FVNEFYAYL	pp1ab	5133	5141	A*02:01	multimer staining/ICS	(Saini et al., 2021; Jin et al., 2021)
FVNEFYAYLR	pp1ab	5133	5142	A*33:01	AIM	(Tarke et al., 2021)
FVVEVVDKY	pp1ab	4863	4871	B*15:01	multimer staining	(Saini et al., 2021)
FVVPGLPGT	pp1ab	2864	2872	A*02:06	AIM	(Tarke et al., 2021)
FVVSTGYHFR	pp1ab	4732	4741	A*68:01	AIM	(Tarke et al., 2021)
FWRNTNPIQL	pp1ab	7028	7037	C*07:01	multimer staining	(Saini et al., 2021)
FYAYLRKHF	pp1ab	5137	5145	A*24:02	ICS/multimer staining	(Saini et al., 2021)
FYLITPVHV	pp1ab	2787	2795	C*07:02	multimer staining	(Saini et al., 2021)
FYYVWKSY	pp1ab	2390	2397	C*07:02	multimer staining	(Saini et al., 2021)
FYYVWKSYV	pp1ab	2390	2398	C*06:02/C*07:02	multimer staining	(Saini et al., 2021)
GADPIHSLR	pp1ab	1155	1163	A*68:01	AIM	(Tarke et al., 2021)
GAMDTTSYR	pp1ab	3219	3227	A*31:01	AIM	(Tarke et al., 2021)
GEAANFCAL	pp1ab	1705	1713	B*40:01	ICS	(Schulien et al., 2021)
GELGDVRETMSYLF	pp1ab	1723	1736	B*44:02	AIM	(Tarke et al., 2021)
GETLPTEVL	pp1ab	744	752	B*40:01	ICS	(Schulien et al., 2021)
GEVITFDNL	pp1ab	1548	1556	B*40:01	ICS	(Schulien et al., 2021)
GFMGRIRSV	pp1ab	295	303	C*06:02	multimer staining	(Saini et al., 2021)
GLLPPKNSI	pp1ab	3827	3835	A*02:01	multimer staining	(Saini et al., 2021)
GNAAISDYDYYRYNl	pp1ab	4838	4852	B*35:01	ELISPOT	(Swadling et al., 2022)
GPKVKYLYF	pp1ab	4222	4230	B*08:01	multimer staining	(Saini et al., 2021)
GPPGTGKSHFAIGLA	pp1ab	282	296	HLA class I	ICS/AIM	(Eggenhuizen et al., 2021)
GRVDGQVDL	pp1ab	6577	6585	C*07:01	multimer staining	(Saini et al., 2021)
GSVAYESLR	pp1ab	2941	2949	A*31:01	AIM	(Tarke et al., 2021)
GTDLEGNFY	pp1ab	3437	3445	A*01:01	ELISA/ICS/cytotoxicity/multimer staining	(Wagner et al., 2022; Titov et al., 2022; Ferretti et al., 2020; Kared et al., 2021)
GTSTDVVYR	pp1ab	4417	4425	A*11:01	proliferation	(Jin et al., 2021)
GVAMPNLYK	pp1ab	6806	6814	HLA class I	HTMA	(Snyder et al., 2020)
GVAPGTAVLRQW	pp1ab	6875	6886	B*57:01	AIM	(Tarke et al., 2021)
GVYDYLVST	pp1ab	3809	3817	A*02:01	multimer staining	(Saini et al., 2021)
HFISNSWLMW	pp1ab	2357	2366	A*24:02	multimer staining	(Saini et al., 2021)
HLDGEVITF	pp1ab	1545	1553	C*07:02	multimer staining	(Saini et al., 2021)
HLKDGTCGL	pp1ab	45	53	B*08:01	multimer staining	(Saini et al., 2021)
HNDILLAKDTTEAFE	pp1ab	3895	3909	B*35:03	ICS	(Le Bert et al., 2020)
HSIGFDYVY	pp1ab	6154	6162	B*35:01	ICS	(Wagner et al., 2022)
HTDFSSEIIGY	pp1ab	2799	2809	HLA class I	HTMA	(Snyder et al., 2020)
HTQVVDMSMTY	pp1ab	1580	1590	A*01:01	multimer staining	(Saini et al., 2021)
HTTDPSFLGR	pp1ab	1636	1645	A*68:01	AIM	(Tarke et al., 2021)
HTTDPSFLGRY	pp1ab	1636	1646	A*01:01	AIM/ELISA/HTMA/multimer staining	(Saini et al., 2021; Snyder et al., 2020; Tarke et al., 2021; Titov et al., 2022; Kared et al., 2021)
HVDTDLTKPY	pp1ab	4648	4657	A*01:01	multimer staining	(Saini et al., 2021)
HVGEIPVAY	pp1ab	110	118	B*15:01	multimer staining	(Saini et al., 2021)
IAATRGATV	pp1ab	4971	4979	B*51:01	AIM	(Tarke et al., 2021)
IAAVITREV	pp1ab	2854	2862	B*51:01	AIM	(Tarke et al., 2021)
IEVNSFSGY	pp1ab	1023	1031	B*44:02	AIM	(Tarke et al., 2021)
IEYPIIGDEL	pp1ab	6219	6228	B*40:01	ELISPOT	(Nelde et al., 2021)
IFFITGNTL	pp1ab	3768	3776	A*24:02	multimer staining	(Saini et al., 2021)
IIWFLLLSV	pp1ab	2230	2238	A*02:01	multimer staining	(Xiao et al., 2022)
ILFTRFFYV	pp1ab	2332	2340	A*02:01	ICS/AIM	(Tarke et al., 2021; Habel et al., 2020; Schulien et al., 2021)
ILGLPTQTV	pp1ab	5849	5857	A*02:01	HTMA/multimer staining	(Saini et al., 2021; Snyder et al., 2020)
ILHCANFNV	pp1ab	4699	4707	A*02:01	HTMA/ICS	(Snyder et al., 2020; Jin et al., 2021)
ILMTARTVY	pp1ab	3693	3701	B*15:01	multimer staining	(Gangaev et al., 2021)
ILSPLYAFA	pp1ab	529	537	A*02:01	multimer staining	(Saini et al., 2021)
ILTSLLVLV	pp1ab	3587	3595	A*02:01	multimer staining	(Saini et al., 2021)
IMASLVLAR	pp1ab	5024	5032	A*33:01	AIM	(Tarke et al., 2021)
IPARARVEC	pp1ab	5658	5666	B*07:02	multimer staining	(Saini et al., 2021)
IPARARVECF	pp1ab	5658	5667	B*07:02	multimer staining	(Saini et al., 2021)
IPRRNVATL	pp1ab	5916	5924	B*08:01/B*07:02	ICS/multimer staining/HTMA/ELISA/cytotoxicity	(Saini et al., 2021; Snyder et al., 2020; Schulien et al., 2021; Ferretti et al., 2020; Kared et al., 2021; Gangaev et al., 2021)
IPTITQMNL	pp1ab	4928	4936	B*07:02	multimer staining	(Saini et al., 2021)
IPVAYRKVLL	pp1ab	114	123	B*07:02	multimer staining	(Saini et al., 2021)
IQITISSFK	pp1ab	2307	2315	A*03:01	multimer staining	(Saini et al., 2021)
IQPGQTFSV	pp1ab	3369	3377	HLA class I	HTMA	(Snyder et al., 2020)
ISLAGSYKDW	pp1ab	1505	1514	B*57:01	AIM	(Tarke et al., 2021)
ISTKHFYW	pp1ab	3148	3155	B*57:01	AIM	(Tarke et al., 2021)
ITDVFYKENSY	pp1ab	1863	1873	A*01:01	AIM/multimer staining	(Saini et al., 2021; Tarke et al., 2021)
ITEEVGHTDLMAAY	pp1ab	2086	2099	A*01:01	AIM/HTMA	(Snyder et al., 2020; Tarke et al., 2021)
ITFDNLKTL	pp1ab	1551	1559	B*57:01	AIM	(Tarke et al., 2021)
IVAGGIVAI	pp1ab	3047	3055	A*02:01	multimer staining	(Saini et al., 2021)
IVDTVSALV	pp1ab	5772	5780	HLA class I	HTMA	(Snyder et al., 2020)
IVDTVSALVY	pp1ab	5772	5781	A*01:01	multimer staining/ cytotoxicity/ICS/AIM	(Pan et al., 2021)
ISDYDYYRY	pp1ab	4842	4850	HLA class I	HTMA	(Snyder et al., 2020)
ITILDGISQY	pp1ab	567	576	B*15:01	multimer staining	(Saini et al., 2021)
IYLYLTFYL	pp1ab	3108	3116	A*24:02	AIM	(Tarke et al., 2021)
KASMPTTIA	pp1ab	2191	2199	A*30:01	AIM	(Tarke et al., 2021)
KENSYTTTIKPVTY	pp1ab	1869	1882	B*44:02	AIM	(Tarke et al., 2021)
KFADDLNQL	pp1ab	1936	1944	C*07:02	multimer staining	(Saini et al., 2021)
KFCLEASFNY	pp1ab	2208	2217	A*29:02	AIM	(Tarke et al., 2021)
KIAEIPKEEV	pp1ab	1202	1211	A*02:01	multimer staining	(Saini et al., 2021)
KIEELFYSY	pp1ab	6287	6295	B*15:01	multimer staining	(Saini et al., 2021)
KIFVDGVPFV	pp1ab	4724	4733	A*02:01	multimer staining/ICS	(Saini et al., 2021; Jin et al., 2021)
KLFAAETLK	pp1ab	5455	5463	A*03:01	HTMA/multimer staining/cytotoxicity/AIM/ICS/ELISPOT	(Snyder et al., 2020; Nelde et al., 2021; Pan et al., 2021)
KLFDRYFKY	pp1ab	4673	4681	A*03:01/A*11:01	multimer staining/ICS	(Saini et al., 2021; Wagner et al., 2022; Kared et al., 2021)
KLINIIIWF	pp1ab	2225	2233	A*32:01	AIM	(Tarke et al., 2021)
KLINITIWFL	pp1ab	2225	2234	A*02:01	multimer staining	(Xiao et al., 2022)
KLKDCVMYA	pp1ab	3678	3686	A*02:01	multimer staining	(Saini et al., 2021)
KLLHKPIVWHV	pp1ab	1984	1994	A*02:01	multimer staining	(Saini et al., 2021)
KLMGHFAWW	pp1ab	6980	6988	A*32:01	AIM	(Tarke et al., 2021)
KLMPVCVET	pp1ab	1387	1395	A*02:01	multimer staining	(Saini et al., 2021)
KLNIKLLGV	pp1ab	3839	3847	A*02:01	multimer staining	(Saini et al., 2021)
KLNVGDYFV	pp1ab	5542	5550	A*02:01	HTMA/multimer staining	(Saini et al., 2021; Snyder et al., 2020)
KLSYGIATV	pp1ab	5470	5478	A*02:01	ELISPOT/HTMA/multimer staining	(Saini et al., 2021; Snyder et al., 2020; Prakash et al., 2021)
KLVNKFLAL	pp1ab	680	688	A*02:01	multimer staining	(Saini et al., 2021)
KLVSSFLEM	pp1ab	1185	1193	B*15:01	multimer staining	(Saini et al., 2021)
KLWAQCVQL	pp1ab	3886	3894	A*02:01/B*07:02	ELISA/HTMA/multimer staining/ELISPOT/ICS/cytotoxicity	(Saini et al., 2021; Snyder et al., 2020; Weingarten-Gabbay et al., 2021; Wagner et al., 2022; Titov et al., 2022; Ferretti et al., 2020; Swadling et al., 2022)
KMADQAMTQMY	pp1ab	4003	4013	B*15:01	multimer staining	(Saini et al., 2021)
KMFDAYVNTF	pp1ab	2589	2598	A*24:02	AIM	(Tarke et al., 2021)
KMQRMLLEK	pp1ab	6814	6822	HLA class I	HTMA	(Snyder et al., 2020)
KMVSLLSVLLSMQGA	pp1ab	3910	3924	HLA class I	ELISPOT	(Swadling et al., 2022)
KNLSDRVVFV	pp1ab	6100	6109	A*02:01	multimer staining	(Saini et al., 2021)
KPHNSHEGKTF	pp1ab	1608	1618	B*07:02	multimer staining	(Saini et al., 2021)
KPLEFGATSAAL	pp1ab	958	969	HLA class I	HTMA	(Snyder et al., 2020)
KPNELSRVL	pp1ab	2109	2117	B*07:02/B*08:01	AIM/ICS/multimer staining	(Saini et al., 2021; Tarke et al., 2021; Wagner et al., 2022)
KPPISFPL	pp1ab	5400	5407	B*07:02	multimer staining	(Saini et al., 2021)
KPRSQMEIDF	pp1ab	6656	6665	B*07:02	multimer staining	(Saini et al., 2021)
KPVETSNSFDVL	pp1ab	2017	2028	B*07:02	AIM	(Tarke et al., 2021)
KPYIKWDLL	pp1ab	4655	4663	B*07:02	multimer staining	(Saini et al., 2021)
KQEILGTVSW	pp1ab	1364	1373	B*44:02/B*44:03	AIM	(Tarke et al., 2021)
KQFDTYNLW	pp1ab	6437	6445	B*15:01	ELISA/HTMA/multimer staining	(Saini et al., 2021; Snyder et al., 2020; Titov et al., 2022)
KQGDDYVYL	pp1ab	5213	5221	A*02:01	multimer staining	(Saini et al., 2021)
KQLIKVTLVF	pp1ab	2771	2780	B*15:01	ICS	(Schulien et al., 2021)
KRVDWTIEY	pp1ab	6213	6221	B*07:02	multimer staining	(Weingarten-Gabbay et al., 2021)
KSAGFPFNK	pp1ab	4892	4900	A*03:01/A*11:01	AIM/proliferation	(Tarke et al., 2021; Jin et al., 2021)
KSAGFPFNKW	pp1ab	4892	4901	B*57:01	AIM	(Tarke et al., 2021)
KTIQPRVEK	pp1ab	282	290	A*30:01/A*11:01/A*03:01	ELISA/ICS/cytotoxicity/multimer staining	(Wagner et al., 2022; Titov et al., 2022; Ferretti et al., 2020; Kared et al., 2021)
KTNCCRFQEK	pp1ab	4442	4451	A*11:01	proliferation	(Jin et al., 2021)
KVAGFAKFL	pp1ab	4433	4441	A*32:01	AIM	(Tarke et al., 2021)
KVAGFAKFLK	pp1ab	4433	4442	A*11:01	AIM	(Tarke et al., 2021)
KVDGVDVEL	pp1ab	6486	6494	A*02:01	multimer staining	(Saini et al., 2021)
KVDGVVQQL	pp1ab	6633	6641	A*02:01	multimer staining	(Saini et al., 2021)
LATNNLVVM	pp1ab	590	598	B*07:02/A*02:01	multimer staining	(Weingarten-Gabbay et al., 2021)
LAYYFMRFR	pp1ab	3060	3068	A*31:01	AIM	(Tarke et al., 2021)
LEFGATSAAL	pp1ab	960	969	B*40:01	AIM	(Tarke et al., 2021)
LEIPRRNVATL	pp1ab	5914	5924	B*07:02	multimer staining	(Saini et al., 2021)
LEMELTPVV	pp1ab	1012	1020	B*40:01	AIM	(Tarke et al., 2021)
LFLLPSLATV	pp1ab	3638	3647	A*02:01	multimer staining	(Saini et al., 2021)
LGDVRETMSY	pp1ab	1725	1734	A*01:01	multimer staining	(Saini et al., 2021)
LHKPIVWHV	pp1ab	1986	1994	C*06:02	multimer staining	(Saini et al., 2021)
LKKLKKSL	pp1ab	3977	3984	B*08:01	multimer staining	(Saini et al., 2021)
LLADKFPVL	pp1ab	6246	6254	A*02:01/B*08:01	ICS/AIM/multimer staining	(Saini et al., 2021; Quiros-Fernandez et al., 2021)
LLLDDFVEI	pp1ab	6749	6757	A*02:01	ELISPOT	(Prakash et al., 2021)
LLLDDFVEII	pp1ab	6749	6758	HLA class I	HTMA	(Snyder et al., 2020)
LLSAGIFGA	pp1ab	1148	1156	HLA class I	HTMA	(Snyder et al., 2020)
LMIERFVSL	pp1ab	5246	5254	A*02:01	HTMA/multimer staining	(Saini et al., 2021; Snyder et al., 2020)
LMVVIPDYNTY	pp1ab	4070	4080	B*15:01	multimer staining	(Saini et al., 2021)
LPFAMGIIAM	pp1ab	3612	3621	B*07:02	AIM	(Tarke et al., 2021)
LPGVYSVI	pp1ab	3101	3108	B*51:01	AIM	(Tarke et al., 2021)
LPKGIMMNV	pp1ab	6834	6842	B*07:02	multimer staining	(Saini et al., 2021)
LPLTQYNRY	pp1ab	3199	3207	B*35:01	AIM	(Tarke et al., 2021)
LPRVFSAV	pp1ab	2885	2892	B*51:01	AIM	(Tarke et al., 2021)
LPYPDPSRI	pp1ab	5221	5229	B*51:01	multimer staining/ICS	(Swaminathan et al., 2022; Gangaev et al., 2021)
LPYPDPSRIL	pp1ab	5221	5230	B*51:01/B*07:02	AIM/ELISPOT/AIM/multimer staining	(Saini et al., 2021; Tarke et al., 2021; Ma et al., 2021)
LQGPPGTGKSHFAIG	pp1ab	5612	5626	HLA class I	ICS/AIM/AIM	(Eggenhuizen et al., 2021)
LQLGFSTGV	pp1ab	6032	6040	HLA class I	HTMA	(Snyder et al., 2020)
LRAKHYVYIGDPAQL	pp1ab	5715	5729	HLA class I	ELISPOT	(Swadling et al., 2022)
LRGTAVMSL	pp1ab	7052	7060	C*07:01	multimer staining	(Saini et al., 2021)
LRIMASLVL	pp1ab	5022	5030	C*07:02	multimer staining	(Saini et al., 2021)
LRKHFSMMI	pp1ab	5141	5149	C*06:02	multimer staining	(Saini et al., 2021)
LRPDTRYV	pp1ab	2948	2955	C*06:02	multimer staining	(Saini et al., 2021)
LRVEAFEYY	pp1ab	1627	1635	C*07:01	multimer staining	(Saini et al., 2021)
LSDDAVVCFNSTY	pp1ab	5150	5162	HLA class I	HTMA	(Snyder et al., 2020)
LSFKELLVYA	pp1ab	4758	4767	A*02:06	ICS	(Jin et al., 2021)
LLMPILTLT	pp1ab	4632	4640	HLA class I	HTMA	(Snyder et al., 2020)
LTAFGLVAEW	pp1ab	2318	2327	B*57:01	AIM	(Tarke et al., 2021)
LTAVVIPTK	pp1ab	1296	1304	A*68:01	AIM	(Tarke et al., 2021)
LTGHMLDMY	pp1ab	5287	5295	A*01:01	multimer staining	(Gangaev et al., 2021)
LTIKKPNEL	pp1ab	2105	2113	B*08:01	multimer staining	(Saini et al., 2021)
LTNDNTSRYW	pp1ab	5299	5308	B*57:01	AIM	(Tarke et al., 2021)
LTNIFGTVY	pp1ab	613	621	A*01:01	ICS	(Wagner et al., 2022)
LVAEWFLAY	pp1ab	2323	2331	A*26:01/A*29:02/B*35:01	AIM/ICS	(Tarke et al., 2021; Wagner et al., 2022)
LVKQGDDYVY	pp1ab	5211	5220	B*15:01	multimer staining	(Saini et al., 2021)
LVLSVNPYV	pp1ab	5365	5373	HLA class I	HTMA	(Snyder et al., 2020)
LVQMAPISAM	pp1ab	2371	2380	B*15:01	ICS	(Schulien et al., 2021)
LVSDIDITF	pp1ab	1270	1278	B*35:01	AIM	(Tarke et al., 2021)
LYDKLVSSF	pp1ab	1182	1190	A*24:02	AIM	(Tarke et al., 2021)
LYLQYIRKL	pp1ab	5275	5283	C*07:02	multimer staining	(Saini et al., 2021)
LYQPPQTSI	pp1ab	3249	3257	A*24:02/C*07:01	multimer staining	(Saini et al., 2021)
LYYQNNVFM	pp1ab	5178	5186	A*24:02	multimer staining	(Saini et al., 2021)
MASLVLARK	pp1ab	5025	5033	A*68:01	AIM	(Tarke et al., 2021)
MELTPVVQTI	pp1ab	1014	1023	B*40:01	AIM	(Tarke et al., 2021)
MFDAYVNTF	pp1ab	2590	2598	B*08:01	multimer staining	(Saini et al., 2021)
MFTPLVPFW	pp1ab	3131	3139	A*24:02	AIM	(Tarke et al., 2021)
MFVKHKHAF	pp1ab	3627	3635	C*07:02	multimer staining	(Saini et al., 2021)
MLAHAEETR	pp1ab	1378	1386	A*68:01	AIM	(Tarke et al., 2021)
MLDMYSVML	pp1ab	5291	5299	A*02:01/A*02:03	ICS/proliferation	(Jin et al., 2021)
MLLGSMLYM	pp1ab			A*02:01/B*07:02	multimer staining	(Weingarten-Gabbay et al., 2021)
MLRIMASL	pp1ab	5021	5028	B*08:01	multimer staining	(Saini et al., 2021)
MLWCKDGHV	pp1ab	6782	6790	HLA class I	HTMA	(Snyder et al., 2020)
MMISAGFSL	pp1ab	6425	6433	A*02:01	HTMA/multimer staining	(Saini et al., 2021; Snyder et al., 2020)
MPASWVMRI	pp1ab	3655	3663	B*07:02	AIM/HTMA/ELISA/multimer staining	(Saini et al., 2021; Snyder et al., 2020; Tarke et al., 2021; Titov et al., 2022)
MPNMLRIMASL	pp1ab	5018	5028	B*07:02	multimer staining	(Saini et al., 2021)
MPTTIAKNTV	pp1ab	2194	2203	B*51:01	AIM	(Tarke et al., 2021)
MPYFFTLL	pp1ab	2169	2176	B*51:01	AIM	(Tarke et al., 2021)
MSALNHTKK	pp1ab	1647	1655	A*30:01	AIM	(Tarke et al., 2021)
MSALNHTKKW	pp1ab	1647	1656	B*57:01	AIM	(Tarke et al., 2021)
MSMTYGQQF	pp1ab	1586	1594	B*57:01	AIM	(Tarke et al., 2021)
MSNLGMPSY	pp1ab	2254	2262	B*57:01/B*15:01	AIM	(Tarke et al., 2021)
MTNRQFHQK	pp1ab	4958	4966	A*30:01	proliferation	(Jin et al., 2021)
MVMCGGSLYV	pp1ab	5058	5067	HLA class I	HTMA	(Snyder et al., 2020)
MVTNNTFTLK	pp1ab	807	816	A*03:01	ELISA	(Titov et al., 2022)
MYASAVVLL	pp1ab	3684	3692	C*07:02	multimer staining	(Saini et al., 2021)
MYKGLPWNV	pp1ab	6078	6086	C*06:02	multimer staining	(Saini et al., 2021)
NAAISDYDY	pp1ab	4839	4847	B35	ELISPOT	(Swadling et al., 2022)
NELSRVLGL	pp1ab	2111	2119	B*44:02/B*40:01	AIM	(Tarke et al., 2021)
NINLHTQVV	pp1ab	1576	1584	B*08:01	multimer staining	(Saini et al., 2021)
NKATYKPNTW	pp1ab	1999	2008	B*57:01	AIM	(Tarke et al., 2021)
NKLCEEMLDNRATLQ	pp1ab	3928	3942	HLA class I	ELISPOT	(Swadling et al., 2022)
NLHSSRLSF	pp1ab	4752	4760	B*08:01	multimer staining	(Saini et al., 2021)
NLIDSYFVV	pp1ab	4456	4464	A*02:01	multimer staining	(Kared et al., 2021)
NLKTLLSL	pp1ab	1555	1562	B*08:01	multimer staining	(Saini et al., 2021)
NLLKDCPAV	pp1ab	4480	4488	A*02:07	proliferation	(Jin et al., 2021)
NLWNTFTRL	pp1ab	6443	6451	A*02:01	HTMA/multimer staining	(Saini et al., 2021; Snyder et al., 2020)
NLYDKLVSSFL	pp1ab	1181	1191	A*02:01	multimer staining	(Saini et al., 2021)
NMLRIMASL	pp1ab	5020	5028	A*02:01	HTMA/ICS	(Snyder et al., 2020; Jin et al., 2021)
NPIQLSSYSL	pp1ab	7033	7042	B*07:02	AIM	(Tarke et al., 2021)
NPKTPKYKF	pp1ab	3358	3366	B*07:02	multimer staining	(Saini et al., 2021)
NRDVDTDFVNEFYAY	pp1ab	5126	5140	HLA class I	HTMA	(Snyder et al., 2020)
NRYFRLTL	pp1ab	3801	3808	C*06:02/C*07:02	multimer staining	(Saini et al., 2021)
NSFSGYLKL	pp1ab	1026	1034	C*06:02	multimer staining	(Saini et al., 2021)
NSTNVTIATY	pp1ab	2272	2281	A*26:01	AIM	(Tarke et al., 2021)
NTCDGTTFTY	pp1ab	4082	4091	A*01:01	ELISA/cytotoxicity	(Titov et al., 2022; Ferretti et al., 2020)
NTFTRLQSL	pp1ab	6446	6454	C*07:01	multimer staining	(Saini et al., 2021)
NTSRYWEPEFY	pp1ab	5303	5313	A*01:01	multimer staining	(Saini et al., 2021)
NTVKSVGKF	pp1ab	2201	2209	A*26:01	AIM	(Tarke et al., 2021)
NVIPTITQM	pp1ab	4926	4934	C*07:01	multimer staining	(Saini et al., 2021)
NVIPTITQMNL	pp1ab	4926	4936	A*02:05	ICS	(Swaminathan et al., 2022)
NVKDFMSL	pp1ab	2714	2721	B*08:01	multimer staining	(Saini et al., 2021)
NYMPYFFTL	pp1ab	2167	2175	A*24:02	ICS/AIM/multimer staining	(Tarke et al., 2021; Schulien et al., 2021; Kared et al., 2021)
NYSGVVTTVMF	pp1ab	3743	3753	HLA class I	HTMA	(Snyder et al., 2020)
NYYKKDNSY	pp1ab	1898	1906	C*07:02	multimer staining	(Saini et al., 2021)
PFMIDVQQW	pp1ab	6164	6172	A*24:02	multimer staining	(Saini et al., 2021)
PTDNYITTY	pp1ab	1321	1329	A*01:01	multimer staining /ELISA/cytotoxicity	(Saini et al., 2021; Titov et al., 2022; Ferretti et al., 2020; Kared et al., 2021; Gangaev et al., 2021; Minervina et al., 2022)
QEILGTVSW	pp1ab	1365	1373	B*44:03	ICS/AIM	(Tarke et al., 2021; Schulien et al., 2021)
QEYADVFHLY	pp1ab	5267	5276	B*44:03/A*29:02	ICS/AIM	(Tarke et al., 2021; Schulien et al., 2021)
QGYKSVNITF	pp1ab	834	843	A*24:02	multimer staining	(Saini et al., 2021)
QIDGYVMHANYIFWR	pp1ab	7016	7030	HLA class I	ELISPOT	(Mateus et al., 2020)
QKYSTLQGPPGTGKS	pp1ab	275	289	HLA class I	ICS/AIM/AIM	(Eggenhuizen et al., 2021)
QLLFVVEVV	pp1ab	4860	4868	A*02:01	ICS	(Jin et al., 2021)
QLMCQPILLL	pp1ab	2563	2572	HLA class I	HTMA	(Snyder et al., 2020)
QLYLGGMSYY	pp1ab	5386	5395	B*15:01	multimer staining	(Saini et al., 2021)
QPGQTFSVL	pp1ab	3370	3378	B*07:02	multimer staining	(Kared et al., 2021)
QPYVFIKRSDARTAP	pp1ab	66	80	HLA class I	ELISPOT	(Mateus et al., 2020)
QSDIEVTGDSCNNY	pp1ab	2660	2673	A*01:01	AIM	(Tarke et al., 2021)
QTVKPGNFNK	pp1ab	4800	4809	A*11:01	AIM	(Tarke et al., 2021)
QVVDMSMTY	pp1ab	1582	1590	A*11:01/A*01:01	AIM/multimer staining	(Saini et al., 2021; Tarke et al., 2021)
QVVNVVTTK	pp1ab	2749	2757	A*03:01	AIM	(Tarke et al., 2021)
REQIDGYVMHANY	pp1ab	7014	7026	B*44:02	AIM	(Tarke et al., 2021)
RIKASMPTT	pp1ab	2189	2197	A*30:01	AIM	(Tarke et al., 2021)
RILGAGCFV	pp1ab	5228	5236	HLA class I	HTMA	(Snyder et al., 2020)
RIMTWLDMV	pp1ab	3662	3670	A*02:01	multimer staining	(Saini et al., 2021)
RLANECAQV	pp1ab	5046	5054	A*02:01	multimer staining/ICS	(Saini et al., 2021; Jin et al., 2021)
RLIDAMMFT	pp1ab	579	587	A*02:01	multimer staining	(Saini et al., 2021)
RLYYDSMSY	pp1ab	4905	4913	B*15:01	HTMA/multimer staining	(Saini et al., 2021; Snyder et al., 2020)
RMYIFFASFY	pp1ab	2382	2391	A*03:01	ICS	(Schulien et al., 2021)
RPDTRYVL	pp1ab	2949	2956	B*07:02	ELISA/cytotoxicity	(Ferretti et al., 2020)
RPDTRYVLM	pp1ab	2949	2957	B*35:01/B*07:02	AIM/multimer staining	(Tarke et al., 2021; Kared et al., 2021)
RPQIGVVREF	pp1ab	5814	5823	B*15:01	multimer staining	(Saini et al., 2021)
RQFHQKLLK	pp1ab	4961	4969	A*11:01	ELISA	(Titov et al., 2022)
RQLLFVVEV	pp1ab	4859	4867	A*02:01	HTMA/multimer staining	(Saini et al., 2021; Snyder et al., 2020)
RTIKVFTTV	pp1ab	1566	1574	A*02:01	multimer staining	(Saini et al., 2021)
RTNVYLAVF	pp1ab	1170	1178	B*57:01	AIM	(Tarke et al., 2021)
RTTNGDFLHF	pp1ab	2875	2884	B*57:01	AIM	(Tarke et al., 2021)
RVESSSKLWAQCVQL	pp1ab	3880	3894	A*02:01	ELISPOT	(Swadling et al., 2022)
RYFKYWDQTY	pp1ab	4677	4686	A*24:02	multimer staining	(Saini et al., 2021)
SAFAMMFVK	pp1ab	3622	3630	A*11:01	ICS/multimer staining	(Schulien et al., 2021; Kared et al., 2021)
SAKNRARTV	pp1ab	4941	4949	C*06:02	multimer staining	(Saini et al., 2021)
SAKSASVYY	pp1ab	2553	2561	B*57:01	AIM	(Tarke et al., 2021)
SALNHTKKW	pp1ab	1648	1656	B*57:01	AIM	(Tarke et al., 2021)
SALWEIQQVV	pp1ab	4093	4102	A*02:01	multimer staining/ICS	(Saini et al., 2021)
SAMVRMYIF	pp1ab	2378	2386	B*08:01	multimer staining	(Saini et al., 2021)
SDGTGTIY	pp1ab	4199	4206	A*01:01	multimer staining	(Saini et al., 2021)
SEDAQGMDNL	pp1ab	2030	2039	B*40:01	AIM	(Tarke et al., 2021)
SAPPAQYEL	pp1ab	1808	1816	C*07:01	multimer staining	(Saini et al., 2021)
SEFSSLPSY	pp1ab	3946	3954	B*44:03/A*02:01/B*07:02/B*44:10	ICS/multimer staining/AIM	(Weingarten-Gabbay et al., 2021; Wagner et al., 2022; Schulien et al., 2021)
SEIIGYKAI	pp1ab	2804	2812	B*40:01	AIM	(Tarke et al., 2021)
SEISMDNSPNL	pp1ab	4112	4122	HLA class I	ELISA/HTMA	(Snyder et al., 2020; Titov et al., 2022)
SELLTPLGI	pp1ab	887	895	B*40:01	AIM	(Tarke et al., 2021)
SEVGPEHSLAEY	pp1ab	376	387	HLA class I	HTMA	(Snyder et al., 2020)
SEYKGPITDVFY	pp1ab	1857	1868	B*44:02	AIM	(Tarke et al., 2021)
SEYTGNYQCGHY	pp1ab	1825	1836	B*44:02	AIM	(Tarke et al., 2021)
SFGPLVRKI	pp1ab	4717	4725	A*24:02	multimer staining	(Saini et al., 2021)
SFLPGVYSV	pp1ab	3099	3107	A*24:02	multimer staining	(Saini et al., 2021)
SFYYVWKSY	pp1ab	2389	2397	A*29:02	AIM	(Tarke et al., 2021)
SICSTMTNR	pp1ab	4953	4961	A*33:01	AIM	(Tarke et al., 2021)
SIIQFPNTY	pp1ab	2960	2968	B*35:01	AIM	(Tarke et al., 2021)
SLAIDAYPL	pp1ab	5253	5261	A*02:01	proliferation	(Jin et al., 2021)
SLDNVLSTF	pp1ab	2625	2633	A*32:01	AIM	(Tarke et al., 2021)
SLDTYPSLETI	pp1ab	2297	2307	A*02:01	multimer staining	(Saini et al., 2021)
SLENVAFNV	pp1ab	6453	6461	A*02:01	multimer staining	(Saini et al., 2021)
SLINTLNDL	pp1ab	1433	1441	A*02:01	multimer staining	(Saini et al., 2021)
SLIYSTAAL	pp1ab	2242	2250	A*02:01	AIM	(Tarke et al., 2021)
SLLMPILTL	pp1ab	4631	4639	A*02:01	multimer staining	(Saini et al., 2021)
SLLSVLLSM	pp1ab	3913	3921	A*02:01	multimer staining	(Saini et al., 2021)
SLPGVFCGV	pp1ab	3013	3021	A*02:01	ELISPOT/multimer staining	(Saini et al., 2021; Prakash et al., 2021)
SLRPDTRYVL	pp1ab	2947	2956	C*07:02	multimer staining	(Saini et al., 2021)
SLSGFKLKDCV	pp1ab	3673	3683	A*02:01	multimer staining	(Xiao et al., 2022)
SLYVNKHAF	pp1ab	6343	6351	B*08:01	multimer staining	(Saini et al., 2021)
SMWALIISV	pp1ab	3732	3740	A*02:01	ELISPOT/multimer staining/ICS	(Saini et al., 2021; Habel et al., 2020; Prakash et al., 2021)
SNEKQEILGTVSWNL	pp1ab	1361	1375	HLA class I	HTMA	(Snyder et al., 2020)
SNSGSDVLY	pp1ab	3242	3250	A*01:01	multimer staining	(Saini et al., 2021)
SPSGVYQCAM	pp1ab	3384	3393	B*07:02	multimer staining	(Saini et al., 2021)
SRVLGLKTL	pp1ab	2114	2122	C*07:01	multimer staining	(Saini et al., 2021)
SRYWEPEF	pp1ab	5305	5312	C*07:01	multimer staining	(Saini et al., 2021)
SSAKSASVY	pp1ab	2552	2560	B*15:01	AIM	(Tarke et al., 2021)
SSEAFLIGCNY	pp1ab	6999	7009	A*01:01	multimer staining	(Saini et al., 2021)
SSNVANYQK	pp1ab	5587	5595	HLA class I	HTMA	(Snyder et al., 2020)
SSTFNVPMEKLK	pp1ab	2599	2610	HLA class I	HTMA	(Snyder et al., 2020)
STAALGVLM	pp1ab	2246	2254	A*26:01	AIM	(Tarke et al., 2021)
STFNVPMEK	pp1ab	2600	2608	A*11:01	ICS/multimer staining	(Wagner et al., 2022; Schulien et al., 2021; Kared et al., 2021)
STNVTIATY	pp1ab	2273	2281	A*01:01/A*32:01	AIM	(Tarke et al., 2021)
STSAFVETV	pp1ab	483	491	A*02:01/B*07:02	multimer staining	(Weingarten-Gabbay et al., 2021)
STVFPPTSF	pp1ab	4710	4718	B*57:01	AIM	(Tarke et al., 2021)
SVPWDTIANY	pp1ab	2132	2141	A*26:01	AIM	(Tarke et al., 2021)
SVVSKVVKV	pp1ab	6764	6772	A*02:01	multimer staining	(Saini et al., 2021)
SVYYTSNPTTF	pp1ab	1534	1544	A*24:02	multimer staining	(Saini et al., 2021)
SYATHSDKF	pp1ab	6294	6302	A*24:02	multimer staining	(Saini et al., 2021)
SYFVVKRHTF	pp1ab	4460	4469	A*24:02	ICS	(Jin et al., 2021)
SYSLFDMSKF	pp1ab	7039	7048	A*24:02	multimer staining	(Saini et al., 2021)
SYYSLLMPI	pp1ab	4628	4636	A*24:02	ICS	(Jin et al., 2021)
TANPKTPKY	pp1ab	3356	3364	C*07:01	multimer staining	(Saini et al., 2021)
TDLEGNFY	pp1ab	3438	3445	A*01:01	multimer staining	(Saini et al., 2021)
TDNYITTY	pp1ab	1322	1329	A*01:01	AIM/multimer staining	(Saini et al., 2021; Tarke et al., 2021)
TEIDPKLDNYY	pp1ab	1890	1900	B*44:02/A*01:01	AIM/multimer staining	(Saini et al., 2021; Tarke et al., 2021)
TETDLTKGPHEF	pp1ab	5193	5204	B*44:02	AIM	(Tarke et al., 2021)
TEVVGDIIL	pp1ab	2069	2077	B*40:01	ICS	(Schulien et al., 2021)
TFISAARQGF	pp1ab	2632	2641	A*24:02	multimer staining	(Saini et al., 2021)
TFNGECPNF	pp1ab	265	273	A*24:02	multimer staining	(Saini et al., 2021)
TFTYASALW	pp1ab	4088	4096	A*24:02	multimer staining	(Saini et al., 2021)
TFYLTNDVSFL	pp1ab	3113	3123	HLA class I	HTMA	(Snyder et al., 2020)
TICAPLTVF	pp1ab	6566	6574	B*15:01	multimer staining	(Saini et al., 2021)
TIEVNSFSGY	pp1ab	1022	1031	A*01:01	multimer staining	(Saini et al., 2021)
TIIQTIVEV	pp1ab	1000	1008	A*02:01	multimer staining	(Xiao et al., 2022)
TISLAGSYK	pp1ab	1504	1512	A*68:01/A*03:01/A*11:01	AIM/multimer staining	(Tarke et al., 2021; Kared et al., 2021)
TITQMNLKY	pp1ab	4930	4938	A*01:01	multimer staining	(Saini et al., 2021)
TIWFLLLSV	pp1ab	2230	2238	A*02:01/A*02:07	ICS/multimer staining	(Zhang et al., 2021; Xiao et al., 2022)
TLGVYDYLVST	pp1ab	3807	3817	HLA class I	HTMA	(Snyder et al., 2020)
TLIGDCATV	pp1ab	6908	6916	HLA class I	HTMA	(Snyder et al., 2020)
TLKEILVTY	pp1ab	4533	4541	A*29:02	AIM	(Tarke et al., 2021)
TLMNVLTLV	pp1ab	3710	3718	A*02:01	ICS	(Habel et al., 2020)
TLVPQEHYV	pp1ab	5563	5571	A*02:01	HTMA/multimer staining/cytotoxicity/ICS/AIM	(Snyder et al., 2020; Pan et al., 2021)
TMADLVYAL	pp1ab	4515	4523	A*02:01	ICS/AIM/multimer staining	(Saini et al., 2021; Habel et al., 2020; Quiros-Fernandez et al., 2021)
TNVLEGSVAY	pp1ab	2936	2945	B*35:01	AIM	(Tarke et al., 2021)
TPHTVLQAV	pp1ab	5318	5326	B*51:01	AIM	(Tarke et al., 2021)
TPKYKFVRI	pp1ab	3361	3369	B*08:01	ELISPOT	(Nelde et al., 2021)
TPRDLGACI	pp1ab	2684	2692	B*07:02	multimer staining	(Saini et al., 2021)
TPSKLIEY	pp1ab	2898	2905	B*35:01	AIM	(Tarke et al., 2021)
TPVVQTIEV	pp1ab	1017	1025	B*07:02	multimer staining	(Saini et al., 2021)
TSDLATNNLVVMAY	pp1ab	587	600	HLA class I	HTMA	(Snyder et al., 2020)
TSEDMLNPNY	pp1ab	3308	3317	A*01:01	multimer staining	(Saini et al., 2021)
TSFGPLVRK	pp1ab	4716	4724	A*03:01	multimer staining	(Kared et al., 2021)
TSLSGFKLKDCV	pp1ab	3672	3683	A*02:01	multimer staining	(Xiao et al., 2022)
TSNPTTFHL	pp1ab	1538	1546	B*57:01	AIM	(Tarke et al., 2021)
TSSGDATTAY	pp1ab	5072	5081	A*01:01	multimer staining	(Saini et al., 2021)
TTDPSFLGRY	pp1ab	1637	1646	A*01:01	AIM/multimer staining/ICS/ELISA/ELISPOT/cytotoxicity	(Saini et al., 2021; Tarke et al., 2021; Titov et al., 2022; Ferretti et al., 2020; Nelde et al., 2021; Gangaev et al., 2021; Minervina et al., 2022)
TTDPSFLGRYM	pp1ab	1637	1647	A*01:01	AIM/multimer staining	(Saini et al., 2021; Tarke et al., 2021)
TTIAKNTVK	pp1ab	2196	2204	A*30:01	AIM	(Tarke et al., 2021)
TTIQTIVEV	pp1ab	1000	1008	A*02:01	multimer staining	(Xiao et al., 2022)
TTLPVNVAF	pp1ab	6499	6507	HLA class I	HTMA	(Snyder et al., 2020)
TTYPGQGLNGY	pp1ab	1327	1337	A*01:01	multimer staining	(Saini et al., 2021)
TVKNGSIHLY	pp1ab	2495	2504	A*26:01	AIM	(Tarke et al., 2021)
TVKPGNFNK	pp1ab	4801	4809	A*11:01	proliferation	(Jin et al., 2021)
TVLSFCAFAV	pp1ab	4265	4274	HLA class I	HTMA	(Snyder et al., 2020)
TVYEKLKPV	pp1ab	619	627	A*02:01	multimer staining	(Saini et al., 2021)
TYACWHHSI	pp1ab	6148	6156	A*24:02	multimer staining	(Saini et al., 2021; Kared et al., 2021)
TYERHSLSHF	pp1ab	2512	2521	A*24:02	multimer staining	(Saini et al., 2021)
TYKNTCDGTTF	pp1ab	4079	4089	A*24:02	multimer staining	(Saini et al., 2021)
VAKSHNIAL	pp1ab	2703	2711	B*07:02	multimer staining	(Saini et al., 2021)
VAMPNLYKM	pp1ab	6807	6815	B*57:01	AIM	(Tarke et al., 2021)
VARDLSLQF	pp1ab	2469	2477	B*57:01	AIM	(Tarke et al., 2021)
VELGTEVNEF	pp1ab	862	871	B*44:02	AIM	(Tarke et al., 2021)
VENMTPRDL	pp1ab	2680	2688	B*44:03	AIM	(Tarke et al., 2021)
VENPDILRV	pp1ab	4558	4566	B*44:03	AIM	(Tarke et al., 2021)
VENPDILRVY	pp1ab	4558	4567	B*44:02	AIM	(Tarke et al., 2021)
VENPHLMGWD	pp1ab	5001	5010	B*44:02	AIM/multimer staining	(Tarke et al., 2021; Minervina et al., 2022)
VEVQPQLEM	pp1ab	1006	1014	B*40:01	AIM	(Tarke et al., 2021)
VKNGSIHLY	pp1ab	2496	2504	C*06:02	multimer staining	(Saini et al., 2021)
VLAAECTIF	pp1ab	2914	2922	B*15:01	multimer staining	(Saini et al., 2021)
VLAWLYAAV	pp1ab	3467	3475	HLA class I	HTMA	(Snyder et al., 2020)
VLNEKCSAY	pp1ab	852	860	B*15:01	multimer staining	(Saini et al., 2021)
VLQAVGACV	pp1ab	5322	5330	HLA class I	HTMA	(Snyder et al., 2020)
VLSEARQHL	pp1ab	38	46	A*02:01	multimer staining	(Saini et al., 2021)
VLWAHGFEL	pp1ab	6109	6117	HLA class I	HTMA	(Snyder et al., 2020)
VMCGGSLYV	pp1ab	5059	5067	A*02:01	ICS	(Jin et al., 2021)
VMVELVAEL	pp1ab	84	92	A*02:01	ELISPOT/ICS/AIM	(Quiros-Fernandez et al., 2021; Prakash et al., 2021)
VMYASAVVLL	pp1ab	3683	3692	A*24:02	multimer staining	(Saini et al., 2021)
VMYMGTLSY	pp1ab	1768	1776	A*03:01	AIM	(Tarke et al., 2021)
VNRFNVAITRAKVGI	pp1ab	558	572	HLA class I	ICS/AIM	(Eggenhuizen et al., 2021)
VPANSTVL	pp1ab	4260	4267	B*07:02	multimer staining	(Saini et al., 2021)
VPANSTVLSF	pp1ab	4260	4269	B*07:02	multimer staining	(Saini et al., 2021)
VPFWITIAY	pp1ab	3136	3144	B*35:01	AIM/ICS	(Tarke et al., 2021; Wagner et al., 2022)
VPGLPGTIL	pp1ab	2866	2874	B*07:02	multimer staining	(Saini et al., 2021)
VPHISRQRL	pp1ab	4503	4511	B*07:02	AIM	(Tarke et al., 2021)
VPHVGEIPV	pp1ab	108	116	B*07:02	multimer staining	(Saini et al., 2021)
VPMEKLKTL	pp1ab	2604	2612	B*51:01	AIM	(Tarke et al., 2021)
VPQEHYVRI	pp1ab	5565	5573	B*08:01	multimer staining	(Saini et al., 2021)
VQSTQWSLF	pp1ab	3595	3603	A*24:02	multimer staining	(Gangaev et al., 2021)
VRETMSYLF	pp1ab	1728	1736	C*07:01	multimer staining	(Saini et al., 2021)
VRIQPGQTF	pp1ab	3367	3375	C*07:01	multimer staining	(Saini et al., 2021)
VRNLQHRLY	pp1ab	5112	5120	C*07:01	multimer staining	(Saini et al., 2021)
VRQALLKTV	pp1ab	4574	4582	C*06:02	multimer staining	(Saini et al., 2021)
VRSIFSRTL	pp1ab	544	552	C*06:02	multimer staining	(Saini et al., 2021)
VSALVYDNKLKAHKD	pp1ab	452	466	HLA class I	ICS/AIM	(Eggenhuizen et al., 2021)
VSSPDAVTAY	pp1ab	1477	1486	B*57:01/A*01:01	AIM/multimer staining	(Saini et al., 2021; Tarke et al., 2021)
VTDTPKGPK	pp1ab	4216	4224	A*11:01	ELISA/cytotoxicity	(Ferretti et al., 2020)
VTVKNGSIHLY	pp1ab	2494	2504	A*01:01	AIM	(Tarke et al., 2021)
VVAIDYKHY	pp1ab	1967	1975	B*15:01	AIM	(Tarke et al., 2021)
VVDKYFDCY	pp1ab	4867	4875	HLA class I	HTMA	(Snyder et al., 2020)
VVDYGARFY	pp1ab	1415	1423	A*01:01	AIM	(Tarke et al., 2021)
VVNARLRAK	pp1ab	5710	5718	A*11:01	multimer staining	(Kared et al., 2021)
VVQQLPETY	pp1ab	6637	6645	B*15:01	multimer staining	(Saini et al., 2021)
VVSTGYHFR	pp1ab	4733	4741	A*11:01	AIM/proliferation	(Tarke et al., 2021; Jin et al., 2021)
VVTTKIALK	pp1ab	2753	2761	A*03:01	AIM	(Tarke et al., 2021)
VVVNAANVY	pp1ab	1056	1064	B*35:01	AIM	(Tarke et al., 2021)
VVYRAFDIY	pp1ab	4422	4430	B*15:01	multimer staining	(Saini et al., 2021)
VVYRGTTTY	pp1ab	5533	5541	HLA class I	HTMA	(Snyder et al., 2020)
VVYRGTTTYK	pp1ab	5533	5542	A*11:01/A*03:01	ICS/multimer staining	(Schulien et al., 2021; Kared et al., 2021)
VYIGDPAQL	pp1ab	5721	5729	A*24:02/C*07:01	ELISA/multimer staining/ICS/AIM/ELISPOT/cytotoxicity	(Saini et al., 2021; Wagner et al., 2022; Titov et al., 2022; Ferretti et al., 2020; Nelde et al., 2021; Kared et al., 2021; Minervina et al., 2022; Pan et al., 2021)
VYLPYPDPSRI	pp1ab	5219	5229	B*51:01	AIM	(Tarke et al., 2021)
VYMPASWVM	pp1ab	3653	3661	A*24:02	AIM/multimer staining	(Saini et al., 2021; Tarke et al., 2021)
VYRGTTTYKL	pp1ab	5534	5543	A*24:02	multimer staining	(Saini et al., 2021)
WEPEFYEAM	pp1ab	5308	5316	B*40:01	AIM	(Tarke et al., 2021)
WFFSNYLKR	pp1ab	3155	3163	A*31:01	AIM	(Tarke et al., 2021)
WKYPQVNGL	pp1ab	1656	1664	C*07:01	multimer staining	(Saini et al., 2021)
WLDMVDTSL	pp1ab	3666	3674	A*02:01	AIM	(Tarke et al., 2021)
WLMWLIINL	pp1ab	2363	2371	A*02:01	ELISPOT	(Prakash et al., 2021)
WRNTNPIQL	pp1ab	7029	7037	C*07:01	multimer staining	(Saini et al., 2021)
WVLNNDYYR	pp1ab	3004	3012	A*31:01	AIM	(Tarke et al., 2021)
YADVFHLYL	pp1ab	5269	5277	C*07:02	multimer staining	(Saini et al., 2021)
YAFEHIVY	pp1ab	6682	6689	B*35:01	ICS	(Swaminathan et al., 2022)
YAISAKNRAR	pp1ab	4938	4947	A*68:01	AIM	(Tarke et al., 2021)
YAKPFLNKV	pp1ab	2141	2149	C*06:02	multimer staining	(Saini et al., 2021)
YASAVVLLI	pp1ab	3685	3693	C*06:02	multimer staining	(Saini et al., 2021)
YAYLRKHF	pp1ab	5138	5145	B*08:01	multimer staining	(Saini et al., 2021)
YDYLVSTQEF	pp1ab	3811	3820	C*07:02	multimer staining	(Saini et al., 2021)
YEKLKPVL	pp1ab	621	628	B*08:01	multimer staining	(Saini et al., 2021)
YENFNQHEV	pp1ab	1135	1143	B*40:01	AIM	(Tarke et al., 2021)
YERHSLSHF	pp1ab	2513	2521	B*44:02	AIM	(Tarke et al., 2021)
YFDKAGQKTY	pp1ab	2504	2513	C*07:02	multimer staining	(Saini et al., 2021)
YFIKGLNNL	pp1ab	4229	4237	C*07:02	multimer staining	(Saini et al., 2021)
YFMRFRRAF	pp1ab	3063	3071	A*24:02	multimer staining	(Saini et al., 2021)
YFVVKRHTF	pp1ab	4461	4469	B*08:01/A*24:02	multimer staining	(Saini et al., 2021)
YIATNGPLK	pp1ab	1090	1098	A*11:01	AIM	(Tarke et al., 2021)
YIFFASFYY	pp1ab	2384	2392	A*29:02	AIM/HTMA	(Snyder et al., 2020; Tarke et al., 2021)
YKIEELFYSY	pp1ab	6286	6295	A*01:01	multimer staining	(Saini et al., 2021)
YLASGGQPI	pp1ab	4283	4291	A*02:01	ELISPOT	(Prakash et al., 2021)
YLATALLTL	pp1ab	1675	1683	A*02:01	AIM/ELISPOT/ICS/multimer staining	(Saini et al., 2021; Tarke et al., 2021; Kared et al., 2021; Quiros-Fernandez et al., 2021; Prakash et al., 2021)
YLDAYNMMI	pp1ab	6419	6427	A*02:01	ELISPOT/HTMA/multimer staining	(Snyder et al., 2020; Kared et al., 2021; Prakash et al., 2021)
YLFDESGEF	pp1ab	906	914	B*15:01	multimer staining	(Saini et al., 2021)
YLFDESGEFKL	pp1ab	906	916	A*02:01	ELISA/multimer staining/cytotoxicity	(Titov et al., 2022; Ferretti et al., 2020)
YLITPVHV	pp1ab	2788	2795	A*02:01	AIM	(Tarke et al., 2021)
YLITPVHVM	pp1ab	2788	2796	B*15:01/A*02:01/C*07:01	multimer staining	(Saini et al., 2021)
YLKLTDNVY	pp1ab	1031	1039	B*15:01	multimer staining	(Saini et al., 2021)
YLKLTDNVYIK	pp1ab	1031	1041	HLA class I	HTMA	(Snyder et al., 2020)
YLKRRVVF	pp1ab	3160	3167	B*08:01	multimer staining	(Saini et al., 2021)
YLNSTNVTI	pp1ab	2270	2278	A*02:01/B*07:02	multimer staining	(Weingarten-Gabbay et al., 2021)
YLNTLTLAV	pp1ab	6851	6859	HLA class I	HTMA	(Snyder et al., 2020)
YLPYPDPSRI	pp1ab	5220	5229	B*51:01/A*02:07	AIM/ICS	(Tarke et al., 2021; Jin et al., 2021)
YLPYPDPSRIL	pp1ab	5220	5230	A*24:02	multimer staining	(Saini et al., 2021)
YLTNDVSFLA	pp1ab	3115	3124	A*02:01	AIM	(Tarke et al., 2021)???
YLYFIKGLNNL	pp1ab	4227	4237	A*02:01	multimer staining	(Saini et al., 2021)
YMHHMELPTGV	pp1ab	3424	3434	A*02:01	multimer staining	(Saini et al., 2021)
YMSALNHTK	pp1ab	1646	1654	A*03:01	AIM	(Tarke et al., 2021)
YNLWNTFTRL	pp1ab	6442	6451	A*02:01	multimer staining	(Saini et al., 2021)
YPQVNGLTSI	pp1ab	1658	1667	B*51:01	AIM	(Tarke et al., 2021)
YQKVGMQKY	pp1ab	5593	5601	HLA class I	HTMA	(Snyder et al., 2020)
YRGTTTYKL	pp1ab	5535	5543	C*06:02	multimer staining	(Saini et al., 2021)
YRSLPGVF	pp1ab	3011	3018	C*07:01	multimer staining	(Saini et al., 2021)
YRYNLPTM	pp1ab	4848	4855	C*07:02	multimer staining	(Saini et al., 2021)
YRYNLPTMC	pp1ab	4848	4856	C*06:02	multimer staining	(Saini et al., 2021)
YSDVENPHLMGW	pp1ab	4998	5009	B*44:02	AIM	(Tarke et al., 2021)
YTELEPPCRF	pp1ab	4206	4215	A*01:01	multimer staining	(Saini et al., 2021)
YTGNYQCGHY	pp1ab	1827	1836	A*01:01	multimer staining	(Saini et al., 2021)
YTMADLVYAL	pp1ab	4514	4523	HLA class I	HTMA	(Snyder et al., 2020)
YTTTIKPVTY	pp1ab	1873	1882	A*26:01/A*01:01	AIM/multimer staining	(Saini et al., 2021; Tarke et al., 2021)
YVFCTVNAL	pp1ab	5679	5687	HLA class I	HTMA	(Snyder et al., 2020)
YVMHANYIF	pp1ab	7020	7028	A*32:01/A*26:01	AIM	(Tarke et al., 2021)
YVYANGGKGF	pp1ab	2435	2444	A*26:01/B*15:01	AIM	(Tarke et al., 2021)
YVYLPYPDPSRILGA	pp1ab	5218	5232	B*51:01	ELISPOT/ICS	(Swadling et al., 2022)
YYKKDNSY	pp1ab	1899	1906	C*07:02	multimer staining	(Saini et al., 2021)
YYKKDNSYF	pp1ab	1899	1907	A*24:02	AIM	(Tarke et al., 2021)
YYPSARIVY	pp1ab	5622	5630	A*24:02	multimer staining	(Saini et al., 2021)
YYRARAGEAANF	pp1ab	1699	1710	HLA class I	HTMA	(Snyder et al., 2020)
YYTSNPTTF	pp1ab	1536	1544	A*24:02	multimer staining/ICS	(Saini et al., 2021; Kared et al., 2021)
YYTSNPTTFHL	pp1ab	1536	1546	A*24:02	multimer staining	(Saini et al., 2021)
VTNNTFTLK	pp1ab	808	816	A*03:01/A*11:01	ICS/multimer staining/cytotoxicity/ELISA	(Wagner et al., 2022; Ferretti et al., 2020; Kared et al., 2021)
ADAGFIKQY	S	829	837	B*44:03/B*44:02	ELISA	(Titov et al., 2022)
AEHVNNSY	S	653	660	B*44:03/B*44:02	AIM	(Tarke et al., 2021)
AEIRASANL	S	1016	1024	B*44:02/B*44:03/B*40:01	AIM	(Tarke et al., 2021)
AEIRASANLAATK	S	1016	1028	HLA class I	HTMA	(Snyder et al., 2020)
AEVQIDRL	S	989	996	B*40:01/B*44:03/B*44:02	AIM	(Tarke et al., 2021)
AEVQIDRLI	S	989	997	B*44:03/B*44:02	AIM/multimer staining	(Tarke et al., 2021; Minervina et al., 2022)
AGFIKQYGDCLGDIA	S	831	845	HLA class I	ICS	(Zhang et al., 2022)
AHFPREGVF	S	1087	1095	B*39:01	AIM	(Tarke et al., 2022)
AIPINFTISV	S	710	719	A*02:01	multimer staining	(Xiao et al., 2022)
AIPTNFTISV	S	713	722	A*02:01	multimer staining	(Xiao et al., 2022)
ALDPLSETK	S	292	300	A*03:01	AIM	(Tarke et al., 2021)
ALNTLVKQL	S	958	966	A*02:01	ELISPOT/multimer staining/AIM/ICS	(Wagner et al., 2022; Hu et al., 2022; Prakash et al., 2021)
APHGVVFL	S	1056	1063	B*07:02	multimer staining	(Kared et al., 2021)
APHGVVFLHV	S	1056	1065	B*07:02	multimer staining	(Saini et al., 2021)
APHGVVFLHVTYV	S	1056	1068	HLA class I	HTMA	(Snyder et al., 2020)
AQALNTLVKQL	S	956	966	HLA class I	HTMA	(Snyder et al., 2020)
ASANLAATK	S	1020	1028	A*11:01	ICS	(Jin et al., 2021)
ASVYAWNRK	S	348	356	A*30:01	ICS	(Jin et al., 2021)
AYSNNSIAI	S	706	714	A*24:02	AIM	(Tarke et al., 2021)
CALDPLSETK	S	291	300	HLA class I	HTMA	(Snyder et al., 2020)
CEFQFCNDPFLGVYY	S	131	145	HLA class I	ICS	(Zhang et al., 2022)
CFTNVYADSF	S	391	400	A*24:02	ICS	(Jin et al., 2021)
CMTSCCSCLK	S	1236	1245	HLA class I	HTMA	(Snyder et al., 2020)
CNDPFLGVY	S	136	144	A*01:01/A*02:01	multimer staining	(Saini et al., 2021; Xiao et al., 2022)
CNDPFLGVYY	S	136	145	A*02:01	multimer staining	(Xiao et al., 2022)
CTFEYVSQPFLM	S	166	177	HLA class I	HTMA	(Snyder et al., 2020)
CTFEYVSQPFLMDLE	S	175	189	C*07:02	ELISPOT	(Peng et al., 2020)
CTLKSFTVEK	S	301	310	A*11:01	ICS	(Jin et al., 2021)
CVADYSVLY	S	361	369	A*29:02/A*26:01/A*01:01/B*15:01	AIM/ICS/multimer staining	(Saini et al., 2021; Tarke et al., 2021; Wagner et al., 2022)
DAVRDPQTL	S	574	582	B*51:01	AIM	(Tarke et al., 2021)
DGVYFASTEK	S	88	97	A*68:01	AIM	(Tarke et al., 2021)
DLPIGINITRFQTL	S	228	241	HLA class I	HTMA	(Snyder et al., 2020)
DSFKEELDKY	S	1146	1155	HLA class I	HTMA	(Snyder et al., 2020)
DSKVGGNYNY	S	442	451	A*26:01	AIM	(Tarke et al., 2021)
EILDITPCSF	S	583	592	A*26:01/A*02:01/B*07:02	AIM/multimer staining/HTMA	(Tarke et al., 2021; Weingarten-Gabbay et al., 2021)
EILDITPCSFG	S	583	593	A*02:01/B*07:02	multimer staining	(Weingarten-Gabbay et al., 2021)
EILPVSMTK	S	725	733	A*03:01/A*68:01	AIM	(Tarke et al., 2021)
EIYQAGSTPCNGVEG	S	471	485	HLA class I	ICS	(Zhang et al., 2022)
ELDSFKEEL	S	1144	1152	A*02:01	AIM	(Tarke et al., 2022)
ELLHAPATV	S	516	524	A*02:01	multimer staining	(Saini et al., 2021)
EPLVDLPI	S	224	231	B*51:01	AIM	(Tarke et al., 2021)
EPVLKGVKL	S	1262	1270	B*07:02	AIM/multimer staining	(Saini et al., 2021; Tarke et al., 2021)
ETKCTLKSF	S	298	306	A*26:01	AIM	(Tarke et al., 2021)
EVFAQVKQI	S	780	788	B*51:01	AIM	(Tarke et al., 2021)
EVFAQVKQIY	S	780	789	A*26:01	AIM	(Tarke et al., 2021)
EVFNATRFASVY	S	340	351	A*26:01	AIM	(Tarke et al., 2021)
EYVSQPFLM	S	169	177	A*24:02	AIM/ELISPOT	(Tarke et al., 2021; Hu et al., 2022)
FAMQMAYRF	S	898	906	B*35:01/B*51:01/B*57:03	ELISPOT/AIM	(Tarke et al., 2021; Somogyi et al., 2021; Tarke et al., 2022)
FASTEKSNI	S	92	100	B*51:01	AIM	(Tarke et al., 2022)
FASVYAWNR	S	347	355	A*68:01	AIM	(Tarke et al., 2021)
FCNDPFLGV	S	135	143	A*02:01	AIM	(Tarke et al., 2022)
FCNDPFLGVY	S	135	144	B*15:01/B*35:01/A*02:01	ELISA/multimer staining	(Titov et al., 2022; Xiao et al., 2022)
FCNDPFLGVYY	S	135	145	A*01:01	HTMA/multimer staining	(Saini et al., 2021; Snyder et al., 2020)
FDEDDSEPVL	S	1256	1265	B*40:01	AIM	(Tarke et al., 2021)
FDNPVLPFNDGVYF	S	79	92	B*35:01	AIM	(Tarke et al., 2021)
FELLHAPATV	S	515	524	A*02:01	multimer staining	(Saini et al., 2021)
FERDISTEI	S	464	472	B*40:01	AIM	(Tarke et al., 2021)
FERDISTEIY	S	464	473	B*44:03/B*15:01	AIM/multimer staining	(Saini et al., 2021; Tarke et al., 2021)
FEYVSQPFL	S	168	176	B*49:01	ICS	(Swaminathan et al., 2022)
FEYVSQPFLM	S	168	177	B*40:01	AIM	(Tarke et al., 2021)
FGEVFNATRFASVY	S	338	351	HLA class I	HTMA	(Snyder et al., 2020)
FIAGLIAIV	S	1220	1228	A*02:01	ELISPOT/multimer staining/AIM/ICS/HTMA	(Saini et al., 2021; Snyder et al., 2020; Jin et al., 2021; Poran et al., 2020; Prakash et al., 2021)
FIEDLLFNK	S	817	825	A*11:01	ICS/proliferation	(Jin et al., 2021)
FKIYSKHTPI	S	201	210	A*02:03	proliferation	(Jin et al., 2021)
FKNLREFVF	S	186	194	C*07:01	multimer staining	(Saini et al., 2021)
FLHVTYVPA	S	1062	1070	A*02:03	multimer staining/proliferation/ICS	(Jin et al., 2021; Deng et al., 2021)
FLPFFSNV	S	55	62	A*02:01	multimer staining	(Saini et al., 2021)
FLPFFSNVTW	S	55	64	B*53:01	AIM	(Tarke et al., 2021)
FLPFFSNVTWFHAI	S	55	68	HLA class I	HTMA	(Snyder et al., 2020)
FPQSAPHGV	S	1052	1060	B*07:02/B*53:01	AIM	(Tarke et al., 2021)
FPQSAPHGVVF	S	1052	1062	B*35:01/B*08:01	AIM/HTMA/multimer staining	(Saini et al., 2021; Snyder et al., 2020; Tarke et al., 2021)
FPREGVFV	S	1089	1096	B*51:01/B*07:02	AIM/multimer staining	(Saini et al., 2021; Tarke et al., 2021)
FQFCNDPFL	S	133	141	A*02:01	multimer staining	(Qiu et al., 2021)
FQPTNGVGY	S	497	505	B*15:01	ELISA/HTMA	(Snyder et al., 2020; Titov et al., 2022)
FRSSVLHST	S	43	51	C*07:01	multimer staining	(Saini et al., 2021)
FTISVTTEI	S	718	726	A*02:01/A*26:01/B*52:01	multimer staining/AIM/ELISPOT	(Tarke et al., 2021; Hu et al., 2022; Tarke et al., 2022; Qiu et al., 2021)
FTISVTTEIL	S	718	727	HLA class I	HTMA	(Snyder et al., 2020)
FVFFVLLPLV	S	2	11	A*02:01	multimer staining	(Qiu et al., 2021)
FVFKNIDGY	S	192	200	A*29:02/A*26:01	AIM/HTMA	(Snyder et al., 2020; Tarke et al., 2021)
FVFLVLLPL	S	2	10	A*02:01	ELISPOT	(Prakash et al., 2021)
FVFLVLLPLV	S	2	11	A*02:01	multimer staining/proliferation	(Jin et al., 2021; Qiu et al., 2021)
FVIRGDEVR	S	400	408	A*68:01	AIM	(Tarke et al., 2021)
FVSNGTHWF	S	1095	1103	A*26:01/B*35:01/C*12:03	AIM	(Tarke et al., 2021; Tarke et al., 2022)
FVSNGTHWFV	S	1095	1104	A*02:03	proliferation	(Jin et al., 2021)
GAAAYYVGY	S	261	269	A*29:02	AIM	(Tarke et al., 2021)
GCVIAWNSNNLDSKV	S	431	445	HLA class I	ICS/AIM	(Mahajan et al., 2021)
GEVFNATRF	S	339	347	B*40:01/B*44:02/B*44:03	AIM	(Tarke et al., 2021)
GGNYNYLYRLFRKSN	S	446	460	HLA class I	ICS/AIM	(Mahajan et al., 2021)
GIYQTSNFR	S	311	319	A*33:03	ICS	(Jin et al., 2021)
GKLQDVVNQNAQALN	S	946	960	HLA class I	ICS/AIM	(Mahajan et al., 2021)
GKYEQYIKW	S	1204	1212	A*24:02	ICS	(Shimizu et al., 2021)
GKYEQYIKWPWYIWL	S	1204	1218	A*24:02	ICS	(Shimizu et al., 2021)
GLTVLPPLL	S	857	865	A*02:01	AIM/multimer staining	(Tarke et al., 2021; Poran et al., 2020)
GNYNYLYRLF	S	447	456	A*24:02	multimer staining	(Saini et al., 2021)
GPKKSTNLV	S	526	534	HLA class I	HTMA	(Snyder et al., 2020)
GPKKSTNLVKNKCVN	S	535	549	A*31:01	ELISPOT	(Peng et al., 2020)
GRLQSLQTY	S	999	1007	B*27:05	ELISA	(Titov et al., 2022)
GSFCTQLNR	S	757	765	HLA class I	HTMA	(Snyder et al., 2020)
GTHWFVTQR	S	1099	1107	A*31:01/A*68:01/A*11:01/B*57:01	AIM/HTMA/multimer staining/ICS	(Snyder et al., 2020; Tarke et al., 2021; Jin et al., 2021; Kared et al., 2021; Tarke et al., 2022)
GTITSGWTF	S	880	888	A*24:02	AIM/HTMA/multimer staining	(Saini et al., 2021; Snyder et al., 2020; Tarke et al., 2021)
GVFVSNGTHW	S	1093	1102	B*57:01	AIM	(Tarke et al., 2021)
GVVFLHVTY	S	1059	1067	A*32:01	AIM	(Tarke et al., 2021)
GVYFASTEK	S	89	97	A*68:01/A*03:01/A*11:01	AIM/ICS/multimer staining	(Tarke et al., 2021; Wagner et al., 2022; Jin et al., 2021; Kared et al., 2021)
GVYHKNNK	S	140	147	A*11:01	ICS	(Zhang et al., 2021)
GVYYHKNNK	S	142	150	A*03:01/A*11:01	ICS/AIM/multimer staining	(Zhang et al., 2021; Tarke et al., 2021; Jin et al., 2021)
GVYYPDKVF	S	35	43	A*32:01	AIM	(Tarke et al., 2022)
GVYYPDKVFR	S	35	44	A*68:01/A*03:01	AIM	(Tarke et al., 2021)
GWTAGAAAYYVGYLQ	S	257	271	HLA class I	ELISA	(Li et al., 2021)
GYLQPRTFL	S	268	276	A*24:02	ELISPOT	(Hu et al., 2022)
GYLQPRTFLL	S	268	277	A*24:02	AIM	(Tarke et al., 2021)
GYQPYRVVVLSF	S	504	515	HLA class I	HTMA	(Snyder et al., 2020)
HADQLTPTW	S	625	633	A*02:01/B*07:02	multimer staining	(Weingarten-Gabbay et al., 2021)
HLMSFPQSA	S	1048	1056	A*02:01	AIM/multimer staining	(Saini et al., 2021; Tarke et al., 2021)
HVSGTNGTK	S	69	77	A*68:01	AIM	(Tarke et al., 2021)
HVTYVPAQEK	S	1064	1073	A*68:01	AIM	(Tarke et al., 2021)
HVTYVPAQEKNF	S	1064	1075	HLA class I	HTMA	(Snyder et al., 2020)
HWFVTQRNF	S	1101	1109	A*24:02	AIM/ELISPOT	(Tarke et al., 2021; Hu et al., 2022)
IAIPTNFTI	S	712	720	B*53:01/B*51:01	AIM	(Tarke et al., 2021)
IANQFNSAI	S	923	931	B*51:01/C*03:04	AIM	(Tarke et al., 2021; Tarke et al., 2022)
IEDLLFNKV	S	818	826	B*52:01	AIM	(Tarke et al., 2022)
IGAEHVNNSY	S	651	660	HLA class I	HTMA	(Snyder et al., 2020)
IGINITRFQTLLALH	S	231	245	HLA class I	ICS	(Zhang et al., 2022)
IITTDNTFV	S	1114	1122	A*02:01	HTMA/multimer staining	(Snyder et al., 2020; Xiao et al., 2022)
IHADQLTPTW	S	624	633	B*53:01	AIM	(Tarke et al., 2021)
IKWPWYIWL	S	1210	1218	A*24:02	ICS	(Shimizu et al., 2021)
ILPDPSKPSK	S	805	814	HLA class I	HTMA	(Snyder et al., 2020)
INITRFQTL	S	233	241	B*08:01	AIM	(Tarke et al., 2021)
IPFAMQMAY	S	896	904	B*35:01/B*51:01	multimer staining/AIM/ICS	(Tarke et al., 2021; Swaminathan et al., 2022)
IPFAMQMAYRFNGIG	S	896	910	HLA class I	ICS/AIM	(Mahajan et al., 2021)
IPIGAGICASY	S	664	674	HLA class I	HTMA	(Snyder et al., 2020)
IPTNFTISV	S	714	722	B*07:02/B*51:01	AIM/ multimer staining	(Tarke et al., 2021; Gangaev et al., 2021)
ISGINASVVNIQKEI	S	1169	1183	HLA class I	ICS	(Titov et al., 2022)
ITGRLQSLQTY	S	997	1007	A*01:01	multimer staining	(Saini et al., 2021)
IWLGFIAGL	S	1216	1224	A*24:02	ICS	(Shimizu et al., 2021)
IYKTPPIKDF	S	788	797	C*07:02/A*24:02	multimer staining/ICS	(Saini et al., 2021; Jin et al., 2021)
IYQTSNFRV	S	312	320	A*24:02	AIM/ELISPOT	(Tarke et al., 2021; Hu et al., 2022)
IYSKHTPINL	S	203	212	HLA class I	HTMA	(Snyder et al., 2020)
KCYGVSPTK	S	378	386	A*03:01/A*11:01	AIM/ELISA/ICS/multimer staining/cytotoxicity	(Saini et al., 2021; Tarke et al., 2021; Wagner et al., 2022; Titov et al., 2022; Ferretti et al., 2020)
KEIDRLNEV	S	1181	1189	B*44:03/B*44:02/B*40:01	AIM/HTMA	(Snyder et al., 2020; Tarke et al., 2021)
KFLPFQQFGR	S	558	567	A*31:01	AIM	(Tarke et al., 2021)
KIADYNYKL	S	417	425	A*02:01	ICS/ multimer staining/AIM/proliferation	(Zhang et al., 2021; Saini et al., 2021; Wagner et al., 2022; Chen et al., 2021)
KIYSKHTPI	S	202	210	B*08:01	AIM	(Tarke et al., 2021)
KLNDLCFTNV	S	386	395	A*02:01	ICS/multimer staining	(Jin et al., 2021; Poran et al., 2020)
KLPDDFTGCV	S	424	433	A*02:01	HTMA/multimer staining	(Saini et al., 2021; Snyder et al., 2020; Pan et al., 2021)
KNIDGYFKIY	S	195	204	A*02:01/B*07:02	multimer staining	(Weingarten-Gabbay et al., 2021)
KNLREFVFK	S	187	195	A*30:01	ICS	(Jin et al., 2021)
KPFERDISTEI	S	462	472	B*07:02	AIM	(Tarke et al., 2021)
KPFERDISTEIY	S	462	473	HLA class I	HTMA	(Snyder et al., 2020)
KQIYKTPPI	S	786	794	B*52:01	AIM	(Tarke et al., 2022)
KQIYKTPPIKDF	S	786	797	HLA class I	HTMA	(Snyder et al., 2020)
KSFTVEKGI	S	304	312	B*52:01	AIM	(Tarke et al., 2022)
KSNLKPFER	S	458	466	A*31:01	AIM	(Tarke et al., 2021)
KSWMESEFRVY	S	150	160	HLA class I	HTMA	(Snyder et al., 2020)
KTSVDCTMYI	S	733	742	HLA class I	HTMA	(Snyder et al., 2020)
KVFRSSVLH	S	41	49	A*30:01/A*03:01	AIM	(Tarke et al., 2021)
KVGGNYNYLY	S	444	453	A*29:02	AIM	(Tarke et al., 2021)
KWPWYIWLG	S	1211	1219	A*24:02	ICS	(Shimizu et al., 2021)
KWPWYIWLGF	S	1211	1220	A*24:02	ICS	(Wagner et al., 2022; Schulien et al., 2021)
KYEQYIKWP	S	1205	1213	A*24:02	ICS	(Shimizu et al., 2021)
KYEQYIKWPWYIWLG	S	1205	1219	HLA class I	ELISA	(Li et al., 2021)
LADAGFIKQY	S	828	837	A*01:01	ELISA/multimer staining	(Saini et al., 2021; Titov et al., 2022)
LEPLVDLPI	S	223	231	HLA class I	HTMA	(Snyder et al., 2020)
LGAENSVAY	S	699	707	B*35:01/C*16:02	AIM	(Tarke et al., 2021; Tarke et al., 2022)
LGAENSVAYSNN	S	699	710	HLA class I	HTMA	(Snyder et al., 2020)
LGFIAGLIA	S	1218	1226	A*24:02	ICS	(Shimizu et al., 2021)
LITGRLQSLQTYV	S	996	1008	HLA class I	HTMA	(Snyder et al., 2020)
LLALHRSYL	S	241	249	HLA class I	HTMA	(Snyder et al., 2020)
LLFNKVTLA	S	821	829	A*02:01	HTMA/multimer staining	(Snyder et al., 2020; Pan et al., 2021)
LLQYGSFCT	S	753	761	HLA class I	HTMA	(Snyder et al., 2020)
LPFNDGVYF	S	84	92	B*07:02/B*35:01/B*51:01	AIM/ICS	(Tarke et al., 2021; Wagner et al., 2022)
LPIGINITRF	S	229	238	B*07:02/B*35:01	AIM	(Tarke et al., 2021)
LPLVSSQCV	S	8	16	B*51:01	AIM	(Tarke et al., 2021)
LPPAYTNSF	S	24	32	B*53:01/B*07:02/B*35:01	AIM/HTMA	(Snyder et al., 2020; Tarke et al., 2021)
LPPLLTDEM	S	861	869	B*35:01/B*51:01	AIM	(Tarke et al., 2021; Tarke et al., 2022)
LPQGFSAL	S	216	223	B*08:01/B*07:02	AIM/HTMA/multimer staining	(Snyder et al., 2020; Tarke et al., 2021)
LPQGFSALEPL	S	216	226	B*07:02	multimer staining	(Saini et al., 2021)
LQELGKYEQY	S	1200	1209	A*01:01	multimer staining	(Saini et al., 2021)
LQELGKYEQYIKWPW	S	1200	1214	A*24:02	ICS	(Shimizu et al., 2021)
LQIPFAMQM	S	894	902	HLA class I	ELISA	(Titov et al., 2022)
LQIPFAMQMAY	S	894	904	HLA class I	HTMA	(Snyder et al., 2020)
LQPELDSFKEELDKY	S	1141	1155	HLA class I	ELISA	(Li et al., 2021)
LQSYGFQPT	S	492	500	A*02:06	proliferation	(Jin et al., 2021)
LQTYVTQQLIRAAEI	S	1004	1018	HLA class I	ELISA/ICS	(Titov et al., 2022)
LSSTASALGK	S	938	947	HLA class I	HTMA	(Snyder et al., 2020)
LLTDEMIAQY	S	864	873	A*01:01	multimer staining	(Saini et al., 2021)
LTDEMIAQY	S	865	873	A*01:01/A*29:02/B*35:01/C*07:02	ICS/AIM/multimer staining/ELISA/ELISPOT	(Saini et al., 2021; Tarke et al., 2021; Wagner et al., 2022; Titov et al., 2022; Schulien et al., 2021; Nelde et al., 2021; Kared et al., 2021; Gangaev et al., 2021; Minervina et al., 2022)
LTDEMIAQYT	S	865	874	A*01:01	multimer staining	(Saini et al., 2021)
LVKNKCVNF	S	533	541	B*15:01	multimer staining	(Saini et al., 2021)
LVKQLSSNF	S	962	970	A*32:01	AIM	(Tarke et al., 2022)
LYNSASFSTF	S	368	377	A*24:02	ICS	(Jin et al., 2021)
MIAQYTSAL	S	869	877	B*07:02/B*08:01/A*02:01	AIM/multimer staining/ICS	(Saini et al., 2021; Tarke et al., 2021; Jin et al., 2021)
MTKTSVDCTMYICGD	S	731	745	HLA class I	ICS	(Zhang et al., 2022)
NASVVNIQK	S	1173	1181	A*68:01	AIM	(Tarke et al., 2021)
NATNVVIKV	S	122	130	A*02:01/B*07:02/B*51:01/B*52:01/C*16:02	multimer staining/AIM	(Weingarten-Gabbay et al., 2021; Tarke et al., 2022)
NATRFASVY	S	343	351	B*35:01	AIM	(Tarke et al., 2021)
NCTFEYVSQPFLMDL	S	165	179	HLA class I	ELISPOT	(Zhao et al., 2021)
NESLIDLQEL	S	1194	1203	B*40:01	AIM	(Tarke et al., 2021)
NFRVQPTESIVRFPN	S	317	331	A*25:02	ELISPOT/AIM	(Zhao et al., 2021)
NGVEGFNCY	S	481	489	HLA class I	HTMA	(Snyder et al., 2020)
NGVEGFNCYFPLQSY	S	481	495	HLA class I	AIM	(Mahajan et al., 2021)
NGVGYQPYR	S	501	509	A*33:03	ICS	(Jin et al., 2021)
NIADYNYKL	S	414	422	A*02:01	ICS	(Zhang et al., 2021)
NITRFQTL	S	234	241	B*08:01	AIM	(Tarke et al., 2021)
NKSWMESEFRVYSSA	S	149	163	HLA class I	ELISPOT	(Zhao et al., 2021)
NLDSKVGGNY	S	440	449	HLA class I	HTMA	(Snyder et al., 2020)
NLNESLIDL	S	1192	1200	HLA class I	HTMA	(Snyder et al., 2020)
NLTTRTQL	S	17	24	HLA class I	HTMA	(Snyder et al., 2020)
NQKLIANQF	S	919	927	B*15:01/B*52:01	HTMA/multimer staining/AIM	(Snyder et al., 2020; Minervina et al., 2022; Tarke et al., 2022)
NSASFSTFK	S	370	378	A*68:01/A*11:01	AIM/ICS	(Tarke et al., 2021; Jin et al., 2021)
NSFTRGVYY	S	30	38	A*68:01/A*29:02/A*26:01	AIM	(Tarke et al., 2021)
NSIAIPTNF	S	710	718	B*57:01/B*52:01	AIM	(Tarke et al., 2021; Tarke et al., 2022)
NTSNQVAVL	S	603	611	C*16:02	AIM	(Tarke et al., 2022)
NTSNQVAVLY	S	603	612	A*26:01	AIM	(Tarke et al., 2021)
NVYADSFVIR	S	394	403	A*68:01/A*33:03	AIM/ICS	(Tarke et al., 2021; Jin et al., 2021)
NYNYLYRLF	S	448	456	A*24:02	multimer staining /AIM/ELISPOT/ICS	(Zhang et al., 2021; Tarke et al., 2021; Wagner et al., 2022; Hu et al., 2022; Jin et al., 2021; Kared et al., 2021; Gangaev et al., 2021; Minervina et al., 2022; Rowntree et al., 2021)
NYNYLYRLFRK	S	448	458	HLA class I	HTMA	(Snyder et al., 2020)
NYNYRYRLF	S	448	456	A*24:02	ICS	(Zhang et al., 2021)
PFFSNVTWF	S	57	65	A*24:02	multimer staining	(Saini et al., 2021)
PWYIWLGFI	S	1213	1221	A*24:02	ICS	(Shimizu et al., 2021)
PYRVVVLSF	S	507	515	A*24:02	ICS	(Jin et al., 2021)
QELGKYEQY	S	1201	1209	B*44:02/B*44:03	AIM	(Tarke et al., 2021)
QEVFAQVKQIY	S	779	789	B*44:02/B*44:03	AIM	(Tarke et al., 2021)
QEVFAQVKQIYK	S	779	790	HLA class I	HTMA	(Snyder et al., 2020)
QIAPGQTGK	S	409	417	A*68:01	AIM	(Tarke et al., 2021)
QIPFAMQMAY	S	895	904	B*35:01	AIM	(Tarke et al., 2021)
QLNRALTGI	S	762	770	A*02:03	proliferation	(Jin et al., 2021)
QLTPTWRVY	S	628	636	A*30:02/A*32:01/ A*02:01/B*07:02	AIM/ multimer staining	(Tarke et al., 2021; Tarke et al., 2022)
QPTESIVRF	S	321	329	B*35:01/B*07:02	AIM/ICS	(Tarke et al., 2021; Wagner et al., 2022)
QPTESIVRFPNITNL	S	321	335	HLA class I	AIM	(Zhao et al., 2021)
QPYRVVVL	S	506	513	B*08:01/B*07:02	AIM	(Tarke et al., 2021)
QPYRVVVLSF	S	506	515	B*07:02	AIM	(Tarke et al., 2021)
QPYRVVVLSFELLHA	S	506	520	HLA class I	ICS/AIM	(Mahajan et al., 2021)
QQLIRAAEIRASANL	S	1010	1024	HLA class I	ICS	(Titov et al., 2022)
QSAPHGVVF	S	1054	1062	C*07:02/C*03:04	multimer staining/AIM	(Saini et al., 2021; Tarke et al., 2022)
QTNSPRRAR	S	677	685	A*31:01/A*33:03	AIM/ICS	(Tarke et al., 2021; Jin et al., 2021)
QYIKWPWYI	S	1208	1216	A*23:01/A*24:02/C*06:02	multimer staining /AIM/ICS/cytotoxicity/ELISA/ELISPOT	(Saini et al., 2021; Tarke et al., 2021; Wagner et al., 2022; Titov et al., 2022; Ferretti et al., 2020; Nelde et al., 2021; Kared et al., 2021; Gangaev et al., 2021; Minervina et al., 2022; Shimizu et al., 2021; Rowntree et al., 2021)
QYIKWPWYIW	S	1208	1217	A*23:01	AIM	(Tarke et al., 2021)
QYIKWPWYIWLGFIA	S	1208	1222	A*24:02	ICS	(Shimizu et al., 2021)
RFPNITNLCPF	S	328	338	A*24:02	AIM	(Tarke et al., 2021)
RASANLAATK	S	1019	1028	A*03:01	AIM	(Tarke et al., 2021)
RDIADTTDAV	S	567	576	A*02:01	multimer staining	(Xiao et al., 2022)
REGVFVSNGTHW	S	1091	1102	B*44:03	AIM/HTMA	(Snyder et al., 2020; Tarke et al., 2021)
RFASVYAWNR	S	346	355	A*31:01	AIM	(Tarke et al., 2021)
RFDNPVLPF	S	78	86	A*24:02/C*07:02	AIM/HTMA/multimer staining	(Saini et al., 2021; Snyder et al., 2020; Tarke et al., 2021; Kared et al., 2021)
RISNCVADY	S	357	365	HLA class I	HTMA	(Snyder et al., 2020)
RISNCVADYSVLYNS	S	357	371	HLA class I	ELISPOT	(Zhao et al., 2021)
RLDKVEAEV	S	983	991	A*02:01	ELISPOT/HTMA/multimer staining /proliferation/ICS	(Saini et al., 2021; Snyder et al., 2020; Hu et al., 2022; Jin et al., 2021; Pan et al., 2021)
RLDKVEAEVQI	S	983	993	A*02:01	multimer staining	(Saini et al., 2021)
RLFRKSNLK	S	454	462	A*31:01/A*03:01/A*11:01	AIM/HTMA/ICS	(Snyder et al., 2020; Tarke et al., 2021; Wagner et al., 2022)
RLITGRLQSL	S	995	1004	A*02:01	multimer staining	(Pan et al., 2021)
RLNEVAKNL	S	1185	1193	A*02:01	multimer staining/HTMA	(Snyder et al., 2020; Gangaev et al., 2021; Qiu et al., 2021)
RLQSLQIYV	S	1000	1008	A*02:01	AIM	(Wu et al., 2022)
RLQSLQTY	S	1000	1007	B*15:01	AIM	(Tarke et al., 2021)
RLQSLQTYV	S	1000	1008	A*02:01/B*13:02/A*02:03	multimer staining /AIM/ELISPOT/ ELISA/ICS/ x-ray crystallography/ SPR	(Tarke et al., 2021; Titov et al., 2022; Jin et al., 2021; Poran et al., 2020; Prakash et al., 2021; Wu et al., 2022)
RNFYEPQII	S	1107	1115	B*52:01	AIM	(Tarke et al., 2022)
RSVASQSII	S	685	693	B*57:01	AIM	(Tarke et al., 2021)
RSVASQSIIAYTMSL	S	685	699	HLA class I	HTMA	(Snyder et al., 2020)
RVDFCGKGY	S	1039	1047	HLA class I	HTMA	(Snyder et al., 2020)
RVQPTESIVRF	S	319	329	B*07:02	multimer staining	(Saini et al., 2021)
RVVVLSFEL	S	509	517	A*32:01	AIM	(Tarke et al., 2022)
RVVVLSFELLHAPAT	S	509	523	B*50:02	ELISPOT	(Zhao et al., 2021)
RVYSTGSNV	S	634	642	A*30:01	AIM	(Tarke et al., 2021)
RVYSTGSNVF	S	634	643	B*15:01/A*24:02	AIM/multimer staining	(Saini et al., 2021; Tarke et al., 2021)
SANNCTFEY	S	162	170	A*29:02/B*35:01	AIM	(Tarke et al., 2021)
SASFSTFKCY	S	371	380	A*01:01	multimer staining	(Saini et al., 2021)
SASFSTFKCYGVSPT	S	371	385	HLA class I	ICS	(Zhang et al., 2022)
SEPVLKGVKL	S	1261	1270	B*40:01	AIM/ELISA/HTMA	(Snyder et al., 2020; Tarke et al., 2021; Titov et al., 2022)
SETKCTLKSF	S	297	306	B*44:02/B*44:03	AIM	(Tarke et al., 2021)
SETKCTLKSFTVEK	S	297	310	HLA class I	HTMA	(Snyder et al., 2020)
SFELLHAPATV	S	514	524	A*02:01	multimer staining	(Saini et al., 2021)
SFIEDLLF	S	816	823	A*24:02	multimer staining	(Saini et al., 2021)
SFKEELDKY	S	1147	1155	A*29:02	AIM	(Tarke et al., 2021)
SFPQSAPHGVVF	S	1051	1062	A*24:02	AIM	(Tarke et al., 2021)
SIIAYTMSL	S	691	699	B*08:01/A*02:01	ICS/AIM/multimer staining/ELISPOT	(Tarke et al., 2021; Habel et al., 2020; Quiros-Fernandez et al., 2021; Agerer et al., 2021; Prakash et al., 2021)
SIIAYTMSLGAENSV	S	691	705	HLA class I	ELISPOT	(Mateus et al., 2020)
SKRVDFCGKGY	S	1037	1047	A*01:01	multimer staining	(Saini et al., 2021)
SLIDLQEL	S	1196	1203	A*02:01	multimer staining	(Saini et al., 2021)
SLIDLQELGK	S	1196	1205	A*11:01	ICS	(Jin et al., 2021)
SNCVADYSVLYNSAS	S	359	373	HLA class I	ELISA	(Li et al., 2021)
SPRRARSV	S	680	687	B*08:01/B*07:02	AIM/multimer staining	(Saini et al., 2021; Tarke et al., 2021)
SPRRARSVA	S	680	688	B*07:02	ICS/multimer staining	(Saini et al., 2021; Schulien et al., 2021)
SRLDKVEAEV	S	982	991	A*02:01	AIM	(Tarke et al., 2022)
SSANNCTFEY	S	161	170	A*01:01	multimer staining	(Saini et al., 2021)
SSANNCTFEYVSQPF	S	161	175	HLA class I	ELISPOT	(Zhao et al., 2021)
STECSNLLLQY	S	746	756	A*01:01	multimer staining	(Saini et al., 2021)
STGSNVFQTR	S	637	646	A*31:01/A*68:01	AIM	(Tarke et al., 2021; Tarke et al., 2022)
STQDLFLPF	S	50	58	A*01:01/C*16:02	ELISPOT/multimer staining/AIM	(Saini et al., 2021; Somogyi et al., 2021; Tarke et al., 2022)
STQDLFLPFF	S	50	59	A*01:01	HTMA/multimer staining	(Saini et al., 2021; Snyder et al., 2020)
SVASQSIIAY	S	686	695	A*26:01/A*29:02	AIM	(Tarke et al., 2021)
SVASQSIIAYTMSLG	S	686	700	HLA class I	ELISPOT	(Mateus et al., 2020)
SVLNDILSR	S	975	983	A*68:01	AIM	(Tarke et al., 2021)
SVLNDILSRL	S	975	984	HLA class I	HTMA	(Snyder et al., 2020)
SVYAWNRKR	S	349	357	A*03:01/A*33:03	AIM/ICS	(Tarke et al., 2021; Jin et al., 2021)
SWMESEFRV	S	151	159	A*24:02	multimer staining	(Saini et al., 2021)
SWMESEFRVY	S	151	160	A*29:02	AIM	(Tarke et al., 2021)
SYQTQTNSPRRA	S	673	684	A*02:01	multimer staining	(Xiao et al., 2022)
TDEMIAQY	S	866	873	A*01:01	multimer staining	(Saini et al., 2021)
TECSNLLLQY	S	747	756	B*44:02/B*44:03	AIM	(Tarke et al., 2021)
TEILPVSMTK	S	724	733	HLA class I	HTMA	(Snyder et al., 2020)
TEKSNIIRGW	S	95	104	B*44:02/B*44:03	AIM/HTMA	(Snyder et al., 2020; Tarke et al., 2021)
TESIVRFPNITNL	S	323	335	B*40:01	AIM	(Tarke et al., 2021)
TESNKKFLPFQQF	S	553	565	B*44:02	AIM	(Tarke et al., 2021)
TFEYVSQPFLM	S	167	177	A*24:02	multimer staining	(Saini et al., 2021)
TIADYNYKL	S	417	425	A*02:01	ICS	(Zhang et al., 2021)
TLADAGFIK	S	827	835	A*03:01	AIM	(Tarke et al., 2021)
TLDSKTQSL	S	109	117	A*02:01/B*08:01//C*07:02	AIM/HTMA/multimer staining	(Saini et al., 2021; Snyder et al., 2020; Tarke et al., 2021; Sekine et al., 2020)
TPCSFGGVSV	S	588	597	B*07:02	AIM/multimer staining	(Saini et al., 2021; Tarke et al., 2021)
TPINLVRDL	S	208	216	B*07:02	AIM/HTMA/multimer staining	(Saini et al., 2021; Snyder et al., 2020; Tarke et al., 2021)
TQDLFLPFF	S	51	59	A*24:02	multimer staining	(Saini et al., 2021)
TQLNRALTGI	S	761	770	HLA class I	HTMA	(Snyder et al., 2020)
TQLNRALTGIAVEQD	S	761	775	HLA class I	ICS	(Zhang et al., 2022)
TQNVLYENQK	S	912	921	HLA class I	HTMA	(Snyder et al., 2020)
TRFASVYAW	S	345	353	C*07:02	multimer staining	(Saini et al., 2021)
TRTQLPPAY	S	20	28	C*07:02	multimer staining	(Saini et al., 2021)
TSNQVAVLY	S	604	612	B*57:01/B*35:01/A*26:01	AIM/HTMA	(Snyder et al., 2020; Tarke et al., 2021)
TVYDPLQPELDSFK	S	1136	1149	A*03:01	AIM/HTMA	(Snyder et al., 2020; Tarke et al., 2021)
TYVPAQEKNFT	S	1066	1076	A*24:02	multimer staining	(Saini et al., 2021)
VAIHADQLTPTW	S	622	633	B*57:01	AIM	(Tarke et al., 2021)
VASQSIIAY	S	687	695	B*35:01/A*29:02/B*15:01	AIM/multimer staining	(Saini et al., 2021; Tarke et al., 2021)
VEAEVQIDRLITGR	S	987	1000	HLA class I	HTMA	(Snyder et al., 2020)
VFAQVKQIY	S	781	789	A*29:02/C*07:01	AIM/multimer staining	(Saini et al., 2021; Tarke et al., 2021)
VFNATRFASVYAWNR	S	341	355	HLA class I	ICS/AIM	(Mahajan et al., 2021)
VFVSNGTHW	S	1094	1102	A*24:02	multimer staining	(Saini et al., 2021)
VFVSNGTHWF	S	1094	1103	A*24:02	AIM	(Tarke et al., 2021)
VGGNYNYLY	S	445	453	A*29:02	AIM	(Tarke et al., 2021)
VGYLQPRTF	S	267	275	A*02:01/B*07:02/B*51:01	multimer staining/AIM	(Weingarten-Gabbay et al., 2021; Tarke et al., 2022)
VGYLQPRTFL	S	267	276	A*24:02	multimer staining	(Saini et al., 2021)
VGYQPYRVV	S	503	511	C*06:02	multimer staining	(Saini et al., 2021)
VFKNIDGYF	S	193	201	A*24:02	AIM/ELISPOT/ICS	(Tarke et al., 2021; Hu et al., 2022; Rowntree et al., 2021)
VLKGVKLHY	S	1264	1272	A*29:02	AIM	(Tarke et al., 2021)
VLNDILARL	S	973	981	A*02:01	multimer staining	(Xiao et al., 2022)
VLNDILSRL	S	976	984	A*02:01/A*32:01	ELISPOT/multimer staining/AIM/ICS	(Saini et al., 2021; Habel et al., 2020; Xiao et al., 2022; Prakash et al., 2021; Tarke et al., 2022)
VLPFNDGVYFA	S	83	93	A*02:01	multimer staining	(Saini et al., 2021)
VLPFNDGVYFASTEK	S	83	97	HLA class I	HTMA	(Snyder et al., 2020)
VLPPLLTDEMIAQYT	S	860	874	HLA class I	HTMA	(Snyder et al., 2020)
VLTESNKKF	S	551	559	B*15:01	multimer staining	(Saini et al., 2021)
VRFPNITNL	S	327	335	B*13:02	ELISA	(Titov et al., 2022)
VTWFHAIHV	S	62	70	A*02:01	multimer staining	(Xiao et al., 2022; Deng et al., 2021)
VTWFHAISG	S	62	70	A*02:01	multimer staining	(Xiao et al., 2022)
VTYVPAQEK	S	1065	1073	A*30:01/A*03:01/A*11:01	AIM/ICS	(Tarke et al., 2021; Jin et al., 2021)
VVFLHVTYV	S	1060	1068	A*02:01/A*02:06/C*16:02	multimer staining/AIM/ELISA/ICS	(Saini et al., 2021; Tarke et al., 2021; Wagner et al., 2022; Titov et al., 2022; Kared et al., 2021; Tarke et al., 2022; Qiu et al., 2021)
VVNQNAQAL	S	951	959	C*15:02	AIM	(Tarke et al., 2022)
VYAWNRKRI	S	350	358	A*24:02	ICS	(Jin et al., 2021)
VYDPLQPEL	S	1137	1145	A*24:02	ELISPOT	(Hu et al., 2022)
VYDPLQPELDSF	S	1137	1148	A*24:02	AIM	(Tarke et al., 2021)
VYSSANNCTF	S	159	168	A*24:02	AIM	(Tarke et al., 2021)
VYSSANNCTFEY	S	159	170	HLA class I	HTMA	(Snyder et al., 2020)
VYSTGSNVFQTR	S	635	646	HLA class I	HTMA	(Snyder et al., 2020)
VYYPDKVF	S	36	43	A*24:02	AIM	(Tarke et al., 2021)
VYYPDKVFR	S	36	44	A*33:03	ICS	(Jin et al., 2021)
VYYPDKVFRSSVLH	S	36	49	HLA class I	HTMA	(Snyder et al., 2020)
WFVTQRNFY	S	1102	1110	A*29:02	AIM	(Tarke et al., 2021)
WIFGTTLDSK	S	104	113	HLA class I	HTMA	(Snyder et al., 2020)
WLGFIAGLI	S	1217	1225	A*24:02	ICS	(Shimizu et al., 2021)
WPWYIWLGF	S	1212	1220	A*24:02	ICS	(Shimizu et al., 2021)
WPWYIWLGFIAGLIA	S	1212	1226	A*24:02	ICS	(Shimizu et al., 2021)
WTAGAAAYY	S	258	266	A*26:01/B*35:01/A*29:02/A*01:01	AIM/ICS	(Tarke et al., 2021; Wagner et al., 2022)
WTAGAAAYYVGY	S	258	269	HLA class I	HTMA	(Snyder et al., 2020)
WTFGAGAAL	S	886	894	A*26:01	AIM	(Tarke et al., 2021)
WYIWLGFIA	S	1214	1222	A*24:02	ICS	(Shimizu et al., 2021)
YAWNRKRI	S	351	358	B*51:01	AIM	(Tarke et al., 2021)
YECDIPIGAGI	S	660	670	B*40:01	AIM	(Tarke et al., 2021)
YENQKLIANQF	S	917	927	B*44:02	AIM	(Tarke et al., 2021)
YEQYIKWPW	S	1206	1214	B*44:03/B*44:02/A*24:02	ICS/AIM	(Tarke et al., 2021; Schulien et al., 2021; Shimizu et al., 2021)
YEQYIKWPWYI	S	1206	1216	A*24:02	HTMA/multimer staining	(Saini et al., 2021; Snyder et al., 2020)
YFPLQSYGF	S	489	497	A*29:01/A*24:02/A*29:02	ICS/HTMA/multimer staining/AIM	(Saini et al., 2021; Snyder et al., 2020; Wagner et al., 2022; Swaminathan et al., 2022; Panikkar et al., 2022)
YFQPRTFLL	S			A*02:01	multimer staining	(Agerer et al., 2021)
YGFQPTNGV	S	495	503	B*51:01/A*02:01	AIM/multimer staining	(Tarke et al., 2021; Xiao et al., 2022)
YHLMSFPQSA	S	1047	1056	HLA class I	HTMA	(Snyder et al., 2020)
YIKWPWYIW	S	1209	1217	A*24:02	ICS	(Shimizu et al., 2021)
YIWLGFIAG	S	1215	1223	A*24:02	ICS	(Shimizu et al., 2021)
YIWLGFIAGL	S	1215	1224	A*02:01	multimer staining	(Qiu et al., 2021)
YLQLRTFLL	S	269	277	A*02:01	AIM	(Wu et al., 2022)
YLQPRIFLL	S	269	277	A*02:01	SPR	(Chaurasia et al., 2021)
YYHKNNKSW	S	144	152	A*24:02	AIM	(Tarke et al., 2021)
YLQPRTFLL	S	269	277	B*08:01/A*02:01/B*07:02/A*24:02	SPR/ELISPOT/multimer staining /AIM /ICS/ELISA/ x-ray crystallography /cytotoxicity	(Saini et al., 2021; Tarke et al., 2021; Weingarten-Gabbay et al., 2021; Wagner et al., 2022; Habel et al., 2020; Titov et al., 2022; Swaminathan et al., 2022; Ferretti et al., 2020; Somogyi et al., 2021; Panikkar et al., 2022; Kared et al., 2021; Gangaev et al., 2021; Sekine et al., 2020; Quiros-Fernandez et al., 2021; Agerer et al., 2021; Minervina et al., 2022; Wu et al., 2022; Chaurasia et al., 2021)
YLYRLFRKSNLKPFE	S	451	465	HLA class I	AIM	(Mahajan et al., 2021)
YNYKLPDDFTGCVIA	S	421	435	HLA class I	ICS/AIM	(Mahajan et al., 2021)
YNYLYRLFR	S	449	457	A*31:01	AIM	(Tarke et al., 2021)
YQAGSTPCNGVEGFN	S	473	487	A*02:06	ELISPOT	(Zhao et al., 2021)
YQDVNCTEV	S	612	620	A*02:01/A*02:06	multimer staining/AIM	(Tarke et al., 2021; Qiu et al., 2021)
YQPYRVVVL	S	505	513	C*06:02	multimer staining	(Saini et al., 2021)
YSVLYNSASFSTFK	S	365	378	HLA class I	HTMA	(Snyder et al., 2020)
YTMSLGAENSVAY	S	695	707	A*26:01	AIM	(Tarke et al., 2021)
YTNSFTRGVY	S	28	37	A*01:01/A*26:01/C*16:02	AIM/multimer staining	(Saini et al., 2021; Tarke et al., 2021; Tarke et al., 2022)
YTNSFTRGVYY	S	28	38	A*01:01	multimer staining	(Saini et al., 2021)
YVGYLQPRTFLLKYN	S	266	280	HLA class I	ICS/AIM	(Mahajan et al., 2021)
YYVGYLQPR	S	265	273	A*33:03	ICS	(Jin et al., 2021)
YYVGYLQPRTF	S	265	275	A*24:02	AIM	(Tarke et al., 2021)
YYVGYLQPRTFLL	S	265	277	A*02:01	HTMA	(Snyder et al., 2020)
AAVYRINW	M	68	75	B*57:01	AIM	(Tarke et al., 2021)
AGDSGFAAY	M	188	196	A*01:01	AIM	(Tarke et al., 2021)
AIAMACLVGLM	M	81	91	HLA class I	HTMA	(Snyder et al., 2020)
AMACLVGLM	M	83	91	A*02:03	ICS	(Jin et al., 2021)
ANRNRFLYI	M	40	48	B*08:01	multimer staining	(Saini et al., 2021)
ASQRVAGDSGFAAY	M	183	196	HLA class I	HTMA	(Snyder et al., 2020)
ATSRTLSYY	M	171	179	A*11:01/B*57:01/A*01:01	AIM/multimer staining /ELISA/cytotoxicity	(Tarke et al., 2021; Titov et al., 2022; Ferretti et al., 2020; Gangaev et al., 2021)
ATSRTLSYYK	M	171	180	A*30:01	AIM/ELISA/multimer staining/ELISPOT/proliferation/cytotoxicity	(Tarke et al., 2021; Titov et al., 2022; Ferretti et al., 2020; Jin et al., 2021; Zhang et al., 2022)
ATSRTLSYYKLGASQ	M	171	185	HLA class I	ICS	(Heide et al., 2021)
AVILRGHLR	M	142	150	A*68:01	AIM/HTMA	(Snyder et al., 2020; Tarke et al., 2021)
AYANRNRF	M	38	45	A*24:02	multimer staining	(Saini et al., 2021)
AYANRNRFL	M	38	46	A*24:02	multimer staining	(Saini et al., 2021)
CLVGLMWLSYFIASF	M	86	100	HLA class I	ICS	(Heide et al., 2021)
DSGFAAYSR	M	190	198	A*68:01	AIM	(Tarke et al., 2021)
EELKKLLEQWNLVIG	M	11	25	HLA class I	ICS	(Heide et al., 2021)
ELVIGAVILR	M	137	146	A*68:01	AIM	(Tarke et al., 2021)
FAYANRNRF	M	37	45	B*35:01/B*15:01	AIM/multimer staining	(Saini et al., 2021; Tarke et al., 2021)
FIASFRLFA	M	96	104	A*02:03	ICS	(Jin et al., 2021)
FIASFRLFARTRSMW	M	96	110	HLA class I	ICS	(Heide et al., 2021)
FLFLTWICL	M	26	34	A*02:01	multimer staining/ICS	(Habel et al., 2020; Poran et al., 2020)
FLFLTWICLL	M	26	35	A*02:01	ICS	(Jin et al., 2021)
FLWLLWPVTL	M	53	62	A*02:01	multimer staining	(Saini et al., 2021; Pan et al., 2021)
FLYIIKLIFL	M	45	54	A*02:07	ICS	(Jin et al., 2021)
FRLFARTRSM	M	100	109	B*08:01	multimer staining	(Saini et al., 2021)
FVLAAVYRI	M	65	73	A*02:01/A*68:02	Multime staining /cytotoxicity/ICS/AIM	(Tarke et al., 2021; Deng et al., 2021; Pan et al., 2021)
GAVILRGHLRIAGHH	M	141	155	HLA class I	ICS	(Heide et al., 2021)
GFMWLSYFI	M	89	97	A*02:01	multimer staining	(Agerer et al., 2021)
GLMWLSYFI	M	89	97	A*02:01	multimer staining/ICS/ELISPOT	(Saini et al., 2021; Jin et al., 2021; Agerer et al., 2021; Prakash et al., 2021; Deng et al., 2021; Pan et al., 2021)
GTITVEELK	M	6	14	A*68:01	AIM/HTMA	(Snyder et al., 2020; Tarke et al., 2021)
GTITVEELKKLLEQW	M	6	20	HLA class I	ICS	(Heide et al., 2021)
HLRIAGHHL	M	148	156	B*08:01/A*30:01	ELISA/multimer staining/ICS	(Saini et al., 2021; Titov et al., 2022; Jin et al., 2021)
HLRIAGHHLGR	M	148	158	HLA class I	HTMA	(Snyder et al., 2020)
IAMACLVGL	M	82	90	A*02:06	ICS/proliferation	(Jin et al., 2021)
IASFRLFAR	M	97	105	A*33:01	AIM	(Tarke et al., 2021)
IFLWLLWPV	M	52	60	A*02:01	ELISPOT	(Prakash et al., 2021)
IKDLPKEITVATSRT	M	161	175	HLA class I	ICS	(Heide et al., 2021)
ILRGHLRIA	M	144	152	A*02:03	proliferation	(Jin et al., 2021)
KEITVATSRTLSYYK	M	166	180	HLA class I	ICS	(Heide et al., 2021)
KLLEQWNLV	M	15	23	A*02:01	AIM/ICS	(Tarke et al., 2021; Habel et al., 2020; Jin et al., 2021)
LAAVYRINW	M	67	75	B*57:01	AIM	(Tarke et al., 2021)
LAAVYRINWI	M	67	76	HLA class I	HTMA	(Snyder et al., 2020)
LLWPVTLAC	M	56	64	A*02:01	multimer staining	(Saini et al., 2021)
LLWPVTLACFV	M	56	66	A*02:01	multimer staining	(Pan et al., 2021)
LPKEITVAT	M	164	172	B*07:02	AIM	(Tarke et al., 2021)
LQFAYANRNRFLY	M	35	47	HLA class I	HTMA	(Snyder et al., 2020)
LSYFIASFR	M	93	101	A*31:01/A*68:01/A*11:01	AIM/proliferation	(Tarke et al., 2021; Jin et al., 2021)
LSYYKLGASQRVAGD	M	176	190	HLA class I	ICS	(Heide et al., 2021)
LVIGAVILR	M	138	146	A*68:01/A*11:01	AIM/ICS	(Tarke et al., 2021; Jin et al., 2021)
LWLLWPVTL	M	54	62	A*24:02	ICS	(Rowntree et al., 2021)
LWPVTLACF	M	57	65	A*24:02	ICS	(Jin et al., 2021; Rowntree et al., 2021)
LYIIKLIFLW	M	46	55	A*24:02	ICS	(Jin et al., 2021)
MACLVGLMW	M	84	92	B*57:01	AIM	(Tarke et al., 2021)
NGTITVEELK	M	5	14	A*68:01	AIM	(Tarke et al., 2021)
NRFLYIIKL	M	43	51	B*08:01/C*07:02	ELISA/multimer staining/ELISPOT/ICS	(Saini et al., 2021; Titov et al., 2022; Nelde et al., 2021)
NRNRFLYIIKLIFLW	M	41	55	HLA class I	ICS	(Heide et al., 2021)
QFAYANRNRFLYIIK	M	36	50	HLA class I	ICS	(Heide et al., 2021)
QWNLVIGFLF	M	19	28	A*24:02	ICS	(Jin et al., 2021)
RFLYIIKLIF	M	44	53	A*24:02	multimer staining/ICS	(Saini et al., 2021; Jin et al., 2021)
RGHLRIAGHHLGRCD	M	146	160	HLA class I	ICS	(Heide et al., 2021)
RIAGHHLGR	M	150	158	A*03:01	AIM	(Tarke et al., 2021)
RLFARTRS	M	101	108	HLA class I	ELISPOT	(Somogyi et al., 2021)
RLFARTRSM	M	101	109	A*30:01	AIM	(Tarke et al., 2021)
RLFARTRSMW	M	101	110	HLA class I	HTMA	(Snyder et al., 2020)
RLFARTRSMWSFNPE	M	101	115	HLA class I	ICS	(Heide et al., 2021)
RNRFLYIIK	M	42	50	A*30:01	AIM/proliferation/ICS	(Tarke et al., 2021; Jin et al., 2021)
RNRFLYIIKL	M	42	51	C*07:01	multimer staining	(Saini et al., 2021)
RPLLESEL	M	131	138	B*07:02	AIM	(Tarke et al., 2021)
RTRSMWSF	M	105	112	B*57:01	AIM	(Tarke et al., 2021)
RTRSMWSFN	M	105	113	A*30:01	proliferation/ICS	(Jin et al., 2021)
RVAGDSGFAAY	M	186	196	B*15:01/A*01:01	AIM/multimer staining/ICS	(Saini et al., 2021; Tarke et al., 2021; Minervina et al., 2022)
RVAGDSGFAAYSRY	M	186	199	A*30:02	AIM	(Tarke et al., 2021)
RVAGDSGFAAYSRYR	M	186	200	HLA class I	ICS	(Heide et al., 2021)
RYRIGNYKL	M	198	206	A*30:01/A*24:02	AIM/ELISA/HTMA/ICS	(Saini et al., 2021; Snyder et al., 2020; Tarke et al., 2021; Titov et al., 2022; Jin et al., 2021; Rowntree et al., 2021)
SELVIGAVI	M	136	144	B*44:02	AIM	(Tarke et al., 2021)
SELVIGAVIL	M	136	145	B*40:10/B*40:01	HTMA/ELISPOT/ICS	(Snyder et al., 2020; Wagner et al., 2022; Nelde et al., 2021)
SELVIGAVILRGHLR	M	136	150	HLA class I	ICS	(Heide et al., 2021)
SFNPETNIL	M	111	119	B*08:01	multimer staining	(Saini et al., 2021)
SFNPETNILLNVPLH	M	111	125	HLA class I	ICS	(Heide et al., 2021)
SFRLFARTR	M	99	107	A*33:03	ICS	(Jin et al., 2021)
SGFAAYSRYRIGNYK	M	191	205	HLA class I	ICS	(Heide et al., 2021)
SMWSFNPET	M	108	116	A*02:01	AIM/multimer staining	(Saini et al., 2021; Tarke et al., 2021)
SMWSFNPETNIL	M	108	119	HLA class I	HTMA	(Snyder et al., 2020)
SQRVAGDSGF	M	184	193	B*15:01	multimer staining	(Saini et al., 2021)
SSSDNIALL	M	212	220	A*68:02	AIM	(Tarke et al., 2021)
SYFIASFRL	M	94	102	A*24:02	ICS	(Rowntree et al., 2021)
SYFIASFRLF	M	94	103	A*24:02	ICS	(Jin et al., 2021)
SYFIASFRLFA	M	94	104	HLA class I	HTMA	(Snyder et al., 2020)
TLACFVLAAV	M	61	70	A*02:07/A*02:01	multimer staining /ICS/proliferation	(Jin et al., 2021; Deng et al., 2021)
TRSMWSFNPETNILL	M	106	120	HLA class I	ICS	(Heide et al., 2021)
TSRTLSYYK	M	172	180	A*30:01	ICS	(Jin et al., 2021)
TVATSRTLSY	M	169	178	A*01:01	multimer staining	(Saini et al., 2021; Gangaev et al., 2021)
TVATSRTLSYYK	M	169	180	HLA class I	HTMA	(Snyder et al., 2020)
VATSRTLSY	M	170	178	B*35:01/B*07:02/A*01:01	AIM/multimer staining	(Saini et al., 2021; Tarke et al., 2021; Weingarten-Gabbay et al., 2021)
VATSRTLSYY	M	170	179	A*01:01	multimer staining	(Saini et al., 2021)
VPLHGTIL	M	122	129	B*07:02	AIM	(Tarke et al., 2021)
VTLACFVLA	M	60	68	A*02:06	proliferation	(Jin et al., 2021)
WICLLQFAY	M	31	39	HLA class I	HTMA	(Snyder et al., 2020)
WLLWPVTLA	M	55	63	A*02:01	ICS	(Habel et al., 2020)
YANRNRFLY	M	39	47	B*35:01/A*01:01	AIM/ELISA	(Tarke et al., 2021; Titov et al., 2022)
YSRYRIGNYK	M	196	205	A*30:01/A*11:01	AIM/proliferation	(Tarke et al., 2021; Jin et al., 2021)
YSRYRIGNYKLNTDH	M	196	210	HLA class I	ICS	(Heide et al., 2021)
YYKLGASQR	M	178	186	A*33:03	ICS	(Jin et al., 2021)
AAGLEAPFLY	ORF3a	98	107	A*01:01	multimer staining	(Saini et al., 2021)
AAGLEAPFLYLY	ORF3a	98	109	B*44:02	AIM	(Tarke et al., 2021)
AGLEAPFLY	ORF3a	99	107	A*29:02	AIM	(Tarke et al., 2021)
ALLAVFQSA	ORF3a	51	59	A*02:01	multimer staining	(Saini et al., 2021)
ALSKGVHFV	ORF3a	72	80	A*02:01	ELISA/HTMA/multimer staining/ELISPOT	(Saini et al., 2021; Snyder et al., 2020; Titov et al., 2022; Nelde et al., 2021; Kared et al., 2021; Minervina et al., 2022)
APFLYLYAL	ORF3a	103	111	B*08:01/B*07:02	multimer staining	(Saini et al., 2021)
ATIPIQASL	ORF3a	33	41	B*57:01	AIM	(Tarke et al., 2021)
CRSKNPLLY	ORF3a	133	141	C*06:02	multimer staining	(Saini et al., 2021)
DYYQLYSTQL	ORF3a	210	219	A*24:02	multimer staining	(Saini et al., 2021)
EEHVQIHTI	ORF3a	241	249	HLA class I	HTMA	(Snyder et al., 2020)
FLYLYALVY	ORF3a	105	113	C*07:02	multimer staining	(Saini et al., 2021)
FTIGTVTLK	ORF3a	8	16	A*68:01	AIM	(Tarke et al., 2021)
FTSDYYQLY	ORF3a	207	215	A*01:01/A*24:02	ICS/multimer staining/AIM/ELISA/cytotoxicity	(Saini et al., 2021; Tarke et al., 2021; Wagner et al., 2022; Titov et al., 2022; Schulien et al., 2021; Swaminathan et al., 2022; Ferretti et al., 2020; Panikkar et al., 2022; Kared et al., 2021; Gangaev et al., 2021; Peng et al., 2020; Minervina et al., 2022)
FVRATATIPI	ORF3a	28	37	HLA class I	HTMA	(Snyder et al., 2020)
FVRIIMRLW	ORF3a	120	128	B*57:01	AIM	(Tarke et al., 2021)
FVTVYSHLL	ORF3a	87	95	A*02:01	multimer staining	(Saini et al., 2021)
GLEAPFLYL	ORF3a	100	108	A*02:01	AIM	(Tarke et al., 2021)
HSYFTSDYY	ORF3a	204	212	A*29:02	AIM	(Tarke et al., 2021)
HVTFFIYNK	ORF3a	227	235	A*68:01	AIM	(Tarke et al., 2021)
IPIQASLPF	ORF3a	35	43	B*35:01/B*51:01	AIM/HTMA	(Snyder et al., 2020; Tarke et al., 2021)
IPYNSVTSSI	ORF3a	158	167	HLA class I	HTMA	(Snyder et al., 2020)
IPYNSVTSSIVI	ORF3a	158	169	B*51:01	AIM	(Tarke et al., 2021)
ITLKKRWQL	ORF3a	63	71	B*08:01/B*57:01	AIM	(Tarke et al., 2021)
ITLKKRWQLAL	ORF3a	63	73	HLA class I	HTMA	(Snyder et al., 2020)
IVGVALLAVF	ORF3a	47	56	HLA class I	HTMA	(Snyder et al., 2020)
IYDEPTTTT	ORF3a	263	271	C*07:02	multimer staining	(Saini et al., 2021)
LEAPFLYLY	ORF3a	101	109	A*29:02	AIM	(Tarke et al., 2021)
LLYDANYFL	ORF3a	139	147	A*02:01	ICS/multimer staining/AIM/ELISA/cytotoxicity	(Saini et al., 2021; Weingarten-Gabbay et al., 2021; Wagner et al., 2022; Titov et al., 2022; Schulien et al., 2021; Swaminathan et al., 2022; Ferretti et al., 2020; Kared et al., 2021; Quiros-Fernandez et al., 2021; Minervina et al., 2022)
LPFGWLIV	ORF3a	41	48	B*51:01	AIM	(Tarke et al., 2021)
LYLYALVYF	ORF3a	106	114	A*24:02	AIM	(Tarke et al., 2021)
MDLFMRIFTI	ORF3a	1	10	HLA class I	HTMA	(Snyder et al., 2020)
NLLLLFVTV	ORF3a	82	90	A*02:01	multimer staining/ICS	(Saini et al., 2021)
NPLLYDANY	ORF3a	137	145	B*53:01	AIM	(Tarke et al., 2021)
NPLLYDANYFL	ORF3a	137	147	A*02:01	multimer staining	(Saini et al., 2021)
NPLLYDANYFLCW	ORF3a	137	149	HLA class I	HTMA	(Snyder et al., 2020)
QSASKIITL	ORF3a	57	65	B*08:01	AIM/multimer staining	(Saini et al., 2021; Tarke et al., 2021)
RIFTIGTVTLK	ORF3a	6	16	HLA class I	HTMA	(Snyder et al., 2020)
SASKIITLK	ORF3a	58	66	A*03:01/A*11:01	multimer staining	(Kared et al., 2021)
SASKIITLKKRW	ORF3a	58	69	B*57:01	AIM	(Tarke et al., 2021)
SEHDYQIGGYTEKW	ORF3a	180	193	HLA class I	HTMA	(Snyder et al., 2020)
SYFTSDYYQLY	ORF3a	205	215	A*24:02	multimer staining	(Saini et al., 2021)
TLKKRWQLA	ORF3a	64	72	B*08:01	multimer staining	(Saini et al., 2021)
TTSPISEHDY	ORF3a	175	184	HLA class I	HTMA	(Snyder et al., 2020)
TVYSHLLLV	ORF3a	89	97	A*02:01	AIM	(Tarke et al., 2021)
VAAGLEAPF	ORF3a	97	105	B*35:01	AIM	(Tarke et al., 2021)
VLHSYFTSDYYQLY	ORF3a	202	215	HLA class I	HTMA	(Snyder et al., 2020)
VYFLQSINF	ORF3a	112	120	A*24:02	ICS/multimer staining/ELISPOT/ELISA/cytotoxicity	(Wagner et al., 2022; Ferretti et al., 2020; Nelde et al., 2021; Kared et al., 2021; Minervina et al., 2022)
VRIIMRLWL	ORF3a	121	129	C*07:02	multimer staining	(Saini et al., 2021)
YFTSDYYQL	ORF3a	206	214	C*07:02	multimer staining	(Saini et al., 2021)
YFTSDYYQLY	ORF3a	206	215	A*29:02/A*29:01/A*01:01	AIM/ICS/multimer staining	(Saini et al., 2021; Tarke et al., 2021; Swaminathan et al., 2022; Panikkar et al., 2022)
YLYALVYFL	ORF3a	107	115	A*02:01	ICS/multimer staining	(Schulien et al., 2021; Kared et al., 2021)
YYQLYSTQL	ORF3a	211	219	A*24:02/C*07:02	/ELISPOTAIM/ELISA/HTMA/multimer staining	(Saini et al., 2021; Snyder et al., 2020; Tarke et al., 2021; Titov et al., 2022; Nelde et al., 2021)
HLVDFQVTI	ORF6	3	11	A*02:01	ELISPOT/ELISA/HTMA/multimer staining	(Saini et al., 2021; Snyder et al., 2020; Titov et al., 2022; Prakash et al., 2021)
HLVDFQVTIA	ORF6	3	12	A*02:01	multimer staining	(Saini et al., 2021)
IIKNLSKSLTENKY	ORF6	36	49	HLA class I	HTMA	(Snyder et al., 2020)
LDYIINLII	ORF6	29	37	HLA class I	HTMA	(Snyder et al., 2020)
LIIMRTFKV	ORF6	16	24	B*08:01	multimer staining	(Saini et al., 2021)
RTFKVSIWNLDY	ORF6	20	31	A*01:01	ELISPOT	(Nelde et al., 2021)
SIWNLDYIINL	ORF6	25	35	A*02:01	multimer staining	(Saini et al., 2021)
TFKVSIWNL	ORF6	21	29	B*08:01	multimer staining	(Saini et al., 2021)
VTIAEILLI	ORF6	9	17	HLA class I	HTMA	(Snyder et al., 2020)
EGNSPFHPL	ORF7a	41	49	B*08:01	multimer staining	(Saini et al., 2021)
FACPDGVKHVY	ORF7a	65	75	A*01:01	multimer staining	(Saini et al., 2021)
FAFACPDGVKHVYQL	ORF7a	63	77	HLA class I	HTMA	(Snyder et al., 2020)
FIRQEEVQELY	ORF7a	87	97	A*01:01/B*15:01	multimer staining	(Saini et al., 2021)
GLITLSYHL	ORF7a			A*02:01/B*07:02	multimer staining	(Weingarten-Gabbay et al., 2021)
HPLADNKFAL	ORF7a	47	56	B*08:01	multimer staining	(Saini et al., 2021)
IRQEEVQEL	ORF7a	88	96	A*02:01/B*07:02	multimer staining	(Weingarten-Gabbay et al., 2021)
KFALTCFSTQF	ORF7a	53	63	A*24:02	multimer staining	(Saini et al., 2021)
KLFIRQEEV	ORF7a	85	93	HLA class I	HTMA	(Snyder et al., 2020)
LLKEPCSSGTY	ORF7a	30	40	B*15:01	multimer staining	(Saini et al., 2021)
QECVRGTTVL	ORF7a	21	30	HLA class I	HTMA	(Snyder et al., 2020)
QLRARSVSPK	ORF7a	76	85	A*03:01	ELISA/ELISPOT	(Titov et al., 2022; Nelde et al., 2021)
RARSVSPKL	ORF7a	78	86	B*07:02	multimer staining	(Kared et al., 2021)
RARSVSPKLFIR	ORF7a	78	89	HLA class I	HTMA	(Snyder et al., 2020)
SPFHPLADNKFAL	ORF7a	44	56	HLA class I	HTMA	(Snyder et al., 2020)
SPIFLIVAA	ORF7a	98	106	B*07:02	multimer staining	(Saini et al., 2021)
VFITLCFTLK	ORF7a	108	117	HLA class I	HTMA	(Snyder et al., 2020)
VQELYSPIFLIV	ORF7a	93	104	HLA class I	HTMA	(Snyder et al., 2020)
YEGNSPFHPL	ORF7a	40	49	B*40:01	HTMA/ELISPOT	(Snyder et al., 2020; Nelde et al., 2021)
IIFWFSLEL	ORF7b	26	34	A*02:01	ELISPOT	(Prakash et al., 2021)
IMLIIFWFSL	ORF7b	23	32	HLA class I	HTMA	(Snyder et al., 2020)
EPKLGSLVV	ORF8	92	100	B*07:02	multimer staining	(Saini et al., 2021)
EYHDVRVVL	ORF8	110	118	A*24:02	multimer staining	(Saini et al., 2021)
EYHDVRVVLDF	ORF8	110	120	A*24:02	multimer staining	(Saini et al., 2021)
FLGIITTV	ORF8	6	13	A*02:01	multimer staining	(Saini et al., 2021)
GARKSAPLI	ORF8	50	58	A*02:01	multimer staining	(Xiao et al., 2022)
GNYTVSCLPFTI	ORF8	77	88	HLA class I	HTMA	(Snyder et al., 2020)
IQYIDIGNY	ORF8	71	79	HLA class I	HTMA	(Snyder et al., 2020)
KLGSLVVRC	ORF8	94	102	A*02:01	multimer staining	(Saini et al., 2021)
LEYHDVRVVL	ORF8	109	118	B*40:01	ELISPOT	(Nelde et al., 2021)
QECSLQSCT	ORF8	18	26	A*02:01	multimer staining	(Xiao et al., 2022)
QSCTQHQPY	ORF8	23	31	A*01:01	multimer staining	(Saini et al., 2021)
RVGARKSAPL	ORF8	48	57	HLA class I	HTMA	(Snyder et al., 2020)
VDDPCPIHFY	ORF8	33	42	A*01:01	multimer staining	(Saini et al., 2021)
YEDFLEYHDVRVVL	ORF8	105	118	HLA class I	HTMA	(Snyder et al., 2020)
YIDIGNYTV	ORF8	73	81	A*02:01	ELISPOT/multimer staining	(Xiao et al., 2022; Prakash et al., 2021)
YVVDDPCPI	ORF8	31	39	A*02:01	ELISPOT	(Prakash et al., 2021)
YVVDDPCPIHFY	ORF8	31	42	HLA class I	HTMA	(Snyder et al., 2020)
DEFVVVTV	ORF9b	89	96	A*02:01/B*07:02	multimer staining	(Weingarten-Gabbay et al., 2021)
ELPDEFVVV	ORF9b	86	94	A*02:01/B*07:02	multimer staining	(Weingarten-Gabbay et al., 2021)
ELPDEFVVVTV	ORF9b	86	96	A*02:01/B*07:02	multimer staining	(Weingarten-Gabbay et al., 2021)
KAFQLTPIAV	ORF9b	67	76	A*02:01/B*07:02	multimer staining	(Weingarten-Gabbay et al., 2021)
LEDKAFQL	ORF9b	64	71	A*02:01/B*07:02	multimer staining	(Weingarten-Gabbay et al., 2021)
SLEDKAFQL	ORF9b	63	71	A*02:01/B*07:02	multimer staining	(Weingarten-Gabbay et al., 2021)
NVFAFPFTI	ORF10	5	13	A*02:01/B*13:01	ELISPOT	(Prakash et al., 2021; Ma et al., 2021)
NYIAQVDVVNFNL	ORF10	25	37	HLA class I	HTMA	(Snyder et al., 2020)
SLLLCRMNSRNYIA	ORF10	15	28	HLA class I	HTMA	(Snyder et al., 2020)
YINVFAFPF	ORF10	3	11	A*02:01	ELISPOT	(Prakash et al., 2021)

Table 2.

List of CD4⁺ T-cell epitopes validated from SARS-CoV-2 antigens.

Sequence	Protein	Start	End	HLA restriction	Methods to validate the epitope peptides	References
AADLDDFSKQLQQSM	N	397	411	DR	ELISPOT/ICS	(Nelde et al., 2021)
AAEASKKPRQKRTAT	N	251	265	HLA class II	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
AALALLLLDRLNQLE	N	217	231	DRB1*11:01	ELISA/CBA/AIM	(Panikkar et al., 2022; Verhagen et al., 2021)
AALALLLLDRLNQLESKMS	N	217	235	HLA class II	ELISA	(Verhagen et al., 2021)
AALALLLLDRLNQLESKMSG	N	217	236	DRB1*03:01/DRB1*11:01/DRB1*11:04/DRB3*01:01	multimer staining	(Johansson et al., 2021)
ADETQALPQRQKKQQ	N	376	390	HLA class II	ICS	(Heide et al., 2021)
AFFGMSRIGMEVTPS	N	313	327	HLA class II	ELISPOT	(Keller et al., 2020)
AFFGMSRIGMEVTPSGTWLT	N	313	332	DRB1*04:01/DRB1*04:04/DRB1*11:01	multimer staining /multimer staining	(Johansson et al., 2021)
AGNGGDAALALLLLD	N	211	225	DQB1*03:01/DQB1*06:02	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
AIKLDDKDPNFKDQV	N	336	350	DRB1*03:01	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
AIVLQLPQGTTLPKG	N	156	170	DR	ELISPOT	(Nelde et al., 2021)
ALALLLLDRLNQLESKM	N	218	234	HLA class II	ELISPOT	(de Castro et al., 2022)
ALPQRQKKQQTVTLL	N	381	395	HLA class II	ICS	(Heide et al., 2021)
ANKDGIIWVATEGALNTPK	N	125	143	HLA class II	ELISA	(Verhagen et al., 2021)
AQFAPSASAFFGMSRIGMEV	N	305	324	DRB1*07:01/DRB1*11:01	multimer staining	(Johansson et al., 2021)
ASAFFGMSRIGMEVT	N	311	325	DRB1*11:01/DRB1*11:04/DRB1*01:02/DRB1*14:01/DQB1*05:03/	ICS/AIM/ELISPOT/ELISA	(Tarke et al., 2021; Titov et al., 2022; Nelde et al., 2021; Heide et al., 2021; Rammensee et al., 2021)
ASWFTALTQHGKEDL	N	50	64	DRB4*01:03	ELISA/ICS/ELISPOT	(Titov et al., 2022; Nelde et al., 2021)
DAALALLLLDRLNQL	N	216	230	DPB1*02:01/DPA1*01:03/DPB1*04:01/DQA1*05:01/DQB1*02:01/DQA1*05:01/DQB1*03:01/DQA1*03:01/DQB1*03:02/DQA1*01:01/DQB1*05:01/DQA1*01:02/DQB1*06:02/DRB1*01:01/DRB1*04:01/DRB1*04:05/DRB1*08:02/DRB1*09:01/DRB1*11:01/DRB1*13:02/DRB3*01:01/DRB4*01:01/DRB5*01:01/DQB1*05:03/DRB1*15:01/DRB1*14:01/DRB1*12:01/DRB1*03:01/DQB1*06:02	ICS/AIM/ELISPOT	(Tarke et al., 2021; Mateus et al., 2020; Heide et al., 2021)
DDFSKQLQQSMSSADSTQA	N	401	419	DRB1*11:01	multimer staining	(Johansson et al., 2021)
DDQIGYYRRATRRIR	N	81	95	DPB1*02:01/DQA1*05:01/DQB1*03:01/DRB1*01:01/DRB1*04:01/DRB1*04:05/DRB1*07:01/DRB1*08:02/DRB1*09:01/DRB1*11:01/DRB3*01:01/DRB3*02:02/DRB5*01:01/DRB1*11:01/DRB1*01:01/DRB1*13:01/DRB1*16:02/DRB1*15:01/DRB1*14:06/DRB1*14:01	ICS/AIM/ELISA/ELISPOT	(Tarke et al., 2021; Le Bert et al., 2020; Mateus et al., 2020; Heide et al., 2021; Verhagen et al., 2021)
DDQIGYYRRATRRIRGG	N	81	97	DRB1*11:01	AIM	(Pogorelyy et al., 2022)
DDQIGYYRRATRRIRGGDG	N	81	99	HLA class II	ELISA	(Verhagen et al., 2021)
DDQIGYYRRATRRIRGGDGK	N	81	100	DRB1*11:01/DRB5*01:01	multimer staining	(Johansson et al., 2021)
DKKKKADETQALPQR	N	371	385	HLA class II	ICS	(Heide et al., 2021)
DLSPRWYFYYLGTGP	N	103	117	HLA class II	ICS	(Schmidt et al., 2021)
DQIGYYRRATRRIRGG	N	82	97	HLA class II	ELISPOT	(de Castro et al., 2022)
DYKHWPQIAQFAPSA	N	297	311	HLA class II	ELISA	(Verhagen et al., 2021)
DYKHWPQIAQFAPSASAFFG	N	297	316	DRB1*07:01	multimer staining	(Johansson et al., 2021)
EGALNTPKDHIGTRN	N	136	150	HLA class II	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
ERSGARSKQRRPQGL	N	31	45	HLA class II	ICS	(Heide et al., 2021)
ESKMSGKGQQQQGQT	N	231	245	HLA class II	ICS	(Heide et al., 2021)
FGDQELIRQGTDYKH	N	286	300	HLA class II	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
FKDQVILLNKHIDAY	N	346	360	DPB1*02:01/DPA1*01:03/DPB1*04:01/DQA1*05:01/DQB1*02:01/DQA1*05:01/DQB1*03:01/DQA1*03:01/DQB1*03:02/DQA1*01:01/DQB1*05:01/DQA1*01:02/DQB1*06:02/DRB1*01:01/DRB1*04:01/DRB1*04:05/DRB1*07:01/DRB1*08:02/DRB1*09:01/DRB1*11:01/DRB1*12:01/DRB1*13:02/DRB3*01:01/DRB3*02:02/DRB4*01:01/DRB5*01:01/DQB1*06:02/DRB1*03:01/DRB1*16:02/DRB1*15:01/DRB1*14:06/DRB1*14:01	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
FPRGQGVPINTNSSP	N	66	80	HLA class II	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
FYAEGSRGGSQASSR	N	171	185	HLA class II	ICS	(Heide et al., 2021)
GGDGKMKDLSPRWYF	N	96	110	HLA class II	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
GIIWVATEGALNTPK	N	129	143	DRB1*04:01/DRB1*04:04	AIM	(Panikkar et al., 2022)
GIIWVATEGALNTPKDHIGT	N	129	148	DRB1*04:01DRB1*04:04/DRB1*07:01	multimer staining	(Johansson et al., 2021)
GKGQQQQGQTVTKKS	N	236	250	HLA class II	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
GMEVTPSGTWLTYTG	N	321	335	HLA class II	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
GMEVTPSGTWLTYTGAIKLD	N	321	340	DRB1*07:01/DRB5*01:01	multimer staining/ICS	(Le Bert et al., 2020; Johansson et al., 2021)
GMSRIGMEVTPSGTW	N	316	330	HLA class II	ICS	(Heide et al., 2021)
GPEAGLPYGANKDGI	N	116	130	HLA class II	ICS	(Heide et al., 2021)
GTWLTYTGAIKLDDK	N	328	342	DR	ELISPOT/ICS/AIM	(Nelde et al., 2021)
GVPINTNSSPDDQIG	N	71	85	HLA class II	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
GYYRRATRRIRGGDG	N	85	99	DRB1*08:01/DRB1*11:01	AIM	(Panikkar et al., 2022)
HIDAYKTFPPTEPKK	N	356	370	HLA class II	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
IGYYRRATRRIRGGD	N	84	98	DR11/DRB1*13:01/DRB1*11:01/DRB1*11:04	ICS/ELISA/ELISPOT/AIM	(Titov et al., 2022; Nelde et al., 2021; Rammensee et al., 2021)
IKLDDKDPNFKDQVI	N	337	351	HLA class II	AIM	(Zhao et al., 2021)
ILLNKHIDAYKTFPP	N	351	365	DRB1*14:06/DRB1*15:01	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
IWVATEGALNTPKDH	N	131	145	HLA class II	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
KAYNVTQAFGRRGPE	N	266	280	DPB1*02:01/DPA1*01:03/DPB1*04:01/DQA1*05:01/DQB1*03:01/DQA1*03:01/DQB1*03:02/DQA1*01:02/DQB1*06:02/DRB1*01:01/DRB1*04:01/DRB1*04:05/DRB1*07:01/DRB1*08:02/DRB1*09:01/DRB1*11:01/DRB1*13:02/DRB1*15:01/DRB3*01:01/DRB3*02:02/DRB4*01:01/DRB5*01:01	ICS/AIM	(Tarke et al., 2021; Le Bert et al., 2020; Heide et al., 2021)
KDGIIWVATEGALNT	N	127	141	DR	ELISPOT/ICS/AIM	(Nelde et al., 2021)
KEDLKFPRGQGVPIN	N	61	75	HLA class II	ICS	(Heide et al., 2021)
KGFYAEGSRGGSQASSRSSS	N	169	188	DRB1*04:01	multimer staining	(Johansson et al., 2021)
KKPRQKRTATKAYNV	N	256	270	HLA class II	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021; Le Bert et al., 2021)
KPRQKRTATKAYNVT	N	257	271	DPA1*02:01/DPB1*14:01	ELISPOT	(Keller et al., 2020)
KPRQKRTATKAYNVTQAFGR	N	257	276	DRB1*07:01/DRB5*01:01	multimer staining	(Johansson et al., 2021)
KQQTVTLLPAADLDDF	N	388	403	DRB1	ELISPOT	(Prakash et al., 2021)
KRTATKAYNVTQAFG	N	261	275	DQB1*06:02/DQB1*06:03	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
KTFPPTEPKKDKKKK	N	361	375	HLA class II	ICS	(Heide et al., 2021)
LIRQGTDYKHWPQIA	N	291	305	HLA class II	ICS/AIM	(Tarke et al., 2021; Le Bert et al., 2020; Heide et al., 2021)
LLLLDRLNQLESKMS	N	221	235	DPB1*02:01/DRB1*03:01/DRB1*04:01/DRB1*04:05/DRB1*07:01/DRB1*08:02/DRB1*09:01/DRB1*11:01/DRB1*12:01/DRB1*13:02/DRB1*15:01/DPA1*01:03/DPB1*04:01/DQA1*05:01/DQB1*02:01/DQA1*03:01/DQB1*03:02/DQA1*01:01/DQB1*05:01/DQA1*01:02/DQB1*06:02/DRB1*01:01/DRB3*01:01/DRB4*01:01/DRB5*01:01/DRB1*01:01/DRB1*11:01/DRB1*03:01/DRB1*15:01/DRB1*14:01/DRB1*12:01	ICS/AIM/ELISPOT	(Tarke et al., 2021; Nelde et al., 2021; Mateus et al., 2020; Heide et al., 2021; Rammensee et al., 2021)
LNKHIDAYKTFPPTEPKKDK	N	353	372	DRB1*11:01/DPB1*04:01	multimer staining	(Johansson et al., 2021)
LPNNTASWFTALTQHGKED	N	45	63	HLA class II	ELISA	(Verhagen et al., 2021)
LPQGTTLPKGFYAEG	N	161	175	HLA class II	ICS	(Heide et al., 2021)
LPQGTTLPKGFYAEGSRGGS	N	161	180	DRB1*04:01	multimer staining	(Johansson et al., 2021)
LPYGANKDGIIWVAT	N	121	135	DPB1*02:01/DPA1*01:03/DPB1*04:01/DQA1*05:01/DQB1*02:01/DQA1*05:01/DQB1*03:01/DQA1*03:01/DQB1*03:02/DQA1*01:02/DQB1*06:02/DRB1*01:01/DRB1*03:01/DRB1*04:01/DRB1*04:05/DRB1*07:01/DRB1*08:02/DRB1*09:01/DRB1*11:01/DRB1*12:01/DRB1*15:01/DRB3*01:01/DRB3*02:02/DRB4*01:01/DRB5*01:01	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
LPYGANKDGIIWVATEGALN	N	121	140	DRB1*04:01/DRB1*04:04/DRB1*07:01	multimer staining	(Johansson et al., 2021)
LTQHGKEDLKFPRGQ	N	56	70	HLA class II	AIM	(Tarke et al., 2021)
LTYTGAIKLDDKDPN	N	331	345	DRB1*07:01	ICS,AIM	(Tarke et al., 2021; Heide et al., 2021)
MKDLSPRWYFYYLGT	N	101	115	HLA class II	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
MKDLSPRWYFYYLGTGPEAG	N	25	44	HLA class II	ICS	(Le Bert et al., 2020)
MSDNGPQNQRNAPRI	N	1	15	HLA class II	ICS	(Heide et al., 2021)
NAPRITFGGPSDSTG	N	11	25	DQB1*03:01	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
NFGDQELIRQGTDYKHWPQ	N	285	303	HLA class II	ELISA/CBA	(Verhagen et al., 2021)
NFKDQVILLNKHIDAYKTF	N	345	363	HLA class II	ELISA	(Verhagen et al., 2021)
NFKDQVILLNKHIDAYKTFP	N	345	364	DRB1*11:01/DRB1*11:04/DPB1*04:01	multimer staining	(Johansson et al., 2021)
NKDGIIWVATEGALN	N	126	140	DPB1*02:01/DPA1*01:03/DPB1*04:01/DQA1*05:01/DQB1*02:01/DQA1*05:01/DQB1*03:01/DQA1*03:01/DQB1*03:02/DQA1*01:02/DQB1*06:02/DRB1*01:01/DRB1*03:01/DRB1*04:01/DRB1*04:05/DRB1*08:02/DRB1*09:01/DRB1*11:01/DRB1*15:01/DRB3*01:01/DRB3*02:02/DRB4*01:01/DRB5*01:01/DQB1*02:01/DRB1*07:01/DRB1*04:04/DQB1*05:03/DQB1*03:02/DQB1*02:02	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
NSTPGSSKRTSPARM	N	196	210	HLA class II	ICS	(Heide et al., 2021)
PANNAAIVLQLPQGT	N	151	165	HLA class II	ICS	(Heide et al., 2021)
PNFKDQVILLNKHIDAYK	N	5	22	HLA class II	ELISPOT	(Peng et al., 2020)
PNNTASWFTALTQHG	N	46	60	HLA class II	ICS	(Heide et al., 2021)
PQNQRNAPRITFGGP	N	6	20	HLA class II	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
PRWYFYYLGTGPEAG	N	106	120	DPB1*02:01/DQA1*05:01/DQB1*02:01/DQA1*05:01/DQB1*03:01/DQA1*03:01/DQB1*03:02/DQA1*01:01/DQB1*05:01/DQA1*01:02/DQB1*06:02/DRB1*01:01/DRB1*04:01/DRB1*04:05/DRB1*07:01/DRB1*08:02/DRB1*09:01/DRB1*11:01/DRB1*12:01/DRB1*15:01/DRB3*01:01/DRB3*02:02/DRB5*01:01/DRB1*01:01/DRB1*11:01/DQB1*05:01/DQB1*05:03/DQB1*02:01	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
PSASAFFGMSRIGMEVTPS	N	309	327	HLA class II	ELISA	(Verhagen et al., 2021)
PSGTWLTYTGAIKLD	N	326	340	DQB1*06:03/DRB1*15:01/DRB1*07:01/DRB1*01:02	ICS/AIM/ELISPOT	(Tarke et al., 2021; Mateus et al., 2020; Heide et al., 2021)
QASSRSSSRSRNSSR	N	181	195	HLA class II	ICS	(Heide et al., 2021)
QELIRQGTDYKHWPQ	N	289	303	HLA class II	ELISA	(Verhagen et al., 2021)
QELIRQGTDYKHWPQIAQF	N	289	307	HLA class II	ELISA	(Verhagen et al., 2021)
QELIRQGTDYKHWPQIAQFA	N	289	308	DRB4*01:01	multimer staining	(Johansson et al., 2021)
QFAPSASAFFGMSRI	N	306	320	DRB1*07:01	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
QKKQQTVTLLPAADL	N	386	400	DRB1*01:02	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
QQGQTVTKKSAAEAS	N	241	255	HLA class II	ICS	(Heide et al., 2021)
QQTVTLLPAADLDDF	N	389	403	HLA class II	ELISA	(Verhagen et al., 2021)
QRNAPRITFGGPSDSTGSN	N	9	27	HLA class II	ELISA	(Verhagen et al., 2021)
QTQGNFGDQELIRQG	N	281	295	HLA class II	ICS	(Heide et al., 2021)
QTQGNFGDQELIRQGTDYKH	N	281	300	DRB4*01:01	multimer staining	(Johansson et al., 2021)
QVILLNKHIDAYKTF	N	349	363	HLA class II	ELISA/AIM	(Zhao et al., 2021; Verhagen et al., 2021)
RATRRIRGGDGKMKD	N	89	103	HLA class II	ELISA	(Verhagen et al., 2021)
RATRRIRGGDGKMKDLSPRW	N	89	108	DRB5*01:01	multimer staining	(Johansson et al., 2021)
RLNQLESKMSGKGQQ	N	226	240	HLA class II	ICS	(Heide et al., 2021)
RMAGNGGDAALALLL	N	209	223	HLA class II	ELISA	(Verhagen et al., 2021)
RMAGNGGDAALALLLLDRL	N	209	227	HLA class II	ELISA	(Verhagen et al., 2021)
RNSSRNSTPGSSKRT	N	191	205	HLA class II	ICS	(Heide et al., 2021)
RPQGLPNNTASWFTA	N	41	55	HLA class II	ICS	(Heide et al., 2021)
RPQGLPNNTASWFTALTQHG	N	41	60	DRB1*04:01	multimer staining	(Johansson et al., 2021)
RQGTDYKHWPQIAQFAPSA	N	293	311	HLA class II	ELISA	(Verhagen et al., 2021)
RQKKQQTVTLLPAADLDDFS	N	385	404	DRB1*01:01	multimer staining	(Johansson et al., 2021)
RRGPEQTQGNFGDQE	N	276	290	HLA class II	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
RSKQRRPQGLPNNTA	N	36	50	HLA class II	ICS	(Heide et al., 2021)
RWYFYYLGTGPEAGL	N	107	121	DRB1*11:01/DRB3*02:02	ELISPOT/ICS/AIM/ELISA	(Titov et al., 2022; Nelde et al., 2021; Rammensee et al., 2021)
SAFFGMSRIGMEVTPSGTW	N	312	330	HLA class II	ELISPOT	(de Castro et al., 2022)
SDSTGSNQNGERSGA	N	21	35	HLA class II	ICS	(Heide et al., 2021)
SNQNGERSGARSKQR	N	26	40	HLA class II	ICS	(Heide et al., 2021)
SPARMAGNGGDAALA	N	206	220	HLA class II	ICS	(Heide et al., 2021)
SPRWYFYYLGTGPEA	N	105	119	HLA class II	ELISA	(Verhagen et al., 2021)
SPRWYFYYLGTGPEAGLPY	N	105	123	HLA class II	ELISA	(Verhagen et al., 2021)
SRGGSQASSRSSSRS	N	176	190	HLA class II	ICS	(Heide et al., 2021)
SSKRTSPARMAGNGG	N	201	215	HLA class II	ICS	(Heide et al., 2021)
SSSRSRNSSRNSTPG	N	186	200	HLA class II	ICS	(Heide et al., 2021)
SWFTALTQHGKEDLK	N	51	65	DQA1*05:01/DQB1*02:01/DPA1*01:03/DPB1*04:01/DQB1*03:01/DQA1*03:01/DQB1*03:02/DQA1*01:02/DQB1*06:02/DRB1*01:01/DRB1*04:01/DRB1*04:05/DRB1*07:01/DRB1*08:02/DRB1*09:01/DRB1*11:01/DRB1*12:01/DRB1*15:01/DRB3*02:02/DRB4*01:01/DRB5*01:01/DRB1*15:01/DQB1*06:02	ICS	(Le Bert et al., 2020; Heide et al., 2021)
TASWFTALTQHGKEDLKFPR	N	49	68	DRB1*04:01/DRB5*01:01	multimer staining	(Johansson et al., 2021)
TDYKHWPQIAQFAPS	N	296	310	HLA class II	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
TEPKKDKKKKADETQ	N	366	380	HLA class II	ICS	(Heide et al., 2021)
TFGGPSDSTGSNQNG	N	16	30	DQB1*03:01	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
TKAYNVTQAFGRRGPEQTQG	N	265	284	DRB1*07:01/DRB5*01:01	multimer staining	(Johansson et al., 2021)
TLPKGFYAEGSRGGS	N	166	180	HLA class II	ICS	(Heide et al., 2021)
TNSSPDDQIGYYRRA	N	76	90	HLA class II	ICS	(Heide et al., 2021)
TPKDHIGTRNPANNA	N	141	155	HLA class II	ICS	(Heide et al., 2021)
TQAFGRRGPEQTQGN	N	271	285	HLA class II	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
TRRIRGGDGKMKDLS	N	91	105	HLA class II	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
TVTLLPAADLDDFSK	N	391	405	DRB1*01:02/DQB1*05:03	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
TWLTYTGAIKLDDKD	N	329	343	HLA class II	ELISA	(Verhagen et al., 2021)
TWLTYTGAIKLDDKDPNF	N	329	346	HLA class II	ELISPOT	(Peng et al., 2020)
TWLTYTGAIKLDDKDPNFKD	N	329	348	DRB5*01:01/DRB1*07:01/DRB1*03:01	multimer staining	(Johansson et al., 2021)
VTKKSAAEASKKPRQ	N	246	260	HLA class II	ICS	(Heide et al., 2021)
WLTYTGAIKL	N	330	339	HLA class II	ICS	(Jin et al., 2021)
WPQIAQFAPSASAFF	N	301	315	DQB1*02:02/DRB1*15:01/DRB1*07:01/DRB1*04:04/DQB1*05:03	ICS/AIM	(Tarke et al., 2021; Le Bert et al., 2020; Heide et al., 2021)
YKHWPQIAQFAPSAS	N	298	312	DR	ELISPOT/ICS	(Nelde et al., 2021)
YKTFPPTEPK	N	360	369	HLA class II	ICS	(Jin et al., 2021)
YTGAIKLDDKDPNFK	N	333	347	HLA class II	ELISA	(Verhagen et al., 2021)
YYLGTGPEAGLPYGA	N	111	125	HLA class II	ICS	(Heide et al., 2021)
YYRRATRRIRG	N	86	96	DRB1*11:01	ICS	(Heide et al., 2021)
YYRRATRRIRGGDGK	N	86	100	DQA1*05:01/DQB1*03:01/DRB1*01:01/DRB1*04:01/DRB1*04:05/DRB1*07:01/DRB1*08:02/DRB1*09:01/DRB1*12:01/DRB1*15:01/DRB3*01:01/DRB3*02:02/DRB4*01:01/DRB5*01:01/DRB1*01:01/DRB1*13:01/DRB1*14:06	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
YYRRATRRIRGGDGKMK	N	86	102	DRB1*11:01	AIM	(Pogorelyy et al., 2022)
AYCCNIVNVSLVKPS	E	41	55	HLA class II	ICS	(Heide et al., 2021)
FLAFVVFLLVTLAIL	E	20	34	DRB1	ELISPOT	(Prakash et al., 2021)
FLLVTLAILTALRLC	E	26	40	DRB1	ICS/ELISPOT	(Prakash et al., 2021; Heide et al., 2021)
FYVYSRVKNLNSSRV	E	56	70	DRB1*01:01/DRB1*04:01/DRB1*15:01/DR11/DR	multimer staining/ICS/ELISPOT	(Poluektov et al., 2021; Nelde et al., 2021; Heide et al., 2021; Rammensee et al., 2021)
IVNVSLVKPSFYVYS	E	46	60	HLA class II	ICS	(Heide et al., 2021)
LAILTALRLCAYCCN	E	31	45	HLA class II	ELISPOT	(Mateus et al., 2020)
LIVNSVLLFL	E	12	21	HLA class II	ICS	(Jin et al., 2021)
LVKPSFYVYSRVKNL	E	51	65	DPB1*02:01/DPA1*01:03/DPB1*04:01/DQA1*05:01/DQB1*03:01/DQA1*01:02/DQB1*06:02/DRB1*01:01/DRB1*04:01/DRB1*04:05/DRB1*07:01/DRB1*08:02/DRB1*09:01/DRB1*11:01/DRB1*12:01/DRB1*13:02/DRB1*15:01/DRB3*01:01/DRB3*02:02/DRB4*01:01/DRB5*01:01/DRB1*11:01/DRB1*01:01	ICS	(Heide et al., 2021)
MYSFVSEETGTLIVN	E	1	15	HLA class II	ICS	(Heide et al., 2021)
RVKNLNSSRVPDLLV	E	61	75	HLA class II	ICS	(Heide et al., 2021)
SEETGTLIVNSVLLF	E	6	20	HLA class II	ELISPOT	(Mateus et al., 2020)
SFYVYSRVKNLNSSRVPD	E	55	72	HLA class II	ELISPOT	(de Castro et al., 2022)
VNSVLLFLAF	E	14	23	HLA class II	ICS	(Jin et al., 2021)
ANVYLKHGGGVAGAL	pp1a	243	257	HLA class II	ICS/AIM	(Eggenhuizen et al., 2021)
LKHGGGVAGALNKAT	pp1a	247	261	HLA class II	ICS	(Eggenhuizen et al., 2021)
YLKHGGGVAGALNKA	pp1a	246	260	HLA class II	ICS/AIM	(Eggenhuizen et al., 2021)
ADAVIKTLQPVSELL	pp1ab	876	890	DRB1*14:01	AIM	(Tarke et al., 2021)
AITILDGISQYSLRL	pp1ab	566	580	HLA class II	ELISPOT	(Mateus et al., 2020)
AMRNAGIVGV	pp1ab	4587	4596	HLA class II	ICS	(Jin et al., 2021)
ASRELKVTFFPDLNG	pp1ab	1951	1965	DQB1*05:03	AIM	(Tarke et al., 2021)
AVITREVGFVVPGLP	pp1ab	2856	2870	HLA class II	AIM	(Tarke et al., 2021)
AVMSLKEGQINDMIL	pp1ab	7056	7070	HLA class II	AIM	(Tarke et al., 2021)
AVTANVNALLSTDGN	pp1ab	5091	5105	HLA class II	AIM	(Tarke et al., 2021)
CCHLAKALNDFSNSG	pp1ab	3231	3245	HLA class II	AIM	(Tarke et al., 2021)
CTFLLNKEMYLKLRS	pp1ab	3181	3195	HLA class II	ELISPOT	(Mateus et al., 2020)
DAFKLNIKLLGVGGK	pp1ab	3836	3850	HLA class II	ELISPOT	(Mateus et al., 2020)
DNFKFVCDNIKFADD	pp1ab	1926	1940	HLA class II	ELISPOT	(Mateus et al., 2020)
DTRYVLMDGSIIQFP	pp1ab	2951	2965	HLA class II	ELISPOT	(Mateus et al., 2020)
DVDTDFVNEFYAYLR	pp1ab	5128	5142	HLA class II	ELISPOT	(Swadling et al., 2022)
DVFHLYLQYIRKLHD	pp1ab	5271	5285	DRB1*13:02/DRB1*04:04	AIM	(Tarke et al., 2021)
EAARYMRSLKVPATV	pp1ab	1461	1475	HLA class II	ELISPOT	(Mateus et al., 2020)
EEIAIILASFSASTS	pp1ab	471	485	HLA class II	ELISPOT	(Mateus et al., 2020)
EFYAYLRKHFSMMIL	pp1ab	5136	5150	HLA class II	ELISPOT	(Mateus et al., 2020)
EIIKSQDLSVVSKVV	pp1ab	6756	6770	HLA class II	ELISPOT	(Mateus et al., 2020)
ELHLSWEVGKPRPPL	pp1ab	5486	5500	HLA class II	AIM	(Tarke et al., 2021)
ENLLLYIDINGNLHP	pp1ab	1251	1265	HLA class II	ELISPOT	(Mateus et al., 2020)
ESDDYIATNGPLKVG	pp1ab	1086	1100	HLA class II	AIM	(Tarke et al., 2021)
ESPFVMMSAPPAQYE	pp1ab	1801	1815	DRB1	ELISPOT	(Prakash et al., 2021)
FDAYVNTFSSTFNVP	pp1ab	2591	2605	HLA class II	ELISPOT	(Mateus et al., 2020)
FGEYSHVVAFNTLLF	pp1ab	3071	3085	HLA class II	ELISPOT	(Mateus et al., 2020)
FGLVAEWFLAYILFT	pp1ab	2321	2335	DRB1*12:01/DQB1*05:03	AIM	(Tarke et al., 2021)
FLHFLPRVFSAVGNI	pp1ab	2881	2895	DRB1*15:01	AIM	(Tarke et al., 2021)
FNICQAVTANVNALL	pp1ab	5086	5100	DRB1*14:01/DQB1*03:01	AIM	(Tarke et al., 2021)
FSNSGSDVLYQPPQT	pp1ab	3241	3255	DQB1*06:02	AIM	(Tarke et al., 2021)
FTGYRVTKNSKVQIG	pp1ab	5506	5520	DRB1*07:01	AIM	(Tarke et al., 2021)
FTSLEIPRRNVATLQ	pp1ab	5911	5925	HLA class II	ELISPOT	(Swadling et al., 2022)
FVSLAIDAYPLTKHP	pp1ab	5251	5265	DQB1*03:02/DQB1*06:04/DRB1*15:01/DQB1*02:02	AIM	(Tarke et al., 2021)
GETFVTHSKGLYRKC	pp1ab	706	720	HLA class II	ELISPOT	(Mateus et al., 2020)
GLVASIKNFKSVLYY	pp1ab	5166	5180	HLA class II	ELISPOT	(Mateus et al., 2020)
GPPGTGKSHFAIGLA	pp1ab	282	296	HLA class II	ICS/AIM	(Eggenhuizen et al., 2021)
GSLIYSTAALGVLMS	pp1ab	2241	2255	HLA class II	ELISPOT	(Mateus et al., 2020)
GYKKPASRELKVTFF	pp1ab	1946	1960	HLA class II	AIM	(Tarke et al., 2021)
HCANFNVLFSTVFPP	pp1ab	4701	4715	DQB1*06:02/DRB1*07:01/DQB1*02:02	AIM	(Tarke et al., 2021)
HTTDPSFLGRYMSAL	pp1ab	1636	1650	HLA class II	AIM	(Tarke et al., 2021)
IAATRGATVVIGTSK	pp1ab	4971	4985	DRB1*07:01/DQB1*03:03	AIM	(Tarke et al., 2021)
IATNGPLKVGGSCVL	pp1ab	1091	1105	DRB1*13:02	AIM	(Tarke et al., 2021)
IDAYPLTKHPNQEYA	pp1ab	5256	5270	HLA class II	AIM	(Tarke et al., 2021)
IQWMVMFTPLVPFWI	pp1ab	3126	3140	DRB1*04:04/DRB1*07:01/DQB1*02:02	AIM	(Tarke et al., 2021)
ISPYNSQNAVASKIL	pp1ab	5836	5850	HLA class II	ELISPOT	(Mateus et al., 2020)
ISSFKWDLTAFGLVA	pp1ab	2311	2325	HLA class II	ELISPOT	(Mateus et al., 2020)
KEGQINDMILSLLSK	pp1ab	7061	7075	HLA class II	AIM	(Tarke et al., 2021)
KGGKIVNNWLKQLIK	pp1ab	2761	2775	HLA class II	ELISPOT	(Mateus et al., 2020)
KHFYWFFSNYLKRRV	pp1ab	3151	3165	DRB1*15:01	AIM/ELISPOT	(Tarke et al., 2021; Mateus et al., 2020)
KLLKSIAATRGATVV	pp1ab	4966	4980	DRB1*07:01/DQB1*03:03	AIM/ELISPOT	(Tarke et al., 2021; Mateus et al., 2020)
KSAFYILPSIISNEK	pp1ab	1350	1364	DRB1	ELISPOT	(Prakash et al., 2021)
KTDGTLMIERFVSLA	pp1ab	5241	5255	HLA class II	AIM	(Tarke et al., 2021)
KVTFFPDLNGDVVAI	pp1ab	1956	1970	DQB1*05:03	AIM/ELISPOT	(Tarke et al., 2021; Mateus et al., 2020)
LCLFLLPSLATVAYF	pp1ab	3636	3650	HLA class II	ELISPOT	(Mateus et al., 2020)
LDAYNMMISAGFSLW	pp1ab	6420	6434	DRB1	ELISPOT	(Prakash et al., 2021)
LDDFVEIIKSQDLSV	pp1ab	6751	6765	DR	ELISPOT	(Nelde et al., 2021)
LEASFNYLKSPNFSK	pp1ab	2211	2225	DRB1*01:01/DRB1*04:01/DRB1*15:01	multimer staining/ELISPOT	(Poluektov et al., 2021; Mateus et al., 2020)
LFVAAIFYLITPVHV	pp1ab	2781	2795	HLA class II	ELISPOT	(Mateus et al., 2020)
LIVTALRANSAVKLQ	pp1ab	4126	4140	HLA class II	ELISPOT	(Mateus et al., 2020)
LLVLVQSTQWSLFFF	pp1ab	3591	3605	HLA class II	ELISPOT	(Mateus et al., 2020)
LMIERFVSLAIDAYP	pp1ab	5246	5260	DQB1*02:02/DRB1*15:01/DRB1*13:02/DRB1*10:01/DRB1*07:01/DRB1*04:04/DRB1*01:01/DQB1*06:04/DQB1*05:01/DQB1*04:02/DQB1*03:02	AIM/ELISPOT	(Tarke et al., 2021; Mateus et al., 2020)
LMIERFVSLAIDAYPLTK	pp1ab	5246	5263	HLA class II	AIM	(Piadel et al., 2022)
LNQLTGYKKPASREL	pp1ab	1941	1955	HLA class II	AIM	(Tarke et al., 2021)
LPNDDTLRVEAFEYY	pp1ab	1621	1635	DQB1*03:02	AIM	(Tarke et al., 2021)
LQGPPGTGKSHFAIG	pp1ab	5612	5626	HLA class II	ICS	(Eggenhuizen et al., 2021)
LRAKHYVYIGDPAQL	pp1ab	5715	5729	HLA class II	ELISPOT	(Swadling et al., 2022)
LRKHFSMMILSDDAV	pp1ab	5141	5155	HLA class II	ELISPOT	(Mateus et al., 2020)
LTQYNRYLALYNKYK	pp1ab	3201	3215	DRB1*15:01	AIM	(Tarke et al., 2021)
LVAEWFLAYILFTRFFYV	pp1ab	2323	2340	HLA class II	AIM	(Piadel et al., 2022)
MAAYVDNSSLTIKKP	pp1ab	2096	2110	DQB1*05:03	AIM	(Tarke et al., 2021)
MFTPLVPFWITIAYI	pp1ab	3131	3145	DRB1*15:01	AIM	(Tarke et al., 2021)
NELSRVLGLKTLATH	pp1ab	2111	2125	HLA class II	ELISPOT	(Mateus et al., 2020)
NHNFLVQAGNVQLRV	pp1ab	3326	3340	HLA class II	ELISPOT	(Mateus et al., 2020)
NHTKKWKYPQVNGLT	pp1ab	1651	1665	HLA class II	AIM	(Tarke et al., 2021)
NKDFYDFAVSKGFFK	pp1ab	4808	4822	HLA class II	ELISPOT	(Swadling et al., 2022)
NLYDKLVSSFLEMKS	pp1ab	1181	1195	DRB1*14:01/DQB1*05:02	AIM	(Tarke et al., 2021)
NMFITREEAIRHVRA	pp1ab	5996	6010	HLA class II	ELISPOT	(Mateus et al., 2020)
NRYFRLTLGVYDYLV	pp1ab	3801	3815	HLA class II	ELISPOT	(Mateus et al., 2020)
NTLLFLMSFTVLCLT	pp1ab	3081	3095	HLA class II	ELISPOT	(Mateus et al., 2020)
NTVKSVGKFCLEASF	pp1ab	2201	2215	HLA class II	AIM	(Tarke et al., 2021)
NVLFSTVFPPTSFGP	pp1ab	4706	4720	DQB1*02:02	AIM	(Tarke et al., 2021)
NVNRFNVAITRAKVG	pp1ab	5881	5895	HLA class II	ELISPOT	(Mateus et al., 2020)
PDILRVYANLGERVR	pp1ab	4561	4575	HLA class II	ELISPOT	(Mateus et al., 2020)
PDLNGDVVAIDYKHY	pp1ab	1961	1975	HLA class II	AIM	(Tarke et al., 2021)
PLMYKGLPWNVVRIK	pp1ab	6076	6090	HLA class II	ELISPOT	(Mateus et al., 2020)
PLNSIIKTIQPRVEK	pp1ab	276	290	HLA class II	ELISPOT	(Mateus et al., 2020)
PNFSKLINIIIWFLL	pp1ab	2221	2235	DRB1*15:01/DRB1*07:01	AIM	(Tarke et al., 2021)
PNMLRIMASLVLARK	pp1ab	5019	5033	DRB1	ELISPOT	(Prakash et al., 2021)
PRPPLNRNYVFTGYR	pp1ab	5496	5510	HLA class II	AIM	(Tarke et al., 2021)
PVYSFLPGVYSVIYL	pp1ab	3096	3110	DRB1*15:01	AIM	(Tarke et al., 2021)
QDALFAYTKRNVIPT	pp1ab	4916	4930	HLA class II	AIM	(Tarke et al., 2021)
QKYSTLQGPPGTGKS	pp1ab	275	289	HLA class II	ICS/AIM	(Eggenhuizen et al., 2021)
QNCVLKLKVDTANPK	pp1ab	3346	3360	HLA class II	ELISPOT	(Mateus et al., 2020)
QTFFKLVNKFLALCA	pp1ab	676	690	HLA class II	ELISPOT	(Mateus et al., 2020)
RAMPNMLRIMASLVL	pp1ab	5016	5030	DRB1*15:01/DQB1*06:02	AIM	(Tarke et al., 2021)
REEAIRHVRAWIGFD	pp1ab	6001	6015	HLA class II	ELISPOT	(Mateus et al., 2020)
RENNRVVISSDVLVN	pp1ab	7081	7095	DRB1*07:01/DQB1*02:02	AIM	(Tarke et al., 2021)
RFYFYTSKTTVASLI	pp1ab	1421	1435	DRB1*14:01/DRB1*15:02/DQB1*06:01	AIM	(Tarke et al., 2021)
RIKIVQMLSDTLKNL	pp1ab	6088	6102	DRB1	ELISPOT	(Prakash et al., 2021)
RRCPAEIVDTVSALVY	pp1ab	5766	5781	HLA class II	AIM	(Piadel et al., 2022)
RVESSSKLWAQCVQL	pp1ab	3880	3894	HLA class II	ICS	(Le Bert et al., 2020)
RYLALYNKYKYFSGA	pp1ab	3206	3220	DRB1*15:01	AIM	(Tarke et al., 2021)
SDVLYQPPQTSITSA	pp1ab	3246	3260	HLA class II	AIM	(Tarke et al., 2021)
SEFSSLPSYAAFATA	pp1ab	3948	3962	DRB1*01:01/DRB1*04:01/DRB1*15:01	multimer staining	(Poluektov et al., 2021)
SEMVMCGGSLYVKPG	pp1ab	5056	5070	HLA class II	AIM	(Tarke et al., 2021)
SFLAHIQWMVMFTPL	pp1ab	3121	3135	DRB1*15:01/DQB1*06:02	AIM	(Tarke et al., 2021)
SFLGRYMSALNHTKK	pp1ab	1641	1655	DRB1*04:04	AIM	(Tarke et al., 2021)
SGHNLAKHCLHVVGP	pp1ab	1106	1120	HLA class II	AIM	(Tarke et al., 2021)
SHNIALIWNVKDFMS	pp1ab	2706	2720	HLA class II	ELISPOT	(Mateus et al., 2020)
SHRFYRLANECAQVL	pp1ab	5041	5055	DRB1*08:01/DRB1*01:01	AIM	(Tarke et al., 2021)
SIVAGGIVAIVVTCL	pp1ab	3046	3060	DQB1*04:02/DQB1*03:02	AIM	(Tarke et al., 2021)
SKLWAQCVQLHNDIL	pp1ab	3885	3899	HLA class II	ICS	(Le Bert et al., 2020)
SLFFFLYENAFLPFA	pp1ab	3601	3615	HLA class II	ELISPOT	(Mateus et al., 2020)
SLLMPILTLTRALTA	pp1ab	4631	4645	HLA class II	ELISPOT	(Mateus et al., 2020)
SPLYAFASEAARVVR	pp1ab	531	545	HLA class II	ELISPOT	(Mateus et al., 2020)
TFTRSTNSRIKASMP	pp1ab	2181	2195	DRB1*14:01	AIM	(Tarke et al., 2021)
TIAYIICISTKHFYW	pp1ab	3141	3155	HLA class II	ELISPOT	(Mateus et al., 2020)
TLRVEAFEYYHTTDP	pp1ab	1626	1640	DQB1*05:03	AIM	(Tarke et al., 2021)
TLVYKVYYGNALDQA	pp1ab	3716	3730	HLA class II	ELISPOT	(Mateus et al., 2020)
TNSRIKASMPTTIAK	pp1ab	2186	2200	DRB1*07:01/DRB1*04:04	AIM	(Tarke et al., 2021)
TPSFKKGAKLLHKPI	pp1ab	1976	1990	HLA class II	AIM	(Tarke et al., 2021)
TQLCQYLNTLTLAVP	pp1ab	6846	6860	HLA class II	ELISPOT	(Mateus et al., 2020)
TSHKLVLSVNPYVCN	pp1ab	5361	5375	HLA class II	ELISPOT	(Mateus et al., 2020)
TSLLVLVQSTQWSLF	pp1ab	3589	3603	HLA class II	ELISPOT	(de Castro et al., 2022)
VLKKLKKSLNVAKSE	pp1ab	3976	3990	HLA class II	ELISPOT	(Mateus et al., 2020)
VLSFCAFAVDAAKAY	pp1ab	4266	4280	HLA class II	ELISPOT	(Mateus et al., 2020)
VNARLRAKHYVYIGD	pp1ab	5711	5725	HLA class II	AIM	(Tarke et al., 2021)
VNRFNVAITRAKVGI	pp1ab	558	572	HLA class II	ICS/AIM	(Eggenhuizen et al., 2021)
VPGLPGTILRTTNGD	pp1ab	2866	2880	HLA class II	AIM	(Tarke et al., 2021)
VSALVYDNKLKAHKD	pp1ab	452	466	HLA class II	ICS/AIM	(Eggenhuizen et al., 2021)
VTKNSKVQIGEYTFE	pp1ab	5511	5525	HLA class II	AIM	(Tarke et al., 2021)
VWHVNNATNKATYKP	pp1ab	1991	2005	HLA class II	AIM	(Tarke et al., 2021)
WDLTAFGLVAEWFLA	pp1ab	2316	2330	DQB1*05:03	AIM	(Tarke et al., 2021)
YCIDGALLTKSSEYK	pp1ab	1846	1860	DRB1*15:02	AIM	(Tarke et al., 2021)
YLTFYLTNDVSFLAH	pp1ab	3111	3125	DRB1*14:01/DRB1*15:01/DRB1*16:01/DQB1*05:02	AIM	(Tarke et al., 2021)
YMSALNHTKKWKYPQ	pp1ab	1646	1660	HLA class II	AIM	(Tarke et al., 2021)
YREAACCHLAKALND	pp1ab	3226	3240	HLA class II	AIM	(Tarke et al., 2021)
YPKCDRAMPNMLRIM	pp1ab	5011	5025	HLA class II	AIM	(Tarke et al., 2021)
AENSVAYSNNSIAIP	S	701	715	DRB1*15:01/DQB1*03:01	AIM/ELISPOT	(Tarke et al., 2021; Mateus et al., 2020)
AGFIKQYGDCLGDIA	S	831	845	DQB1*05:03	AIM/ICS	(Tarke et al., 2021; Zhang et al., 2022; Tarke et al., 2022)
AIPTNFTISVTTEILPVSMT	S	713	732	DRB1*07:01	multimer staining	(Johansson et al., 2021)
ALLAGTITSGWTFGA	S	876	890	DQB1*06:02	AIM	(Tarke et al., 2021)
ALQIPFAMQMAYRFNGIGV	S	893	911	HLA class II	ELISA	(Verhagen et al., 2021)
APHGVVFLHVTYVPA	S	1056	1070	DRB1*12:01	AIM/ELISPOT	(Tarke et al., 2021; Mateus et al., 2020)
AQALNTLVKQLSSNF	S	956	970	HLA class II	AIM/ELISPOT	(Mateus et al., 2020; Tarke et al., 2022)
AQYTSALLAGTITSG	S	871	885	DQB1*06:02	AIM/ELISPOT	(Tarke et al., 2021; Mateus et al., 2020; Tarke et al., 2022)
ARDLICAQKFNGLTV	S	846	860	HLA class II	AIM	(Tarke et al., 2021)
ASFSTFKCYGVSPTKLN	S	372	388	DRB1*15:02/DPA1*01:03/DPB1*06:01	ELISPOT	(Woldemeskel et al., 2021)
ASVYAWNRKRISN	S	348	360	DR	ICS/ELISPOT	(Rammensee et al., 2021)
AYSNNSIAIPTNFTI	S	706	720	DQB1*03:01	AIM/ELISPOT	(Tarke et al., 2021; Mateus et al., 2020; Tarke et al., 2022)
CAQKFNGLTVLPPLL	S	851	865	DQB1*06:02/DRB1*16:01/DQB1*05:02	AIM/ELISPOT	(Tarke et al., 2021; Mateus et al., 2020)
CEFQFCNDPFLGVYY	S	131	145	DQB1*05:02/DQB1*05:03	AIM/ELISPOT/ICS	(Tarke et al., 2021; Mateus et al., 2020; Zhang et al., 2022; Tarke et al., 2022)
CPFGEVFNATRFASV	S	336	350	DRB1*07:01/DRB1*13:01/DQB1*06:03	AIM/ELISPOT	(Tarke et al., 2021; Mateus et al., 2020)
CPFGEVFNATRFASVYAWNR	S	336	355	HLA class II	proliferation	(Low et al., 2021)
CSNLLLQYGSFCTQL	S	749	763	DRB1*15:01	AIM,ELISA	(Panikkar et al., 2022; Li et al., 2021; Loyal et al., 2021)
CTFEYVSQPFLMDLE	S	166	180	DQB1*02:01/DRB1*16:01/DRB1*07:01/DQB1*05:03/DQB1*05:02/DQB1*02:02	AIM,ICS,ELISPOT	(Tarke et al., 2021; Mateus et al., 2020; Tarke et al., 2022; Le Bert et al., 2021)
CTFEYVSQPFLMDLEGK	S	166	182	DPA1*01:03/DPB1*04:01	AIM	(Pogorelyy et al., 2022)
CTLKSFTVEKGIYQT	S	301	315	HLA class II	ELISPOT	(Mateus et al., 2020)
CVADYSVLYNSASFS	S	361	375	DQB1*06:02/DQB1*05:03	AIM	(Tarke et al., 2021)
DCTMYICGDSTECSN	S	737	751	HLA class II	ELISA	(Verhagen et al., 2021)
DKVEAEVQIDRLITGRLQSL	S	985	1004	DRB1*03:01	multimer staining	(Johansson et al., 2021)
DSFKEELDKYFKNHT	S	1146	1160	HLA class II	AIM	(Tarke et al., 2022)
DSKTQSLLIVNNATN	S	111	125	HLA class II	AIM	(Tarke et al., 2021)
DSKVGGNYNYLYRLFRK	S	442	458	DRB1*11:01	ELISPOT	(Woldemeskel et al., 2021)
DSLSSTASALGKLQDVV	S	936	952	HLA class II	ICS	(Bartolo et al., 2021)
DSTECSNLLLQYGSF	S	745	759	HLA class II	ELISA	(Li et al., 2021)
DSTECSNLLLQYGSFCTQLN	S	745	764	DRB1*15:01	multimer staining	(Johansson et al., 2021)
ECDIPIGAGICASYQ	S	661	675	HLA class II	ELISA/ELISPOT	(Mateus et al., 2020; Verhagen et al., 2021)
EFVFKNIDGYFKIYS	S	191	205	DRB1*14:01/DRB1*15:01/DQB1*05:03	AIM	(Tarke et al., 2021; Tarke et al., 2022)
EIRASANLAATKMSECVLGQ	S	1017	1036	DRB1*04:01/DRB1*04:04	multimer staining	(Johansson et al., 2021)
EIYQAGSTPCNGVEG	S	471	485	HLA class II	AIM/ICS	(Tarke et al., 2021; Zhang et al., 2022)
EKSNIIRGWIFGTTL	S	96	110	DRB1*15:01	AIM	(Tarke et al., 2021)
ELDKYFKNHTSPDVD	S	1151	1165	HLA class II	AIM/ELISPOT	(Tarke et al., 2021; Mateus et al., 2020)
ELLHAPATVCGPKKSTNLVK	S	516	535	HLA class II	proliferation	(Low et al., 2021)
ENQKLIANQFNSAIGKI	S	918	934	DRB3*02:02	ELISPOT	(Woldemeskel et al., 2021)
EPQIITTDNTFVSGN	S	1111	1125	HLA class II	AIM	(Tarke et al., 2022)
EVRQIAPGQTGKIADYNYKL	S	406	425	HLA class II	proliferation	(Low et al., 2021)
FGEVFNATRFASVYA	S	338	352	HLA class II	ELISPOT	(de Castro et al., 2022)
FGGFNFSQILPDPSK	S	797	811	HLA class II	ELISPOT	(Zhao et al., 2021)
FGGFNFSQILPDPSKPSKR	S	797	815	HLA class II	ELISA	(Verhagen et al., 2021)
FGTTLDSKTQSLLIV	S	106	120	HLA class II	AIM	(Tarke et al., 2021)
FIEDLLFNKVTLADA	S	817	831	HLA class II	AIM	(Loyal et al., 2021)
FIEDLLFNKVTLADAGFIKQ	S	817	836	DPB1*04:01	multimer staining	(Johansson et al., 2021)
FKIYSKHTPINLVRD	S	201	215	DRB1*13:01/DRB1*07:01	AIM/ELISPOT	(Tarke et al., 2021; Zhao et al., 2021)
FKIYSKHTPINLVRDLPQGF	S	201	220	DRB1*07:01/DRB3*01:01	multimer staining	(Johansson et al., 2021)
FNCYFPLQSYGFQPT	S	486	500	DRB1*12:01/DQB1*05:03	AIM/ELISPOT	(Tarke et al., 2021; Mateus et al., 2020)
FNCYFPLQSYGFQPTNGVGY	S	486	505	HLA class II	proliferation	(Low et al., 2021)
FNFNGLTGTGVLTES	S	541	555	HLA class II	ELISA/AIM/ELISPOT	(Mateus et al., 2020; Tarke et al., 2022; Verhagen et al., 2021)
FNGLTVLPPLLTDEM	S	855	869	DR	ELISPOT	(Nelde et al., 2021)
FQFCNDPFLGVYYHK	S	133	147	HLA class II	ELISA	(Verhagen et al., 2021)
FQFCNDPFLGVYYHKNNK	S	133	150	HLA class II	ELISA	(Verhagen et al., 2021)
FRKSNLKPFERDISTEIYQA	S	456	475	HLA class II	proliferation	(Low et al., 2021)
FTGCVIAWNSNNLDSKVGG	S	429	447	HLA class II	ELISA	(Verhagen et al., 2021)
FTVEKGIYQTSNFRV	S	306	320	DRB1*07:01	AIM/ELISPOT	(Tarke et al., 2021; Mateus et al., 2020)
FVIRGDEVRQIAPGQTG	S	400	416	DQA1*05:05/DQB1*03:01	ELISPOT	(Woldemeskel et al., 2021)
FVSGNCDVVIGIVNN	S	1121	1135	HLA class II	AIM	(Tarke et al., 2021)
FYEPQIITTDNTFVSGNCD	S	1109	1127	HLA class II	ELISA	(Verhagen et al., 2021)
GAAAYYVGYLQPRTF	S	261	275	HLA class II	AIM	(Tarke et al., 2022)
GAALQIPFAMQMAYR	S	891	905	HLA class II	AIM	(Tarke et al., 2022)
GAEHVNNSYECDIPIGA	S	652	668	DQA1*02:01/DQB1*02:02	ELISPOT	(Woldemeskel et al., 2021)
GAGAALQIPFAMQMAYRFNG	S	889	908	DRB1*01:01/DRB1*07:01/DRB1*11:04/DRB5*01:01	multimer staining	(Johansson et al., 2021)
GAISSVLNDILSRLD	S	971	985	HLA class II	ELISPOT	(Mateus et al., 2020)
GCVIAWNSNNLDSKV	S	431	445	HLA class II	ICS/AIM/ELISPOT	(Mateus et al., 2020; Tarke et al., 2022; Mahajan et al., 2021)
GFQPTNGVGYQPYRVVVLSF	S	496	515	HLA class II	proliferation	(Low et al., 2021)
GGNYNYLYRLFRKSN	S	446	460	HLA class II	ICS/AIM/ELISPOT	(Mateus et al., 2020; Mahajan et al., 2021)
GGNYNYLYRLFRKSNLKPFE	S	446	465	HLA class II	proliferation	(Low et al., 2021)
GINASVVNIQKEIDR	S	1171	1185	HLA class II	AIM/ELISPOT	(Tarke et al., 2021; Mateus et al., 2020)
GINITRFQTLLALHRSY	S	232	248	HLA class II	AIM	(Dykema et al., 2021)
GIVNNTVYDPLQPEL	S	1131	1145	DQB1*03:02/DQB1*02:02	AIM	(Tarke et al., 2021)
GIYQTSNFRVQPTES	S	311	325	HLA class II	AIM/ELISPOT	(Mateus et al., 2020; Tarke et al., 2022)
GKIADYNYKLPDDFT	S	416	430	HLA class II	ELISPOT	(Mateus et al., 2020)
GKIADYNYKLPDDFTGCVIA	S	416	435	HLA class II	proliferation	(Low et al., 2021)
GKLQDVVNQNAQALN	S	946	960	HLA class II	ICS/AIM	(Mahajan et al., 2021)
GKQGNFKNLREFVFK	S	181	195	HLA class II	AIM	(Tarke et al., 2021)
GLTVLPPLLTDEMIAQYTSA	S	857	876	DRB1*03:01	multimer staining	(Johansson et al., 2021)
GNYNYLYRLFRKSNL	S	447	461	HLA class II	ELISA	(Li et al., 2021)
GNYNYLYRLFRKSNLKPFER	S	447	466	HLA class II	ELISPOT	(de Castro et al., 2022)
GPKKSTNLVKNKCVNFNFNG	S	526	545	HLA class II	proliferation	(Low et al., 2021)
GSTPCNGVEGFNCYFPLQSY	S	476	495	HLA class II	proliferation	(Low et al., 2021)
GVSPTKLNDLCFTNV	S	390	404	HLA class II	ELISPOT	(Peng et al., 2020)
GWTAGAAAYYVGYLQ	S	257	271	HLA class II	ELISA/AIM	(Li et al., 2021)
GWTFGAGAALQIPFA	S	885	899	DQB1*03:01	ELISA	(Titov et al., 2022; Verhagen et al., 2021)
HADQLTPTWRVYSTGSNVFQ	S	625	644	DRB1*07:01	multimer staining	(Johansson et al., 2021)
HKNNKSWMESEFRVY	S	146	160	DQB1*05:03	AIM	(Tarke et al., 2021)
HWFVTQRNFYEPQII	S	1101	1115	HLA class II	AIM/ELISA/CBA/ELISPOT	(Tarke et al., 2021; Mateus et al., 2020; Tarke et al., 2022; Verhagen et al., 2021)
HWFVTQRNFYEPQIITTDN	S	1101	1119	HLA class II	ELISA	(Verhagen et al., 2021)
IDGYFKIYSKHTPIN	S	197	211	HLA class II	ELISPOT	(Zhao et al., 2021)
IDRLITGRLQSLQTYVTQQL	S	993	1012	DRB1*01:01/DRB1*04:04	multimer staining	(Johansson et al., 2021)
IEDLLFNKVTLADAG	S	818	832	DRB3*02:02/DRB4*01:03	ELISA	(Titov et al., 2022)
IGAGICASYQTQTNS	S	666	680	HLA class II	AIM	(Tarke et al., 2022)
IGINITRFQTLLALH	S	231	245	DRB1*07:01	AIM/ELISPOT/ICS	(Tarke et al., 2021; Mateus et al., 2020; Zhang et al., 2022; Tarke et al., 2022)
ILPVSMTKTSVDCTM	S	726	740	HLA class II	AIM	(Tarke et al., 2022)
INITRFQTLLALHRSYLTPG	S	233	252	DRB1*04:04/DRB1*15:01/DRB5*01:01	multimer staining	(Johansson et al., 2021)
IPFAMQMAYRFNGIG	S	896	910	DQB1*05:03/DRB1*12:01/DRB1*14:01/DRB1*15:01/DQB1*04:02	AIM/ICS/ELISPOT	(Tarke et al., 2021; Mateus et al., 2020; Tarke et al., 2022; Mahajan et al., 2021)
IPFAMQMAYRFNGIGVTQNV	S	896	915	HLA class II	ELISPOT	(de Castro et al., 2022)
IRGWIFGTTLDSKTQ	S	101	115	HLA class II	AIM	(Tarke et al., 2021)
ISGINASVVNIQKEI	S	1169	1183	HLA class II	ELISA	(Titov et al., 2022)
ISSVLNDILSRLDKV	S	973	987	HLA class II	AIM	(Loyal et al., 2021)
ITRFQTLLALHRSYL	S	235	249	DR	ELISPOT/ICS	(Nelde et al., 2021)
IVRFPNITNLCPFGE	S	326	340	DRB1*15:01	AIM/ELISPOT	(Tarke et al., 2021; Mateus et al., 2020)
IYKTPPIKDF	S	788	797	HLA class II	ICS	(Jin et al., 2021)
KAHFPREGVFVSNGT	S	1086	1100	HLA class II	ELISPOT	(Mateus et al., 2020)
KAHFPREGVFVSNGTHWFVT	S	1086	1105	HLA class II	ELISPOT	(de Castro et al., 2022)
KCVNFNFNGLTGTGVLTESN	S	537	556	DRB1*01:01	multimer staining	(Johansson et al., 2021)
KEELDKYFKNHTSPD	S	1149	1163	HLA class II	ELISA	(Verhagen et al., 2021)
KHTPINLVRDLPQGF	S	206	220	DRB1*03:01	AIM	(Tarke et al., 2021)
KLIANQFNSAIGKIQ	S	921	935	HLA class II	ELISA/AIM	(Tarke et al., 2022; Verhagen et al., 2021)
KLNDLCFTNVYADSF	S	386	400	DQB1*02:02/DRB1*07:01/DQB1*02:01	AIM	(Tarke et al., 2021; Tarke et al., 2022)
KLNDLCFTNVYADSFVI	S	386	402	DPA1*02:01/DPB1*14:01	ELISPOT	(Woldemeskel et al., 2021)
KLNDLCFTNVYADSFVIRGD	S	386	405	HLA class II	proliferation	(Low et al., 2021)
KNFTTAPAICHDGKAHFPRE	S	1073	1092	DRB1*03:01	multimer staining	(Johansson et al., 2021)
KNTQEVFAQVKQIYK	S	776	790	HLA class II	AIM	(Tarke et al., 2021)
KPSKRSFIEDLLFNK	S	811	825	DQB1*05:03/DQB1*02:02	AIM/ELISPOT	(Tarke et al., 2021; Mateus et al., 2020)
KRISNCVADYSVLYN	S	356	370	DQB1*02:02/DRB1*03:01/DQB1*02:01	AIM	(Tarke et al., 2021; Tarke et al., 2022)
KRISNCVADYSVLYNSASFS	S	356	375	HLA class II	proliferation	(Low et al., 2021)
KSNIIRGWIFGTTLDSKTQS	S	97	116	DRB1*15:01	multimer staining	(Johansson et al., 2021)
KVCEFQFCNDPFLGVYYHK	S	129	147	HLA class II	ELISA/CBA	(Verhagen et al., 2021)
KVCEFQFCNDPFLGVYYHKN	S	129	148	DPB1*04:01	multimer staining	(Johansson et al., 2021)
KVFRSSVLHSTQDLF	S	41	55	HLA class II	AIM	(Tarke et al., 2022)
KVFRSSVLHSTQDLFLPFFS	S	41	60	DRB1*07:01	multimer staining	(Johansson et al., 2021)
KYEQYIKWPWYIWLG	S	1205	1219	HLA class II	ELISA	(Li et al., 2021)
LDSKVGGNYNYLYRLFRKS	S	441	459	HLA class II	ELISA	(Verhagen et al., 2021)
LDSKVGGNYNYLYRLFRKSN	S	441	460	DRB1*11:01/DRB1*11:04	multimer staining	(Johansson et al., 2021)
LGDIAARDLICAQKF	S	841	855	HLA class II	AIM	(Tarke et al., 2021)
LGDISGINASVVNIQ	S	1166	1180	HLA class II	ELISPOT	(Mateus et al., 2020)
LGVYYHKNNKSWMES	S	141	155	HLA class II	AIM/ELISPOT	(Tarke et al., 2021; Mateus et al., 2020)
LGVYYHKNNKSWMESEF	S	141	157	DRB3*02:02	ELISPOT	(Woldemeskel et al., 2021)
LKPFERDISTEIYQA	S	461	475	DRB1	AIM/multimer staining/ICS/ELISA	(Tarke et al., 2021; Prakash et al., 2021; Verhagen et al., 2021)
LLALHRSYLTPGDSS	S	241	255	HLA class II	ELISPOT	(Mateus et al., 2020)
LLFNKVTLADAGFIK	S	821	835	DQB1*06:02	AIM/ELISPOT	(Tarke et al., 2021; Mateus et al., 2020)
LLQYGSFCTQLNRAL	S	753	767	DRB1*15:01	AIM/ELISA	(Panikkar et al., 2022; Verhagen et al., 2021; Loyal et al., 2021)
LLQYGSFCTQLNRALTGIAV	S	753	772	DRB1*15:01	multimer staining	(Johansson et al., 2021)
LITGRLQSLQTYVTQ	S	996	1010	HLA class II	ELISPOT	(Mateus et al., 2020)
LMDLEGKQGNFKNLR	S	176	190	HLA class II	AIM	(Tarke et al., 2021; Tarke et al., 2022)
LNEVAKNLNESLIDL	S	1186	1200	HLA class II	ELISPOT	(Mateus et al., 2020)
LPDDFTGCVIAWNSNNLDSK	S	425	444	DRB1*15:01	multimer staining	(Johansson et al., 2021)
LPDPSKPSKRSFIED	S	806	820	HLA class II	AIM	(Tarke et al., 2021)
LPFFSNVTWFHAIHV	S	56	70	DRB1*15:01/DRB1*16:01/DQB1*05:02	AIM	(Tarke et al., 2021; Tarke et al., 2022)
LPLVSSQCVNLTTRTQL	S	8	24	DRB4*01:01	ELISPOT	(Woldemeskel et al., 2021)
LPPLLTDEMIAQYTS	S	861	875	DQB1*04:02	AIM	(Tarke et al., 2021)
LPQGFSALEPLVDLP	S	216	230	DQB1*03:03/DQB1*05:03/DQB1*02:02	AIM/ELISPOT	(Tarke et al., 2021; Mateus et al., 2020)
LQPELDSFKEELDKY	S	1141	1155	HLA class II	AIM/ELISA	(Tarke et al., 2021; Tarke et al., 2022; Li et al., 2021; Verhagen et al., 2021)
LQSLQTYVTQQLIRA	S	1001	1015	HLA class II	AIM/ELISA	(Titov et al., 2022; Loyal et al., 2021)
LQSLQTYVTQQLIRAAEIRA	S	1001	1020	DRB1*15:01	AIM/multimer staining	(Johansson et al., 2021)
LQTYVTQQLIRAAEI	S	1004	1018	HLA class II	ELISA	(Titov et al., 2022)
LSFELLHAPATVCGP	S	513	527	HLA class II	ELISA	(Verhagen et al., 2021)
LSFELLHAPATVCGPKKSTN	S	513	532	DRB1*01:01	multimer staining	(Johansson et al., 2021)
LSRLDKVEAEVQIDR	S	981	995	HLA class II	proliferation	(Low et al., 2021)
LSRLDKVEAEVQIDRLITGR	S	981	1000	HLA class II	proliferation	(Low et al., 2021)
LTDEMIAQYTSALLA	S	865	879	DRB1*15:01	AIM/ELISA	(Panikkar et al., 2022; Li et al., 2021)
LTDEMIAQYTSALLAGTITS	S	865	884	DRB1*15:01	multimer staining	(Johansson et al., 2021)
LTGTGVLTESNKKFL	S	546	560	HLA class II	AIM	(Tarke et al., 2021; Tarke et al., 2022)
LYENQKLIANQFNSA	S	916	930	DRB1*12:01	AIM	(Tarke et al., 2021)
LYNSASFSTF	S	368	377	HLA class II	ICS	(Jin et al., 2021)
MFVFLVLLPLVSS	S	1	13	DRB1	ELISPOT	(Prakash et al., 2021)
MIAQYTSALLAGTIT	S	869	883	DRB1*15:01	AIM/ELISA	(Panikkar et al., 2022; Li et al., 2021)
MTKTSVDCTMYICGD	S	731	745	HLA class II	ICS	(Zhang et al., 2022)
NCTFEYVSQPFLMDL	S	165	179	DPB1*04:01	ELISA/CBA/AIM	(Panikkar et al., 2022; Verhagen et al., 2021)
PPAYTNSFTRGVYYP	S	25	39	HLA class II	ELISA	(Verhagen et al., 2021)
PPAYTNSFTRGVYYPDKVFR	S	25	44	DRB1*01:01/DRB3*01:01/DRB1*04:01/DRB1*07:01	multimer staining	(Johansson et al., 2021)
PRRARSVASQSIIAYTMSLG	S	681	700	DRB1*07:01	multimer staining	(Johansson et al., 2021)
PSKPSKRSFIEDLLFNKVTL	S	809	828	DPB1*04:01	multimer staining/AIM	(Johansson et al., 2021)
PTNFTISVTTEILPVSM	S	715	731	DRB1*07:01	ELISPOT	(Woldemeskel et al., 2021)
QALNTLVKQLSSNFG	S	957	971	HLA class II	AIM	(Loyal et al., 2021)
QDVNCTEVPVAIHADQLTP	S	613	631	HLA class II	ELISA	(Verhagen et al., 2021)
QELGKYEQYIKWPWY	S	1201	1215	HLA class II	AIM	(Tarke et al., 2021)
QFCNDPFLGVYHKNNK	S	134	149	HLA class II	AIM	(Dykema et al., 2021)
QFCNDPFLGVYYHKNNK	S	134	150	DRB1*11:01	ELISPOT	(Woldemeskel et al., 2021)
QIITTDNTFVSGNCDVVIGI	S	1113	1132	DRB1*03:01/DRB1*04:01	multimer staining	(Johansson et al., 2021)
QIPFAMQMAYRFNGI	S	895	909	HLA class II	ELISA/ICS	(Titov et al., 2022)
QLIRAAEIRASANLAATK	S	1011	1028	HLA class II	ELISPOT	(de Castro et al., 2022)
QLIRAAEIRASANLAATKM	S	1011	1029	DRB1	multimer staining/AIM/ICS	(Prakash et al., 2021)
QLSSNFGAISSVLND	S	965	979	HLA class II	ELISA	(Verhagen et al., 2021)
QMAYRFNGIGVTQNV	S	901	915	DQB1*03:01	AIM/ELISPOT	(Tarke et al., 2021; Mateus et al., 2020; Tarke et al., 2022)
QNVLYENQKLIANQF	S	913	927	HLA class II	ELISA	(Verhagen et al., 2021)
QNVLYENQKLIANQFNSAIG	S	913	932	DRB1*11:01/DRB1*11:04/DRB1*15:01	multimer staining	(Johansson et al., 2021)
QPTESIVRFPNITNL	S	321	335	HLA class II	AIM/ELISPOT	(Zhao et al., 2021; Mateus et al., 2020)
QPTESIVRFPNITNLCPFGE	S	321	340	DRB1*04:04/DRB1*15:01	multimer staining	(Johansson et al., 2021)
QPYRVVVLSFELLHA	S	506	520	DRB1*14:01/DQB1*05:03	AIM/ICS	(Tarke et al., 2021; Mahajan et al., 2021)
QPYRVVVLSFELLHAPATVC	S	506	525	HLA class II	proliferation	(Low et al., 2021)
QQLIRAAEIRASANL	S	1010	1024	HLA class II	ELISA	(Titov et al., 2022)
QRNFYEPQIITTDNT	S	1106	1120	HLA class II	AIM	(Tarke et al., 2021; Tarke et al., 2022)
NFGAISSVLNDILSR	S	969	983	HLA class II	AIM	(Loyal et al., 2021)
NFKNLREFVFKNIDGYFKIY	S	185	204	DRB5*01:01	multimer staining	(Johansson et al., 2021)
NFRVQPTESIVRFPN	S	317	331	DRB1*04:01	ELISA/AIM	(Panikkar et al., 2022; Verhagen et al., 2021)
NFSQILPDPSKPSKR	S	810	824	DRB1*03:01	ELISPOT/AIM/ELISA/CBA	(Tarke et al., 2021; Zhao et al., 2021; Peng et al., 2020; Mateus et al., 2020; Verhagen et al., 2021; Loyal et al., 2021)
NFSQILPDPSKPSKRSFIE	S	801	819	HLA class II	ELISA	(Verhagen et al., 2021)
NFSQILPDPSKPSKRSFIED	S	801	820	DRB1*03:01/DRB1*04:01/DRB1*04:04	multimer staining	(Johansson et al., 2021)
NGVEGFNCYFPLQSY	S	481	495	HLA class II	ICS	(Mahajan et al., 2021)
NGVEGFNCYFPLQSYGFQPT	S	481	500	DRB5*01:01	multimer staining	(Johansson et al., 2021)
NIDGYFKIYSKHTPI	S	196	210	DRB1*07:01/DRB1*16:01/DRB1*15:01	AIM/ELISPOT	(Tarke et al., 2021; Mateus et al., 2020; Tarke et al., 2022)
NIIRGWIFGTTLDSKTQ	S	99	115	DPA1*01:03	ELISPOT	(Woldemeskel et al., 2021)
NKSWMESEFRVYSSA	S	149	163	HLA class II	ELISA	(Li et al., 2021)
NLLLQYGSFCTQLNR	S	760	774	DQB1*05:03/DRB1*15:01/DRB1*04:04	ELISPOT/AIM	(Tarke et al., 2021; Peng et al., 2020; Mateus et al., 2020; Tarke et al., 2022)
NLLLQYGSFCTQLNRAL	S	751	767	DRB1*15:01	AIM	(Pogorelyy et al., 2022)
NLVRDLPQGFSALEP	S	211	225	DRB1*03:01	AIM	(Tarke et al., 2021)
NNATNVVIKVCEFQF	S	121	135	HLA class II	ELISPOT	(Mateus et al., 2020)
NNSYECDIPIGAGIC	S	657	671	HLA class II	ELISA	(Verhagen et al., 2021)
NNSYECDIPIGAGICASYQ	S	657	675	HLA class II	ELISA/CBA	(Verhagen et al., 2021)
NPVLPFNDGVYFAST	S	81	95	HLA class II	AIM	(Tarke et al., 2021)
NQNAQALNTLVKQLSSNFG	S	953	971	HLA class II	ELISA	(Verhagen et al., 2021)
NQNAQALNTLVKQLSSNFGA	S	953	972	DRB1*01:01/DRB1*04:04/DRB1*11:01/DRB1*11:04	multimer staining	(Johansson et al., 2021)
NRKRISNCVAD	S	354	364	DP	proliferation	(Low et al., 2021)
NTLVKQLSSNFGAISSV	S	960	976	DRB3*02:02	ELISPOT	(Woldemeskel et al., 2021)
NTQEVFAQVKQIYKTPPIKD	S	777	796	DRB1*11:04/DRB5*01:01	multimer staining	(Johansson et al., 2021)
NVFQTRAGCLIGAEH	S	641	655	HLA class II	AIM	(Tarke et al., 2022)
NVFQTRAGCLIGAEHVNNS	S	641	659	HLA class II	ELISA	(Verhagen et al., 2021)
NVTWFHAIHVSGTNG	S	61	75	HLA class II	ELISA/ELISPOT	(Keller et al., 2020; Verhagen et al., 2021)
NVVIKVCEFQFCNDP	S	125	139	HLA class II	ELISA	(Verhagen et al., 2021)
PAYTNSFTRGVYYPD	S	26	40	HLA class II	AIM	(Tarke et al., 2022)
PDDFTGCVIAWNSNN	S	426	440	HLA class II	AIM	(Tarke et al., 2022)
PDDFTGCVIAWNSNNLDSKV	S	426	445	HLA class II	proliferation	(Low et al., 2021)
PFAMQMAYRFNGIGV	S	897	911	HLA class II	ELISA	(Verhagen et al., 2021)
PFAMQMAYRFNGIGVTQNVL	S	897	916	DRB1*01:01/DRB1*11:01/DRB1*11:04/DRB5*01:01	multimer staining	(Johansson et al., 2021)
PFFSNVTWFHAIHVS	S	57	71	HLA class II	ELISPOT	(Keller et al., 2020)
PFFSNVTWFHAIHVSGTNGT	S	57	76	DRB1*01:01/DRB1*07:01/DRB1*15:01	multimer staining	(Johansson et al., 2021)
PFGEVFNATRFASVYAWNRK	S	337	356	DRB5*01:01/DPB1*04:01	multimer staining	(Johansson et al., 2021)
PFNDGVYFASTEKSNII	S	85	101	DRB3*02:02	ELISPOT	(Woldemeskel et al., 2021)
PHGVVFLHVTYVPAQEKNFT	S	1057	1076	DRB5*01:01	multimer staining	(Johansson et al., 2021)
PINLVRDLPQGFSAL	S	209	223	DRB1*03:01/DRB3*01:01	ELISA/ELISPOT	(Verhagen et al., 2021),25
PINLVRDLPQGFSALEPLVD	S	209	228	DRB3*01:01	multimer staining	(Johansson et al., 2021)
PLVDLPIGINITRFQTLLAL	S	225	244	DRB1*04:04	multimer staining	(Johansson et al., 2021)
QTYVTQQLIRAAEIR	S	1005	1019	HLA class II	ELISA	(Titov et al., 2022)
QYGDCLGDIAARDLI	S	836	850	HLA class II	AIM	(Tarke et al., 2021)
RALTGIAVEQDKNTQ	S	765	779	HLA class II	ELISA	(Verhagen et al., 2021)
RDISTEIYQAGSTPCNGVEG	S	466	485	HLA class II	proliferation	(Low et al., 2021)
RFASVYAWNRKR	S	346	357	DR	proliferation	(Low et al., 2021)
RFASVYAWNRKRISN	S	346	360	DRB1*07:01/DRB1*14:01/DRB1*13:01	AIM/ELISPOT	(Tarke et al., 2021; Mateus et al., 2020; Tarke et al., 2022)
RFASVYAWNRKRISNCVADY	S	346	365	HLA class II	proliferation	(Low et al., 2021)
RFNGIGVTQNVLYENQKLIA	S	905	924	DRB1*11:04/DRB1*15:01	multimer staining	(Johansson et al., 2021)
REFVFKNIDGYFKIYSK	S	190	206	DRB3*02:02/DRB5*01:01	ELISPOT	(Woldemeskel et al., 2021)
REGVFVSNGTHWFVT	S	1091	1105	HLA class II	ELISPOT	(Mateus et al., 2020)
RISNCVADYSVLYNSASFS	S	357	375	HLA class II	ELISA	(Verhagen et al., 2021)
RKRISNCVAD	S	355	364	HLA class II	proliferation	(Low et al., 2021)
RKSNLKPFERDISTEIYQAG	S	457	476	DRB1*04:01/DRB3*01:01	multimer staining	(Johansson et al., 2021)
RSFIEDLLFNKVT	S	815	827	DPA1*01:03/DPB1*04:01	ELISPOT/ICS	(Woldemeskel et al., 2022)
RTQLPPAYTNSFTRG	S	21	35	HLA class II	AIM	(Tarke et al., 2022)
RVVVLSFELLHAPATVCGP	S	509	527	HLA class II	ELISA	(Verhagen et al., 2021)
SAIGKIQDSLSSTASALGKL	S	929	948	DRB1*04:01/DRB1*04:04	multimer staining	(Johansson et al., 2021)
SALEPLVDLPIGINI	S	221	235	HLA class II	AIM	(Tarke et al., 2021)
SANNCTFEYVSQPFLMD	S	162	178	DPA1*01:03/DPB1*04:01	ELISPOT	(Woldemeskel et al., 2021)
SASFSTFKCYGVSPT	S	371	385	DRB1*15:01	AIM/ELISA/ICS	(Tarke et al., 2021; Zhang et al., 2022; Tarke et al., 2022; Li et al., 2021)
SCGSCCKFDEDDSEPVLKGV	S	1249	1268	DRB3*01:01	multimer staining	(Johansson et al., 2021)
SETKCTLKSFTVEKGIYQTS	S	297	316	DRB1*04:01	multimer staining	(Johansson et al., 2021)
SFIEDLLFNKVTLAD	S	816	830	DRB1*03:01/DRB1*12:01/DRB1*14:01/DQB1*05:03	proliferation/AIM/ELISPOT	(Tarke et al., 2021; Mateus et al., 2020; Tarke et al., 2022; Low et al., 2021; Loyal et al., 2021)
SFTRGVYYPDKVFRS	S	31	45	HLA class II	AIM/ELISPOT	(Mateus et al., 2020; Tarke et al., 2022)
SFTVEKGIYQTSNFRVQPTE	S	305	324	DRB1*04:01/DRB1*07:01	multimer staining	(Johansson et al., 2021)
SGWTAGAAAYYVGYL	S	256	270	HLA class II	AIM	(Tarke et al., 2022)
SIAIPTNFTISVTTE	S	711	725	HLA class II	AIM/ELISPOT	(Tarke et al., 2021; Mateus et al., 2020; Tarke et al., 2022)
SIIAYTMSLGAENSV	S	691	705	HLA class II	AIM/ELISPOT	(Mateus et al., 2020; Tarke et al., 2022)
SKHTPINLVRDLPQG	S	205	219	HLA class II	ELISPOT	(Keller et al., 2020)
SKRSFIEDLLFNKVT	S	813	827	DRB1*07:01	AIM	(Panikkar et al., 2022; Loyal et al., 2021)
SKRSFIEDLLFNKVTLA	S	813	829	DPA1*01:03/DPB1*04:01/DPA1*01:03/DPB1*04:01/DPA1*02:01/DPB1*01:01/DPA1*02:02/DPB1*02:01	AIM/ELISPOT	(Woldemeskel et al., 2021; Dykema et al., 2021)
SKRSFIEDLLFNKVTLADA	S	813	831	HLA class II	ELISA	(Verhagen et al., 2021)
SLIDLQELGK	S	1196	1205	HLA class II	ICS	(Jin et al., 2021)
SLLIVNNATNVVIKV	S	116	130	DRB1*14:01/DRB1*12:01	AIM/ELISPOT	(Tarke et al., 2021; Mateus et al., 2020)
SLSSTASALGKLQDVVNQNA	S	937	956	DRB1*04:01	multimer staining	(Johansson et al., 2021)
SNFRVQPTESIVRFP	S	316	330	DRB1*07:01	AIM/ELISPOT	(Tarke et al., 2021; Mateus et al., 2020; Tarke et al., 2022)
SNFRVQPTESIVRFPNITNL	S	316	335	HLA class II	proliferation	(Low et al., 2021)
SNGTHWFVTQRNFYEPQIIT	S	1097	1116	DRB1*04:01	multimer staining	(Johansson et al., 2021)
SNLLLQYGSFCTQLNRA	S	750	766	DRB1*15:01	ELISPOT	(Woldemeskel et al., 2021)
SPRRARSVASQSIIAYT	S	680	696	DQA1*01:03/DQB1*06:03	ELISPOT	(Woldemeskel et al., 2021)
SQSIIAYTMSLGAENSVAYS	S	689	708	DRB1*04:01/DRB1*04:04/DRB1*07:01/DRB1*15:01	multimer staining	(Johansson et al., 2021)
SSANNCTFEYVSQPF	S	161	175	HLA class II	AIM	(Tarke et al., 2021)
SSANNCTFEYVSQPFLM	S	161	177	HLA class II	AIM	(Pogorelyy et al., 2022)
SSANNCTFEYVSQPFLMDL	S	161	179	HLA class II	ELISA	(Verhagen et al., 2021)
SSANNCTFEYVSQPFLMDLE	S	161	180	DPB1*04:01	multimer staining	(Johansson et al., 2021)
STECSNLLLQYGSFC	S	746	760	DQB1*06:02	AIM/ELISPOT	(Tarke et al., 2021; Mateus et al., 2020; Tarke et al., 2022)
STECSNLLLQYGSFCTQ	S	746	762	DRB1*15:01	AIM	(Pogorelyy et al., 2022)
STEIYQAGSTPCNGV	S	469	483	HLA class II	ELISA	(Verhagen et al., 2021)
SVASQSIIAYTMSLG	S	686	700	HLA class II	AIM	(Tarke et al., 2022)
SVLHSTQDLFLPFFS	S	46	60	DRB1*07:01/DQB1*02:02	AIM/ELISPOT	(Tarke et al., 2021; Mateus et al., 2020; Tarke et al., 2022)
SVLYNSASFSTFKCY	S	366	380	DRB1*15:01	AIM	(Tarke et al., 2021; Tarke et al., 2022)
SVLYNSASFSTFKCYGVSPT	S	366	385	HLA class II	proliferation	(Low et al., 2021)
SVTTEILPVSMTKTS	S	721	735	HLA class II	AIM	(Tarke et al., 2021)
SYQTQTNSPRRARSVASQSI	S	673	692	DRB1*07:01	multimer staining	(Johansson et al., 2021)
TAPAICHDGKAHFPR	S	1077	1091	HLA class II	ELISA	(Verhagen et al., 2021)
TDEMIAQYTSALLAG	S	875	889	DRB1*04:04/DRB1*15:01/DQB1*06:02	ELISPOT/AIM/ELISA	(Tarke et al., 2021; Titov et al., 2022; Peng et al., 2020; Mateus et al., 2020; Tarke et al., 2022)
TDNTFVSGNCDVVIG	S	1117	1131	HLA class II	ELISA	(Verhagen et al., 2021)
TECSNLLLQYGSFCTQL	S	747	763	HLA class II	ELISPOT	(de Castro et al., 2022)
TESNKKFLPFQQFGRDIADT	S	553	572	DRB5*01:01	multimer staining	(Johansson et al., 2021)
TFKCYGVSPTKLNDL	S	376	390	HLA class II	AIM/ICS	(Tarke et al., 2021; Mahajan et al., 2021)
TFKCYGVSPTKLNDLCFTNV	S	376	395	HLA class II	proliferation	(Low et al., 2021)
TITSGWTFGAGAALQ	S	881	895	DQB1*06:02/DQB1*04:02	AIM	(Tarke et al., 2021; Tarke et al., 2022)
TKLNDLCFTNVYADS	S	385	399	HLA class II	ELISA	(Verhagen et al., 2021)
TLEILDITPCSFGGV	S	581	595	HLA class II	AIM/ELISA	(Tarke et al., 2021; Verhagen et al., 2021)
TLVKQLSSNFGAISS	S	961	975	DRB1*04:04	AIM/ELISPOT	(Panikkar et al., 2022; Mateus et al., 2020)
TLVKQLSSNFGAISSVLNDI	S	961	980	DRB1*01:01/DRB1*04:04	multimer staining/AIM	(Johansson et al., 2021)
TNVYADSFVIRGDEVRQIAP	S	393	412	DRB1*03:01/DRB3*01:01	multimer staining	(Johansson et al., 2021)
TPPIKDFGGFNFSQI	S	791	805	DRB1*15:01	AIM	(Tarke et al., 2021)
TQLNRALTGIAVEQD	S	761	775	DQB1*06:02/DQB1*04:02	AIM/ELISPOT/ICS	(Tarke et al., 2021; Mateus et al., 2020; Zhang et al., 2022; Tarke et al., 2022)
TQLNRALTGIAVEQDKNTQ	S	761	779	HLA class II	ELISA	(Verhagen et al., 2021)
TQQLIRAAEIRASANLAATK	S	1009	1028	DRB1*03:01/DRB1*04:01	multimer staining	(Johansson et al., 2021)
TQRNFYEPQIITTDNTFVSG	S	1105	1124	DRB1*03:01/DRB1*04:01	multimer staining	(Johansson et al., 2021)
TRFASVYAWNRKRIS	S	345	359	HLA class II	ELISA	(Verhagen et al., 2021)
TRFASVYAWNRKRISNCVA	S	345	363	HLA class II	ELISA	(Verhagen et al., 2021)
TRFASVYAWNRKRISNCVAD	S	345	364	DRB1*03:01/DRB1*11:01/DRB5*01:01	multimer staining	(Johansson et al., 2021)
TRFQTLLALHRSYLT	S	236	250	DRB1*01:01/DRB1*04:01/DRB1*15:01/DRB1*12:01/DRB1*14:01/DQB1*05:03	multimer staining/AIM/ELISPOT	(Poluektov et al., 2021; Tarke et al., 2021; Mateus et al., 2020)
TRGVYYPDKVFRSSV	S	33	47	HLA class II	ELISA	(Verhagen et al., 2021)
TRGVYYPDKVFRSSVLHSTQ	S	33	52	DRB1*04:01/DRB3*01:01	multimer staining	(Johansson et al., 2021)
TVYDPLQPELDSFKE	S	1136	1150	HLA class II	AIM	(Tarke et al., 2022)
VLLPLVSSQCVNLTT	S	6	20	HLA class II	ELISPOT	(Mateus et al., 2020)
VLYQDVNCTEVPVAIHA	S	610	626	DRB1*13:01	ELISPOT	(Woldemeskel et al., 2021)
VFAQVKQIYKTPPIK	S	781	795	DRB1*15:01	AIM/ELISPOT	(Tarke et al., 2021; Mateus et al., 2020; Tarke et al., 2022)
VFKNIDGYFKIYSKHTPINL	S	193	212	DRB5*01:01	multimer staining	(Johansson et al., 2021)
VFNATRFASVYAWNR	S	341	355	HLA class II	ICS/AIM/ELISPOT	(Mateus et al., 2020; Mahajan et al., 2021)
VGGNYNYLYRLFRKS	S	445	459	HLA class II	ELISA	(Verhagen et al., 2021)
VGGNYNYLYRLFRKSNLKP	S	445	463	HLA class II	ELISA/CBA	(Verhagen et al., 2021)
VGYQPYRVVVLSFELLHAPA	S	503	522	HLA class II	ELISPOT	(de Castro et al., 2022)
VIAWNSNNLDSKVGGNYNYL	S	433	452	DRB1*15:01	multimer staining	(Johansson et al., 2021)
VIRGDEVRQIAPGQT	S	401	415	DRB1*13:01	AIM	(Tarke et al., 2021)
VIRGDEVRQIAPGQTGKIAD	S	401	420	DRB3*01:01	multimer staining	(Johansson et al., 2021)
VNLTTRTQLPPAYTN	S	16	30	HLA class II	AIM	(Tarke et al., 2021)
VNNATNVVIKVCEFQFC	S	120	136	DRB3*02:02	ELISPOT	(Woldemeskel et al., 2021)
VNNSYECDIPIGAGI	S	656	670	HLA class II	AIM	(Tarke et al., 2021)
VNNTVYDPLQPELDS	S	1133	1147	HLA class II	AIM	(Loyal et al., 2021)
VQIDRLITGRLQSLQ	S	991	1005	HLA class II	AIM/ELISPOT	(Mateus et al., 2020; Tarke et al., 2022)
VSMTKTSVDCTMYICGD	S	729	745	DQA1*02:01/DQB1*02:02//DQB1*03:03	ELISPOT	(Woldemeskel et al., 2021)
VSQPFLMDLEGKQGN	S	171	185	DRB1*03:01	AIM	(Tarke et al., 2021)
VSSQCVNLTTRTQLP	S	11	25	HLA class II	AIM	(Tarke et al., 2021)
VTLADAGFIKQYGDC	S	826	840	HLA class II	AIM	(Tarke et al., 2021)
VTQNVLYENQKLIAN	S	911	925	DRB1*12:01/DRB1*03:01	AIM	(Tarke et al., 2021)
VVIKVCEFQFCNDPF	S	126	140	HLA class II	AIM/ELISPOT	(Tarke et al., 2021; Tarke et al., 2022)34
VVLSFELLHAPATVC	S	511	525	DRB1*12:01/DRB1*14:01/DQB1*05:03	ELISPOT/AIM	(Tarke et al., 2021; Peng et al., 2020)
VVNQNAQALNTLVKQ	S	951	965	HLA class II	AIM	(Tarke et al., 2022)
VYAWNRKRIS	S	350	359	DR	proliferation	(Low et al., 2021)
VYYPDKVFRSSVLHS	S	36	50	DRB1*13:01/DRB1*14:01/DRB1*03:01	AIM	(Tarke et al., 2021)
VYYPDKVFRSSVLHSTQ	S	36	52	DPA1*01:03/DPB1*04:01	ELISPOT	(Woldemeskel et al., 2021)
TNFTISVTTEILPVS	S	716	730	DQB1*06:03/DRB1*07:01/DRB1*14:01/DQB1*02:02	AIM/ELISPOT	(Tarke et al., 2021; Mateus et al., 2020; Tarke et al., 2022)
TTAPAICHDGKAHFP	S	1076	1090	HLA class II	AIM/ELISPOT	(Mateus et al., 2020; Tarke et al., 2022)
TTDNTFVSGNCDVVI	S	1116	1130	HLA class II	AIM	(Tarke et al., 2022)
WNRKRISNCVADYSV	S	353	367	HLA class II	ELISA	(Verhagen et al., 2021)
WNRKRISNCVADYSVLYNS	S	353	371	HLA class II	ELISA/CBA	(Verhagen et al., 2021)
WNRKRISNCVADYSVLYNSA	S	353	372	DRB1*03:01/DRB4*01:01	multimer staining	(Johansson et al., 2021)
WNSNNLDSKVGGNYN	S	436	450	HLA class II	AIM	(Tarke et al., 2021)
WNSNNLDSKVGGNYNYLYRL	S	436	455	HLA class II	proliferation	(Low et al., 2021)
WRVYSTGSNVFQTRAGCLIG	S	633	652	DRB1*07:01	multimer staining	(Johansson et al., 2021)
WTFGAGAALQIPFAM	S	886	900	HLA class II	ELISPOT	(Mateus et al., 2020)
YADSFVIRGDEVRQI	S	396	410	DRB1*13:01/DQB1*02:02	AIM	(Tarke et al., 2021; Tarke et al., 2022)
YADSFVIRGDEVRQIAPGQT	S	396	415	HLA class II	proliferation	(Low et al., 2021)
YAWNRKRISNCVADY	S	360	374	DRB1*13:01	ELISPOT/AIM	(Tarke et al., 2021; Peng et al., 2020; Tarke et al., 2022)
YAWNRKRISNCVADYSV	S	351	367	DRB3*02:02/DRB4*01:03	ELISPOT	(Woldemeskel et al., 2021)
YENQKLIANQFNSAI	S	917	931	HLA class II	ELISA	(Verhagen et al., 2021)
YENQKLIANQFNSAIGKIQ	S	917	935	HLA class II	ELISA	(Verhagen et al., 2021)
YEQYIKWPWYIWLGF	S	1206	1220	HLA class II	ELISPOT	(Mateus et al., 2020)
YFPLQSYGFQPTNGVGYQPY	S	489	508	DRB5*01:01	multimer staining	(Johansson et al., 2021)
YGSFCTQLNRALTGI	S	756	770	HLA class II	ELISPOT	(Mateus et al., 2020)
YLYRLFRKSNLKPFE	S	451	465	HLA class II	ICS/AIM	(Mahajan et al., 2021)
YNYLYRLFRKSNLKP	S	449	463	DPA1*01:03/DPB1*02:01	ELISA/ELISPOT	(Keller et al., 2020; Verhagen et al., 2021)
YNYLYRLFRKSNLKPFERDI	S	449	468	DRB1*11:01/DRB1*11:04/DRB3*01:01	multimer staining	(Johansson et al., 2021)
YQPYRVVVLSFELLHAPATV	S	505	524	DRB1*01:01	multimer staining	(Johansson et al., 2021)
YQTSNFRVQPTESIVRFPN	S	313	331	HLA class II	ELISA	(Verhagen et al., 2021)
YQTSNFRVQPTESIVRFPNI	S	313	332	DRB1*04:01/DRB1*01:01	multimer staining	(Johansson et al., 2021)
YVGYLQPRTFLLKYN	S	266	280	HLA class II	ICS/AIM	(Tarke et al., 2022)
ACFVLAAVYRINWITGGIA	M	63	81	HLA class II	ELISPOT	(de Castro et al., 2022)
AIAMACLVGLMWLSY	M	81	95	HLA class II	AIM	(Tarke et al., 2021)
ASFRLFARTRSMWSFN	M	98	113	HLA class II	ELISPOT	(de Castro et al., 2022)
ATSRTLSYYKLGASQ	M	171	185	DQB1*05:03/DRB1*16:01/DQB1*05:01	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
AVYRINWITGGIAIA	M	69	83	DRB1*01:02	AIM	(Panikkar et al., 2022)
CLVGLMWLSYFIASF	M	86	100	DQB1*05:01/DRB1*12:02/DRB1*12:01/DQB1*05:03	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
EELKKLLEQWNLVIG	M	11	25	DQB1*05:02/DQB1*05:01	ICS,AIM	(Tarke et al., 2021; Heide et al., 2021)
FIASFRLFARTRSMW	M	96	110	DRB1*03:01/DRB1*14:01/DQB1*05:03	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
FLFLTWICLLQFAYA	M	26	40	DQB1*05:03/DRB1*01:02/DQB1*05:01	AIM	(Tarke et al., 2021)
FLWLLWPVTLACFVLA	M	53	68	HLA class II	AIM	(Hu et al., 2021)
FVLAAVYRINWITGGIAIAM	M	65	84	DRB1*01:01	multimer staining	(Johansson et al., 2021)
GAVILRGHLRIAGHH	M	141	155	DRB1*15:01/DRB1*13:01	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
GAVILRGHLRIAGHHLG	M	141	157	DRB1*11:01	AIM	(Pogorelyy et al., 2022)
GAVILRGHLRIAGHHLGR	M	141	158	DRB1*11:01/DRB1*13:01/DRB1*11:04	ELISPOT/ELISA	(Titov et al., 2022; Peng et al., 2020)
GHHLGRCDIKDLPKEITVAT	M	153	172	DRB1*11:01/DRB1*11:04	multimer staining	(Johansson et al., 2021)
GLMWLSYFIASFRLFARTRS	M	89	108	DRB1*01:01/DRB1*11:01	multimer staining	(Johansson et al., 2021)
GTILTRPLLESELVI	M	126	140	DRB1*13:01	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
GTITVEELKKLLEQW	M	6	20	HLA class II	ICS	(Heide et al., 2021)
HLRIAGHHLGR	M	148	158	DRB1*11:01	ICS/multimer staining/AIM	(Heide et al., 2021)
IAGHHLGRCDIKDLP	M	151	165	HLA class II	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
IASFRLFARTRSMWSFNPET	M	97	116	DRB1*04:01/DRB1*07:01/DRB1*11:01	multimer staining	(Johansson et al., 2021)
IGNYKLNTDHSSSSD	M	201	215	DRB1*03:01	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
IGNYKLNTDHSSSSDNIALL	M	201	220	DRB1*04:01	multimer staining	(Johansson et al., 2021)
IKDLPKEITVATSRT	M	161	175	HLA class II	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
IKDLPKEITVATSRTLSYYK	M	161	180	DRB1*03:01/DRB1*15:01	multimer staining	(Johansson et al., 2021)
ITGGIAIAMACLVGL	M	76	90	DQB1*03:01	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
KEITVATSRTLSYYK	M	166	180	DPB1*02:01/DPA1*01:03/DPB1*04:01/DQA1*05:01/DQB1*02:01/DQA1*05:01/DQB1*03:01/DQA1*03:01/DQB1*03:02/DQA1*01:02/DQB1*06:02/DRB1*01:01/DRB1*03:01/DRB1*04:01/DRB1*04:05/DRB1*07:01/DRB1*08:02/DRB1*09:01/DRB1*11:01/DRB1*12:01/DRB1*13:02/DRB1*15:01/DRB3*01:01/DRB3*02:02/DRB4*01:01/DRB5*01:01/DQB1*06:03/DRB1*16:02/DRB1*15:01/DRB1*14:06/DRB1*14:01/DRB1*07:01/DRB1*03:01	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
LGASQRVAGDSGFAA	M	181	195	HLA class II	ICS/AIM/ELISPOT	(Tarke et al., 2021; Keller et al., 2020; Heide et al., 2021)
LGRCDIKDLPKEITV	M	156	170	HLA class II	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
LIFLWLLWPVTLACF	M	51	65	DQB1*05:03/DRB1*01:02/DQB1*05:01	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
LLEQWNLVIGFLFLT	M	16	30	DQB1*05:03/DQB1*02:01	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
LLWPVTLACFVLAAV	M	56	70	DQB1*05:03/DQB1*06:03/DQB1*05:01	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
LNTDHSSSSDNIALL	M	206	220	HLA class II	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
LRGHLRIAGHHLGRC	M	145	159	DRB1*11:01/DRB1*11:04/DRB1*08:01	ELISPOT/AIM	(Panikkar et al., 2022; Keller et al., 2020)
LRGHLRIAGHHLGRCDIKDL	M	145	164	DRB1*03:01/DRB1*11:01/DRB1*11:04/DRB4*01:01	multimer staining	(Johansson et al., 2021)
LRIAGHHLGRCDIKD	M	149	163	HLA class II	ELISPOT	(Keller et al., 2020)
LSYYKLGASQRVAGD	M	176	190	DRB1*01:01/DRB1*04:01/DRB1*15:01/DPB1*02:01/DQA1*05:01/DQB1*02:01/DQA1*05:01/DQB1*03:01/DQA1*01:01/DQB1*05:01/DQA1*01:02/DQB1*06:02/DRB1*03:01/DRB1*04:01/DRB1*04:05/DRB1*08:02/DRB1*09:01/DRB1*11:01/DRB1*12:01/DRB1*13:02/DRB3*01:01/DRB3*02:02/DRB4*01:01/DRB5*01:01/DQB1*03:01/DRB1*16:02/DRB1*16:01/DRB1*15:01/DRB1*14:06/DRB1*07:01/DRB1*01:01/DQB1*06:03/DQB1*06:02/DRB1*01:01/DRB3*02:02/DQB1*03:01/DQB1*02:01	multimer staining /ICS/AIM/ELISPOT/ELISA	(Poluektov et al., 2021; Tarke et al., 2021; Titov et al., 2022; Nelde et al., 2021; Prakash et al., 2021; Heide et al., 2021)
LYIIKLIFLWLLWPV	M	46	60	DRB1*12:01/DQB1*02:01	AIM	(Tarke et al., 2021)
MADSNGTITVEELKK	M	1	15	HLA class II	ICS	(Heide et al., 2021)
NLVIGFLFLTWICLL	M	21	35	DRB1*01:02/DQB1*05:01	AIM	(Tarke et al., 2021)
NRFLYIIKLIFLWLLWPVTL	M	43	62	HLA class II	ELISPOT	(de Castro et al., 2022)
NRNRFLYIIKLIFLW	M	41	55	DQB1*05:03/DRB1*03:01/DRB1*12:01/DQB1*02:01	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
NVPLHGTILTRPLLE	M	121	135	HLA class II	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
QFAYANRNRFLYIIK	M	36	50	DRB1*14:01	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
QFAYANRNRFLYIIKLI	M	36	52	DRB1*11:01	multimer staining	(Johansson et al., 2021)
MWLSYFIASFRLFAR	M	91	105	DQB1*02:01/DRB1*16:02/DRB1*16:01/DRB1*14:06/DRB1*14:01/DRB1*03:01/DQB1*05:03/DQB1*05:02/DQB1*05:01	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
RGHLRIAGHHLGRCD	M	146	160	DPB1*02:01/DPA1*01:03/DPB1*04:01/DQA1*05:01/DQB1*03:01/DQA1*01:01/DQB1*05:01/DRB1*01:01/DRB1*03:01/DRB1*04:01/DRB1*04:05/DRB1*08:02/DRB1*09:01/DRB1*12:01/DRB1*13:02/DRB3*01:01/DRB3*02:02/DRB4*01:01/DRB5*01:01/DRB1*07:01/DRB1*15:01/DRB1*14:01/DRB1*13:01	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021; Le Bert et al., 2021)
RGHLRIAGHHLGRCDIK	M	146	162	DRB1*11:01	AIM	(Pogorelyy et al., 2022)
RLFARTRSMWSFNPE	M	101	115	DRB1*14:01/DQB1*05:03	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
RPLLESELVIGAVIL	M	131	145	DQB1*02:02	AIM	(Tarke et al., 2021)
RTRSMWSFNPETNILLNVPL	M	105	124	DRB1*01:01/DRB1*04:01	multimer staining	(Johansson et al., 2021)
RVAGDSGFAAYSRYR	M	186	200	HLA class II	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
SELVIGAVILRGHLR	M	136	150	DQB1*06:02/DRB1*16:01/DRB1*15:01/DRB1*14:01/DRB1*13:01/DRB1*01:02/DQB1*06:03	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
SFNPETNILLNVPLH	M	111	125	DRB1*01:02	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
SGFAAYSRYRIGNYK	M	191	205	DRB1*15:01	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
SRTLSYYKLGASQRV	M	173	187	DRB5*01:02/DRB5*01:01	ELISPOT	(Keller et al., 2020)
SYFIASFRLF	M	94	103	HLA class II	ICS	(Jin et al., 2021)
SYYKLGASQRVAGDS	M	177	191	DRB1*07:01/DQA1*05:01/DQB1*03:01/DRB1*01:01	ELISPOT	(Keller et al., 2020)
SYYKLGASQRVAGDSGFAAY	M	177	196	DRB1*04:01/DRB1*07:01/DRB1*11:01/DRB5*01:01	multimer staining	(Johansson et al., 2021)
TNILLNVPLHGTILT	M	116	130	DRB1*10:01/DRB1*16:02/DRB1*15:01/DRB1*14:06/DRB1*14:01/DRB1*12:02	AIM	(Tarke et al., 2021)
TRSMWSFNPETNILL	M	106	120	DQB1*05:02/DQB1*05:03/DRB1*01:02/DQB1*05:01	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
TNILLNVPLHGTILTRP	M	116	132	DRB3*02:02	AIM	(Pogorelyy et al., 2022)
TSRTLSYYKLGASQRVA	M	172	188	DRB1*07:01/DRB1*01:01	ELISPOT/ELISA/ICS	(Titov et al., 2022; Peng et al., 2020)
TVATSRTLSYYKLGASQRVA	M	169	188	DRB1*03:01/DRB1*04:01/DRB1*07:01/DRB1*11:01/DRB5*01:01/DRB1*04:01/DRB1*04:01	multimer staining	(Johansson et al., 2021)
TVEELKKLLEQWNLVIGFLF	M	9	28	DRB1*07:01	multimer staining	(Johansson et al., 2021)
VLAAVYRINWITGGI	M	66	80	DQB1*05:01/DRB1*14:01/DRB1*12:02/DQB1*05:03	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
WICLLQFAYANRNRF	M	31	45	DRB1*03:01/DRB1*14:01/DQB1*05:03	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
YRINWITGGIAIAMA	M	71	85	DQB1*02:02/DRB1*16:01/DRB1*15:01/DRB1*14:01/DRB1*13:01/DRB1*12:01/DRB1*10:01/DRB1*07:01/DQB1*06:03/DQB1*06:02/DQB1*05:03/DQB1*05:02/DQB1*05:01/DQB1*03:01	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
YSRYRIGNYK	M	196	205	HLA class II	proliferation	(Jin et al., 2021)
YSRYRIGNYKLNTDH	M	196	210	HLA class II	ICS/AIM	(Tarke et al., 2021; Heide et al., 2021)
YYKLGASQRVA	M	178	188	DRB1*01:01	ICS	(Heide et al., 2021)
ALLAVFQSASKIITL	ORF3a	51	65	DRB1*11:01/DQB1*03:01	AIM/ELISPOT	(Tarke et al., 2021; Mateus et al., 2020)
CNLLLLFVTVYSHLL	ORF3a	81	95	DRB1*07:01/DRB1*11:01/DQB1*02:01	AIM	(Tarke et al., 2021)
EHVTFFIYNKIVDEP	ORF3a	226	240	DQB1*05:01/DRB1*08:01/DRB1*11:01/DQB1*02:01	AIM	(Tarke et al., 2021)
FIYNKIVDEPEEHVQ	ORF3a	231	245	DRB1*08:01/DQB1*05:01	AIM	(Tarke et al., 2021)
FLCWHTNCYDYCIPY	ORF3a	146	160	DQB1*05:03	AIM	(Tarke et al., 2021)
FMRIFTIGTVTLKQG	ORF3a	4	18	DR	ELISPOT/ICS	(Nelde et al., 2021)
GSSGVVNPVMEPIYD	ORF3a	251	265	DQB1*04:02	AIM	(Tarke et al., 2021)
INFVRIIMRLWLCWKCRSKN	ORF3a	118	137	HLA class II	ELISPOT	(de Castro et al., 2022)
KIITLKKRWQLALSK	ORF3a	61	75	DRB1*11:01	AIM	(Tarke et al., 2021)
KKRWQLALSKGVHFV	ORF3a	66	80	DRB1*07:01	AIM/ELISPOT	(Tarke et al., 2021; Mateus et al., 2020)
KNPLLYDANYFLCWH	ORF3a	136	150	DRB1*15:01/DQB1*05:03	AIM/ELISPOT	(Tarke et al., 2021; Mateus et al., 2020)
LEAPFLYLYALVYFL	ORF3a	101	115	DRB1*11:01/DQB1*02:01	AIM	(Tarke et al., 2021)
LVAAGLEAPFLYLYA	ORF3a	96	110	DQB1*02:02/DQB1*02:01	AIM	(Tarke et al., 2021)
LVYFLQSINFVRIIM	ORF3a	111	125	DRB1*12:01/DRB1*14:01/DQB1*05:03	AIM/ELISPOT	(Tarke et al., 2021; Mateus et al., 2020)
LYLYALVYFLQSINF	ORF3a	106	120	DQB1*02:01/DRB1*12:01/DRB1*11:01/DQB1*05:03/DQB1*03:02	AIM	(Tarke et al., 2021)
RLWLCWKCRSKNPLL	ORF3a	126	140	HLA class II	AIM	(Tarke et al., 2021)
SDFVRATATIPIQAS	ORF3a	26	40	HLA class II	ELISPOT	(Mateus et al., 2020; de Castro et al., 2022)
TDTGVEHVTFFIYNK	ORF3a	221	235	HLA class II	AIM	(Tarke et al., 2021)
TNCYDYCIPYNSVTS	ORF3a	151	165	DQB1*05:01	AIM	(Tarke et al., 2021)
QSINFVRIIMRLWLC	ORF3a	116	130	DQB1*06:02/DRB1*15:01/DRB1*14:01/DRB1*12:01/DRB1*11:01/DRB1*03:01	AIM/ELISPOT	(Tarke et al., 2021; Mateus et al., 2020)
VRIIMRLWLCWKCRS	ORF3a	121	135	DRB1*11:01	AIM	(Tarke et al., 2021)
YFTSDYYQLYSTQLS	ORF3a	206	220	DRB1*16:02	AIM	(Tarke et al., 2021)
YDANYFLCWHTNCYD	ORF3a	141	155	HLA class II	AIM	(Tarke et al., 2021)
AEILLIIMRTFKVSI	ORF6	12	26	DRB1	ELISPOT	(Prakash et al., 2021)
IAEILLIIMRTFKVS	ORF6	11	25	HLA class II	ELISPOT	(Mateus et al., 2020)
IWNLDYIINLIIKNL	ORF6	26	40	DR	ELISPOT/ICS	(Nelde et al., 2021; Mateus et al., 2020)
LIIMRTFKVSIWNLD	ORF6	16	30	HLA class II	ELISPOT	(Mateus et al., 2020)
MFHLVDFQVTIAEIL	ORF6	1	15	HLA class II	ELISPOT	(Mateus et al., 2020)
TFKVSIWNLDYIINL	ORF6	21	35	HLA class II	ELISPOT	(Mateus et al., 2020)
YIINLIIKNLSKSLT	ORF6	31	45	HLA class II	ELISPOT	(Mateus et al., 2020)
AAIVFITLCFTLKRKT	ORF7a	105	120	HLA class II	ELISPOT	(de Castro et al., 2022)
DGVKHVYQLRARSVSPKL	ORF7a	4	21	HLA class II	ELISPOT	(Peng et al., 2020)
QEEVQELYSPIFLIV	ORF7a	90	104	DR	ELISPOT	(Nelde et al., 2021)
IILFLALITLATCEL	ORF7a	3	17	DRB1	ELISPOT	(Prakash et al., 2021)
LYSPIFLIVAAIVFI	ORF7a	96	110	HLA class II	ELISPOT	(Mateus et al., 2020)
MKIILFLALITLATC	ORF7a	1	15	DRB1	ELISPOT	(Prakash et al., 2021; Mateus et al., 2020)
SPIFLIVAAIVFITL	ORF7a	98	112	DRB1	ELISPOT	(Prakash et al., 2021)
VKHVYQLRARSVSPK	ORF7a	71	85	HLA class II	ELISPOT	(Mateus et al., 2020)
DFYLCFLAFLLFLVL	ORF7b	8	22	DRB1	ELISPOT	(Prakash et al., 2021)
ARKSAPLIELCVDEA	ORF8	51	65	HLA class II	AIM	(Tarke et al., 2021)
CVDEAGSKSPIQYID	ORF8	61	75	HLA class II	AIM	(Tarke et al., 2021)
DFLEYHDVRVVLDFI	ORF8	107	121	DQB1*06:04/DRB1*15:02/DQB1*05:02	AIM	(Tarke et al., 2021)
EDFLEYHDVRVVLDF	ORF8	106	120	DQB1*06:04/DRB1*13:02/DRB1*15:02/DQB1*05:02	AIM	(Tarke et al., 2021)
FHQECSLQSCTQHQP	ORF8	16	30	HLA class II	AIM	(Tarke et al., 2021)
FLGIITTVAAFHQEC	ORF8	6	20	HLA class II	AIM/ELISPOT	(Tarke et al., 2021; Mateus et al., 2020)
FTINCQEPKLGSLVV	ORF8	86	100	HLA class II	AIM	(Tarke et al., 2021)
FYSKWYIRVGARKSA	ORF8	41	55	DQB1*06:01/DRB1*14:01/DRB1*13:03/DRB1*11:04/DRB1*11:01/DRB1*07:01/DRB1*04:02/DRB1*14:06/DRB1*15:01/DRB1*15:02/DRB1*16:01/DRB1*16:02	AIM/ELISPOT	(Tarke et al., 2021; Mateus et al., 2020)
GSLVVRCSFYEDFLE	ORF8	96	110	DQB1*05:02/DQB1*05:03	AIM	(Tarke et al., 2021)
IGNYTVSCLPFTINC	ORF8	76	90	DQB1*03:03/DRB1*15:02	AIM	(Tarke et al., 2021)
IQYIDIGNYTVSCLP	ORF8	71	85	DRB1*13:02/DRB1*11:04	AIM	(Tarke et al., 2021)
PCPIHFYSKWYIRVG	ORF8	36	50	DRB1*08:02/DRB1*16:01/DRB1*15:02/DRB1*15:01/DRB1*13:01	AIM	(Tarke et al., 2021)
PLIELCVDEAGSKSP	ORF8	56	70	HLA class II	AIM	(Tarke et al., 2021)
QEPKLGSLVVRCSFY	ORF8	91	105	DRB1*11:04	AIM	(Tarke et al., 2021)
MKFLVFLGIITTVAA	ORF8	1	15	DRB1	ELISPOT	(Prakash et al., 2021)
MKFLVFLGIITTVAAFH	ORF8	1	17	HLA class II	ELISPOT	(de Castro et al., 2022)
RCSFYEDFLEYHDVR	ORF8	101	115	DQB1*05:02	AIM	(Tarke et al., 2021)
SKWYIRVGARKSAPL	ORF8	43	57	DR	ELISPOT/ICS	(Nelde et al., 2021; de Castro et al., 2022)
SLQSCTQHQPYVVDD	ORF8	21	35	HLA class II	AIM	(Tarke et al., 2021)
TQHQPYVVDDPCPIH	ORF8	26	40	DRB1*13:02	AIM	(Tarke et al., 2021)
TTVAAFHQECSLQSC	ORF8	11	25	DQB1*05:02	AIM	(Tarke et al., 2021)
YIRVGARKSAPLIEL	ORF8	46	60	DRB1*11:04/DRB1*13:02/DRB1*15:01/DRB1*16:01/DQB1*03:01	AIM/ELISPOT	(Tarke et al., 2021; Mateus et al., 2020)
YVVDDPCPIHFYSKW	ORF8	31	45	DRB1*13:02/DRB1*15:02	AIM	(Tarke et al., 2021)
FAFPFTIYSL	ORF10	7	16	HLA class II	ELISPOT	(Ma et al., 2021)
INVFAFPFTIYSLLL	ORF10	4	18	DR	ELISPOT	(Nelde et al., 2021)

Notes:

HTMA: high throughput multiplexed assay, is one method analyzing TCRs after sorting antigen-specific (CD3CD8CD137) T cells.

SPR: surface plasmon resonance, is one method detctcting the binding of MHC-peptide complex and the TCRs.

CBA: cytometric bead array.

Among all the studies collected here, 19 reported both CD8⁺ T-cell epitopes and CD4⁺ T-cell epitopes, 35 only reported CD8⁺ T-cell epitopes, and 16 only reported CD4⁺ T-cell epitopes. A total of 2214 SARS-CoV-2 antigen-specific T-cell epitopes were involved, including 1349 CD8⁺ T-cell epitopes and 790 CD4⁺ T-cell epitopes. Fig. 1A and 1B display the predominant HLA class I allotypes and HLA class II allotypes presenting these epitope peptides, respectively. Of these, 678 (50.2%) CD8⁺ T-cell epitopes are restricted by HLA-A0201, A2402, B0702, A0101, A1101, or B0801. The remainder are restricted mainly by 12 HLA-A, 8 HLA-B and 4 HLA-C supertypes. For the CD4⁺ T-cell epitopes, the majority of currently described restrictions apply to 10 DRB1 and 5 DQB1 supertypes. Obviously, these HLA allotypes cannot yet cover the major populations in an indicated geographic region. Further efforts are required to focus more on the regional dominant HLA supertypes for the design of regional vaccines and SARA-CoV-2-specific T-cell detection systems. In addition, 74.54% of all CD8⁺ T-cell epitopes were derived from the S protein and nonstructural proteins (Fig. 1C), while 80.91% of all CD4⁺ T-cell epitopes were derived from the S protein, N protein and nonstructural proteins (Fig. 1D).

Fig. 1.

HLA restriction and protein distribution of validated CD8⁺ T cell epitopes and CD4⁺ T cell epitopes in SARS-CoV-2 proteome. (A) and (B) displayed the number of CD8⁺ T-cell epitopes and CD4⁺ T-cell epitopes restricted by each HLA allotype, respectively. (C) and (D) showed the fraction of CD8⁺ T-cell epitopes and CD4⁺ T-cell epitopes in each SARS-CoV-2 protein, respectively.

6. Conclusion

This review systemically collected the CD8⁺ T-cell epitopes and CD4⁺ T-cell epitopes defined from the SARS-CoV-2 proteome during the last three years and displayed their HLA restrictions and the methods verifying their immunogenicity. These data will benefit the investigation of host cellular immunity and the development of vaccines and specific T-cell detection systems for SARS-CoV-2 infection.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Data Availability

• The data that has been used is confidential.